nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,days_since_update
NCT04380701,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2021-04-20,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-20,2021-04-22,Actual,"April 23, 2020",Actual,2020-04-23,April 2021,2021-04-30,April 2023,Anticipated,2023-04-30,April 2023,Anticipated,2023-04-30,NA,Interventional,NA,,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy and Immunocompromised Adults",Recruiting,NA,Phase 1/Phase 2,476,Anticipated,BioNTech SE,,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:25:37Z,2021-10-17T08:25:37Z,193
NCT04380532,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-29,NA,NA,2020-05-22,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"June 15, 2021",Anticipated,2021-06-15,"May 15, 2021",Anticipated,2021-05-15,NA,Interventional,COVID-19,,Tableted COVID-19 Therapeutic Vaccine,Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,Immunitor LLC,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,when become public,non-confidential data,http://immunitor.com,Yes,Free dissemination of published data,2021-10-17T08:25:40Z,2021-10-17T08:25:40Z,526
NCT04379336,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-04,NA,NA,2021-10-12,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Actual,"May 4, 2020",Actual,2020-05-04,October 2021,2021-10-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,"Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial","Active, not recruiting",NA,Phase 3,1000,Actual,TASK Applied Science,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,IPD will only be shared among researchers included in the protocol team at this stage.,2021-10-17T08:25:53Z,2021-10-17T08:25:53Z,18
NCT04373291,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-01,NA,NA,2021-10-07,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-08,Actual,"May 18, 2020",Actual,2020-05-18,October 2021,2021-10-31,"October 1, 2021",Actual,2021-10-01,"July 31, 2021",Actual,2021-07-31,NA,Interventional,NA,,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial,Completed,NA,Phase 3,1293,Actual,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,When follow-up has been completed and the dataset have been closed,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,2021-10-17T08:26:45Z,2021-10-17T08:26:45Z,23
NCT04368988,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2021-07-23,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"May 25, 2020",Actual,2020-05-25,July 2021,2021-07-31,"May 21, 2022",Anticipated,2022-05-21,"May 21, 2022",Anticipated,2022-05-21,NA,Interventional,NA,,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-Mâ„¢ Adjuvant In Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,1419,Actual,Novavax,,12,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:23Z,2021-10-17T08:27:23Z,99
NCT04372589,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-24,NA,NA,2021-07-26,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"May 20, 2020",Actual,2020-05-20,January 2021,2021-01-31,"May 17, 2021",Actual,2021-05-17,"May 17, 2021",Actual,2021-05-17,NA,Interventional,ATTACC,,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC), in Collaboration With Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4)",Completed,NA,Phase 2/Phase 3,1200,Actual,University of Manitoba,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:26:52Z,2021-10-17T08:26:52Z,96
NCT04369794,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-27,NA,NA,2020-08-05,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"August 10, 2020",Anticipated,2020-08-10,August 2020,2020-08-31,August 2023,Anticipated,2023-08-31,June 2021,Anticipated,2021-06-30,NA,Interventional,BATTLE,,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,NA,Phase 4,1000,Anticipated,"University of Campinas, Brazil",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:27:16Z,2021-10-17T08:27:16Z,451
NCT04352608,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-14,NA,NA,2021-07-26,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-29,Actual,"April 16, 2020",Actual,2020-04-16,July 2021,2021-07-31,"September 30, 2021",Anticipated,2021-09-30,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years","Active, not recruiting",NA,Phase 1/Phase 2,744,Anticipated,"Sinovac Biotech Co., Ltd",,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:29:45Z,2021-10-17T08:29:45Z,96
NCT04348370,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-30,NA,NA,2021-10-05,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"April 20, 2020",Actual,2020-04-20,October 2021,2021-10-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,BADAS,,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses,"Active, not recruiting",NA,Phase 4,1800,Anticipated,Texas A&M University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,There is not a plan to make IPD available.,2021-10-17T08:30:26Z,2021-10-17T08:30:26Z,25
NCT04341389,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-07,NA,NA,2020-05-14,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 12, 2020",Actual,2020-04-12,May 2020,2020-05-31,"January 31, 2021",Anticipated,2021-01-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CTII-nCoV,,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Active, not recruiting",NA,Phase 2,508,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:31:26Z,2021-10-17T08:31:26Z,534
NCT04336410,"ClinicalTrials.gov processed this data on October 15, 2021",2020-04-03,NA,NA,2021-10-01,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"April 3, 2020",Actual,2020-04-03,October 2021,2021-10-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers","Active, not recruiting",NA,Phase 1,120,Actual,Inovio Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-10-17T08:32:14Z,2021-10-17T08:32:14Z,29
NCT04334980,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-31,NA,NA,2021-03-03,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-03-03,2021-03-04,Actual,"November 2, 2020",Actual,2020-11-02,September 2020,2020-09-30,"February 28, 2022",Anticipated,2022-02-28,"February 8, 2022",Anticipated,2022-02-08,NA,Interventional,NA,,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults","Active, not recruiting",NA,Phase 1,24,Anticipated,Symvivo Corporation,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:32:28Z,2021-10-17T08:32:28Z,241
NCT04328441,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-27,NA,NA,2021-05-09,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"March 25, 2020",Actual,2020-03-25,May 2021,2021-05-31,"May 30, 2021",Anticipated,2021-05-30,"March 31, 2021",Actual,2021-03-31,NA,Interventional,BCG-CORONA,,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial.","Active, not recruiting",NA,Phase 3,1500,Anticipated,UMC Utrecht,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,"The content of the study protocol is published. The statistical analysis plan is attached. The informed consent form (in Dutch) could be obtained by sending a mail to one of the contact persons.
The clinical study report and analytic code could be obtained by sending a mail to one of the contact persons after publication of the study in a peer-reviewed journal.",NA,NA,Yes,The results of this study will be disclosed unreservedly at the end of the study.,2021-10-17T08:33:35Z,2021-10-17T08:33:35Z,174
NCT04327206,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-25,NA,NA,2021-06-23,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2021-06-23,2021-06-28,Actual,"March 30, 2020",Actual,2020-03-30,June 2021,2021-06-30,"March 30, 2022",Anticipated,2022-03-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,BRACE,,BCG Vaccination to Protect Healthcare Workers Against COVID-19,BCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers (BRACE) Trial,"Active, not recruiting",NA,Phase 3,10078,Anticipated,Murdoch Childrens Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,"Beginning 6 months following analysis and article publications, for long-term use","Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement",NA,Yes,"Beginning 6 months following analysis and article publications, the following may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement, for accessing:
Individual participant data that underlie the results reported in our articles after de-identification (text, tables, figures and appendices)
Study protocol, Statistical Analysis Plan, Participant Informed Consent Form (PICF)",2021-10-17T08:33:47Z,2021-10-17T08:33:47Z,129
NCT04324606,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-20,NA,NA,2021-04-08,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2021-04-08,2021-04-13,Actual,"April 23, 2020",Actual,2020-04-23,March 2021,2021-03-31,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,1090,Actual,University of Oxford,,19,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:34:09Z,2021-10-17T08:34:09Z,205
NCT04313127,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-15,NA,NA,2021-08-02,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"February 20, 2021",Actual,2021-02-20,"January 20, 2021",Actual,2021-01-20,NA,Interventional,CTCOVID-19,,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old",Completed,NA,Phase 1,108,Actual,CanSino Biologics Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available beginning 3 months and ending one year following article publication,"Data access requests will be reviewed by the sponsorï¼Œinvestigator and collaborators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.",http://www.jshealth.com/,Yes,"We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this article, after deidentiï¬cation (text, tables, figures, and appendixes) will be shared. Individual participant data will be available beginning 3 months and ending one year following article publication. Supporting clinical documents including study protocol, statistical analysis plan (SAP), and the informed consent form (ICF) will be available immediately following publication for at least one year. Supporting clinical documents access information will be available at http://www.jshealth.com/. Researchers who provide a scientifically sound proposal will be allowed to access to the individual participant data. Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.",2021-10-17T08:36:07Z,2021-10-17T08:36:07Z,89
NCT04299724,"ClinicalTrials.gov processed this data on October 15, 2021",2020-03-05,NA,NA,2020-03-06,2020-03-06,2020-03-09,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:38:05Z,2021-10-17T08:38:05Z,603
NCT04283461,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-21,NA,NA,2021-09-09,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-16,Actual,"March 16, 2020",Actual,2020-03-16,"August 26, 2021",2021-08-26,"November 22, 2022",Anticipated,2022-11-22,"November 22, 2022",Anticipated,2022-11-22,NA,Interventional,NA,,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","Active, not recruiting",NA,Phase 1,120,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,15,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T08:40:37Z,2021-10-17T08:40:37Z,51
NCT04276896,"ClinicalTrials.gov processed this data on October 15, 2021",2020-02-17,NA,NA,2020-03-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 24, 2020",Anticipated,2020-03-24,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:41:36Z,2021-10-17T08:41:36Z,592
NCT05028361,"ClinicalTrials.gov processed this data on October 18, 2021",2021-08-30,NA,NA,2021-10-13,2021-08-30,2021-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-18,Estimate,"October 4, 2021",Actual,2021-10-04,July 2021,2021-07-31,"July 14, 2022",Anticipated,2022-07-14,"April 5, 2022",Anticipated,2022-04-05,NA,Interventional,NA,,Simultaneous mRNA COVID-19 and IIV4 Vaccination Study,Safety of Simultaneous Versus Sequential Administration of mRNA COVID-19 Vaccines and Quadrivalent Inactivated Influenza (IIV4) in Adults and Adolescents: A Randomized Observer Blinded Study,Recruiting,NA,Phase 4,450,Anticipated,Duke University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-19T08:25:40Z,2021-10-19T08:25:40Z,17
NCT05012943,"ClinicalTrials.gov processed this data on October 18, 2021",2021-08-13,NA,NA,2021-10-15,2021-08-13,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-18,Estimate,"August 15, 2021",Actual,2021-08-15,October 2021,2021-10-31,"August 31, 2023",Anticipated,2023-08-31,"February 28, 2023",Anticipated,2023-02-28,NA,Interventional,ARCT-154-01,,The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01),"A Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the SARS-CoV-2 Self- Amplifying RNA Vaccine ARCT-154 in Adults",Recruiting,NA,Phase 2/Phase 3,21000,Anticipated,Vinbiocare Biotechnology Joint Stock Company,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,IPD is the sole property of VinBioCare. VinBioCare may share a copy of the study IPD with their collaborative partners if requested.,2021-10-19T08:25:50Z,2021-10-19T08:25:50Z,15
NCT04838795,"ClinicalTrials.gov processed this data on October 18, 2021",2021-02-17,NA,NA,2021-10-13,2021-04-06,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-18,Estimate,"February 18, 2021",Actual,2021-02-18,October 2021,2021-10-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,Sisonke,,Sisonke (Together): OPEN LABEL TRIAL COVID-19,"Open-label, Single-arm Phase 3B Implementation Study to Monitor the Effectiveness of the Single-dose Ad26.COV2.S COVID-19 Vaccine Among Health Care Workers in South Africa (VAC31518COV3012)",Recruiting,NA,Phase 3,500000,Anticipated,Wits Health Consortium (Pty) Ltd,,NA,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-19T08:27:14Z,2021-10-19T08:27:14Z,17
NCT04522089,"ClinicalTrials.gov processed this data on October 18, 2021",2020-08-12,NA,NA,2021-10-14,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-18,Estimate,"August 24, 2020",Actual,2020-08-24,August 2021,2021-08-31,"October 31, 2021",Anticipated,2021-10-31,"November 20, 2020",Actual,2020-11-20,NA,Interventional,NA,,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,"A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers","Active, not recruiting",NA,Phase 1,70,Anticipated,Adimmune Corporation,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-19T08:28:55Z,2021-10-19T08:28:55Z,16
NCT04951336,"ClinicalTrials.gov processed this data on October 19, 2021",2021-06-30,NA,NA,2021-10-11,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-19,Estimate,"June 10, 2021",Actual,2021-06-10,October 2021,2021-10-31,"June 1, 2022",Anticipated,2022-06-01,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,MACH19,,RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination,"Multicenter Double-Blind, Placebo-Controlled RCT of Fomitopsis Officinalis/Trametes Versicolor for COVID-19",Recruiting,NA,N/A,66,Anticipated,"University of California, San Diego",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-20T09:39:49Z,2021-10-20T09:39:49Z,19
NCT04942405,"ClinicalTrials.gov processed this data on October 19, 2021",2021-06-24,NA,NA,2021-10-18,2021-06-24,2021-06-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"June 21, 2021",Actual,2021-06-21,June 2021,2021-06-30,"March 31, 2023",Anticipated,2023-03-31,"January 21, 2022",Anticipated,2022-01-21,NA,Interventional,NA,,"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine","Efficacy, Immunogenicity, and Safety of the Two-Dose Inactivated COVID-19 Vaccine (TURKOVAC) Versus the Two-Dose CoronaVac (Sinovac) Vaccine in Healthy Subjects: A Randomized, Observer-Blinded, Phase III Clinical Trial",Recruiting,NA,Phase 3,40800,Anticipated,Health Institutes of Turkey,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-20T09:39:53Z,2021-10-20T09:39:53Z,12
NCT04852861,"ClinicalTrials.gov processed this data on October 19, 2021",2021-04-14,NA,NA,2021-10-18,2021-04-19,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-19,Estimate,"May 10, 2021",Actual,2021-05-10,October 2021,2021-10-31,"September 30, 2022",Anticipated,2022-09-30,"July 30, 2021",Actual,2021-07-30,NA,Interventional,REDU-VAC,,COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine,COVID-19: Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine in a Healthy Population,Enrolling by invitation,NA,Phase 4,150,Anticipated,Sciensano,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-20T09:40:39Z,2021-10-20T09:40:39Z,12
NCT05085145,"ClinicalTrials.gov processed this data on October 20, 2021",2021-08-20,NA,NA,2021-10-18,2021-10-18,2021-10-20,Estimate,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-20,Estimate,"September 1, 2021",Actual,2021-09-01,August 2021,2021-08-31,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,NA,,Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV,The Efficacy of COVID-19 Vaccine in Patients With HIV Infectionï¼Œa Prospective and Multicenter Clinical Trial,Recruiting,NA,Phase 4,200,Anticipated,Beijing 302 Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-21T09:50:30Z,2021-10-21T09:50:30Z,12
NCT05028257,"ClinicalTrials.gov processed this data on October 20, 2021",2021-07-31,NA,NA,2021-10-15,2021-08-30,2021-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-20,Estimate,"September 15, 2021",Actual,2021-09-15,October 2021,2021-10-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,COVALL,,Allergy and COVID-19 Vaccines,Pursuit of Vaccination in Anaphylactic Reaction to COVID19 Vaccines,Recruiting,NA,Phase 3,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-21T09:52:00Z,2021-10-21T09:52:00Z,15
NCT05047770,"ClinicalTrials.gov processed this data on October 20, 2021",2021-09-15,NA,NA,2021-10-19,2021-09-15,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-20,Estimate,"October 7, 2021",Actual,2021-10-07,October 2021,2021-10-31,"July 21, 2022",Anticipated,2022-07-21,"March 29, 2022",Anticipated,2022-03-29,NA,Interventional,NA,,A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine,"A Phase III, Randomized, Open-label, Controlled, Multicenter Study to Evaluate the Immune Response and Safety of Both Herpes Zoster Subunit Vaccine in Healthy Adults Aged 50 Years and Older AND the Influenza Virus Vaccine in Healthy Adults Aged 18 Years and Older When Administered Sequentially or Coadministered With mRNA-1273 Booster Vaccination",Recruiting,NA,Phase 3,1546,Anticipated,GlaxoSmithKline,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",NA,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2021-10-21T09:51:45Z,2021-10-21T09:51:45Z,11
NCT04790851,"ClinicalTrials.gov processed this data on October 20, 2021",2021-03-08,NA,NA,2021-10-12,2021-03-08,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-20,Estimate,"March 10, 2021",Actual,2021-03-10,October 2021,2021-10-31,"September 5, 2021",Actual,2021-09-05,"September 5, 2021",Actual,2021-09-05,NA,Interventional,NA,,Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Beijing) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)",Completed,NA,Phase 4,1133,Actual,China National Biotec Group Company Limited,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-21T09:53:40Z,2021-10-21T09:53:40Z,18
NCT04400838,"ClinicalTrials.gov processed this data on October 20, 2021",2020-05-12,NA,NA,2021-10-14,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-20,Estimate,"May 28, 2020",Actual,2020-05-28,June 2021,2021-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Investigating a Vaccine Against COVID-19,"A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19","Active, not recruiting",NA,Phase 2/Phase 3,12390,Anticipated,University of Oxford,,29,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-21T09:55:41Z,2021-10-21T09:55:41Z,16
NCT05087173,"ClinicalTrials.gov processed this data on October 21, 2021",2021-10-20,NA,NA,2021-10-20,2021-10-20,2021-10-21,Estimate,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-21,Estimate,"October 11, 2021",Actual,2021-10-11,October 2021,2021-10-31,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination,Effectiveness of Using Interactive Consulting System to Enhance Decision Aids of COVID-19 Vaccination,Recruiting,NA,N/A,1200,Anticipated,Sun Yat-sen University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-22T09:33:44Z,2021-10-22T09:33:44Z,10
NCT04904471,"ClinicalTrials.gov processed this data on October 21, 2021",2021-05-26,NA,NA,2021-10-19,2021-05-26,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,"June 15, 2021",Actual,2021-06-15,May 2021,2021-05-31,"December 31, 2022",Anticipated,2022-12-31,"February 28, 2022",Anticipated,2022-02-28,NA,Interventional,NA,,A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells),"A Global Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cells), for the Prevention of COVID-19 in Adults Aged 18 Years and Older",Enrolling by invitation,NA,Phase 3,40000,Anticipated,"WestVac Biopharma Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-22T09:36:11Z,2021-10-22T09:36:11Z,11
NCT04952376,"ClinicalTrials.gov processed this data on October 21, 2021",2021-06-07,NA,NA,2021-10-19,2021-07-02,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-21,Estimate,January 2022,Anticipated,2022-01-31,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,,Equitable Access to COVID-19 Vaccines,Enabling Equitable Access to COVID-19 Vaccine in Under-Resourced Communities,Recruiting,NA,N/A,1500,Anticipated,Mayo Clinic,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-22T09:35:40Z,2021-10-22T09:35:40Z,11
NCT05089045,"ClinicalTrials.gov processed this data on October 22, 2021",2021-10-11,NA,NA,2021-10-21,2021-10-21,2021-10-22,Estimate,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"August 31, 2021",Actual,2021-08-31,October 2021,2021-10-31,"September 30, 2021",Actual,2021-09-30,"September 16, 2021",Actual,2021-09-16,NA,Interventional,NA,,Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity,A Clinical Study to Evaluate the Immunogenicity and Safety of Recombinant New Coronavirus Vaccine (CHO Cells) After Vaccination With Two Inactivated Vaccine in Healthy People Aged 18 and Above,Completed,NA,N/A,360,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-25T08:55:23Z,2021-10-25T08:55:23Z,9
NCT05077267,"ClinicalTrials.gov processed this data on October 22, 2021",2021-10-11,NA,NA,2021-10-14,2021-10-11,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-22,Estimate,"August 19, 2021",Actual,2021-08-19,October 2021,2021-10-31,"February 1, 2024",Anticipated,2024-02-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,,ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects,"An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects",Recruiting,NA,Phase 2,210,Anticipated,Bavarian Nordic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-25T08:56:13Z,2021-10-25T08:56:13Z,16
NCT05075083,"ClinicalTrials.gov processed this data on October 22, 2021",2021-10-04,NA,NA,2021-10-20,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-25T08:56:15Z,2021-10-25T08:56:15Z,10
NCT05075070,"ClinicalTrials.gov processed this data on October 22, 2021",2021-10-05,NA,NA,2021-10-21,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With Human Immunodeficiency Virus Infected,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-25T08:56:15Z,2021-10-25T08:56:15Z,9
NCT05075057,"ClinicalTrials.gov processed this data on October 22, 2021",2021-10-05,NA,NA,2021-10-20,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥60 Years With Chronic Bronchitis and COPD,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥60 Years With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-25T08:56:16Z,2021-10-25T08:56:16Z,10
NCT05075044,"ClinicalTrials.gov processed this data on October 22, 2021",2021-10-05,NA,NA,2021-10-20,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"December 30, 2022",Anticipated,2022-12-30,"December 30, 2022",Anticipated,2022-12-30,NA,Interventional,NA,,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged â‰¥18 Years With HIV Infected,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged â‰¥18 Years With Human Immunodeficiency Virus Infected,Recruiting,NA,Phase 4,400,Anticipated,China National Biotec Group Company Limited,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-25T08:56:16Z,2021-10-25T08:56:16Z,10
NCT04979949,"ClinicalTrials.gov processed this data on October 22, 2021",2021-07-15,NA,NA,2021-10-20,2021-07-26,2021-07-28,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-22,Estimate,"July 12, 2021",Actual,2021-07-12,July 2021,2021-07-31,"July 12, 2022",Anticipated,2022-07-12,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,,Booster Vaccination Against SARS-CoV-2,"Double-Blind, Randomized, Controlled, Multi-Center Phase 2 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2",Recruiting,NA,Phase 2,222,Anticipated,Health Institutes of Turkey,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-25T08:57:19Z,2021-10-25T08:57:19Z,10
NCT05007951,"ClinicalTrials.gov processed this data on October 22, 2021",2021-08-09,NA,NA,2021-10-14,2021-08-09,2021-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-22,Estimate,"August 30, 2021",Actual,2021-08-30,September 2021,2021-09-30,September 2022,Anticipated,2022-09-30,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,,Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19),"A Phase III, Randomized, Active-controlled, Observer-blind, Parallel-group, Multi-center Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine Adjuvanted With AS03 (GBP510) in Adults Aged 18 Years and Older",Recruiting,NA,Phase 3,3990,Anticipated,"SK Bioscience Co., Ltd.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-25T08:57:08Z,2021-10-25T08:57:08Z,16
NCT04889209,"ClinicalTrials.gov processed this data on October 22, 2021",2021-05-13,NA,NA,2021-10-21,2021-05-13,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-22,Estimate,"May 28, 2021",Actual,2021-05-28,"September 7, 2021",2021-09-07,"December 1, 2022",Anticipated,2022-12-01,"December 1, 2022",Anticipated,2022-12-01,NA,Interventional,NA,,Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines,A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines,Recruiting,NA,Phase 1/Phase 2,950,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,15,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-25T08:58:22Z,2021-10-25T08:58:22Z,9
NCT05091411,"ClinicalTrials.gov processed this data on October 25, 2021",2021-10-12,NA,NA,2021-10-12,2021-10-12,2021-10-25,Estimate,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-25,Estimate,"September 9, 2021",Actual,2021-09-09,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells),"Randomized, Double-blind, Parallel-controlled Evaluation of the Immunogenicity Consistency and Safety of the Three Batches of Recombinant Novel Coronavirus Vaccine (CHO Cells) After Process Verification in the 18-59-year-old Population, and the Comparison With the Pilot-scale Batch Immunogenicity Non-inferiority Bridging and Safety Clinical Trials",Recruiting,NA,Phase 3,1680,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-26T08:50:48Z,2021-10-26T08:50:48Z,18
NCT05069129,"ClinicalTrials.gov processed this data on October 25, 2021",2021-10-03,NA,NA,2021-10-17,2021-10-05,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-17,2021-10-25,Estimate,"October 14, 2021",Actual,2021-10-14,October 2021,2021-10-31,February 2024,Anticipated,2024-02-29,December 2023,Anticipated,2023-12-31,NA,Interventional,NA,,"Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above","A Randomized, Controlled Phase I and Sequential Study to Evaluate the Safety and Immunogenicity Following Immunization of GEN2-Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above",Recruiting,NA,Phase 1/Phase 2,1848,Anticipated,"National Vaccine and Serum Institute, China",,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-26T08:52:02Z,2021-10-26T08:52:02Z,13
NCT04860297,"ClinicalTrials.gov processed this data on October 25, 2021",2021-04-21,NA,NA,2021-10-15,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-15,2021-10-25,Estimate,"April 16, 2021",Actual,2021-04-16,October 2021,2021-10-31,"March 31, 2023",Anticipated,2023-03-31,"March 31, 2023",Anticipated,2023-03-31,NA,Interventional,NA,,A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants,"A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls",Recruiting,NA,Phase 3,240,Anticipated,"ModernaTX, Inc.",,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-26T08:53:57Z,2021-10-26T08:53:57Z,15
NCT04852978,"ClinicalTrials.gov processed this data on October 25, 2021",2021-04-19,NA,NA,2021-10-22,2021-04-19,2021-04-21,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-25,Estimate,"April 29, 2021",Actual,2021-04-29,October 2021,2021-10-31,"November 22, 2022",Anticipated,2022-11-22,"December 29, 2021",Anticipated,2021-12-29,NA,Interventional,NA,,"COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers",Recruiting,NA,Phase 2,286,Anticipated,Regeneron Pharmaceuticals,,12,NA,NA,TRUE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,"When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf,https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2021-10-26T08:54:01Z,2021-10-26T08:54:01Z,8
NCT05054621,"ClinicalTrials.gov processed this data on October 26, 2021",2021-09-13,NA,NA,2021-10-19,2021-09-22,2021-09-23,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-26,Estimate,"September 15, 2021",Actual,2021-09-15,August 2021,2021-08-31,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Interventional,NA,,Immunogenicity of COVID-19 Vaccine on Heterologous Schedule,"A Single-blind, Randomized Study to Evaluate the Immunogenicity of Heterologous Prime-boost COVID-19 Vaccine Schedule",Recruiting,NA,Phase 2,110,Anticipated,Chang Gung Memorial Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-27T11:14:12Z,2021-10-27T11:14:12Z,11
NCT05037201,"ClinicalTrials.gov processed this data on October 26, 2021",2021-09-07,NA,NA,2021-10-21,2021-09-07,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-26,Estimate,"October 11, 2021",Actual,2021-10-11,October 2021,2021-10-31,"November 8, 2021",Anticipated,2021-11-08,"October 25, 2021",Anticipated,2021-10-25,NA,Interventional,NA,,Text Message Nudges for COVID-19 Vaccination,A Randomized Trial of Text Message-Based Nudges to Increase COVID-19 Vaccination,"Active, not recruiting",NA,N/A,2000,Actual,Ascension South East Michigan,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Individual patient data will not be shared,2021-10-27T11:14:26Z,2021-10-27T11:14:26Z,9
NCT04969250,"ClinicalTrials.gov processed this data on October 26, 2021",2021-07-16,NA,NA,2021-10-22,2021-07-16,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-22,2021-10-26,Estimate,"August 25, 2021",Actual,2021-08-25,October 2021,2021-10-31,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Interventional,NA,,Vaccination for Recovered Inpatients With COVID-19 (VATICO),SARS-CoV-2 Vaccination Strategies in Previously Hospitalized and Recovered COVID-19 Patients,Recruiting,NA,Phase 4,640,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-27T11:15:18Z,2021-10-27T11:15:18Z,8
NCT04642638,"ClinicalTrials.gov processed this data on October 26, 2021",2020-11-23,NA,NA,2021-10-18,2020-11-23,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-18,2021-10-26,Estimate,"November 30, 2020",Actual,2020-11-30,October 2021,2021-10-31,January 2023,Anticipated,2023-01-31,January 2023,Anticipated,2023-01-31,NA,Interventional,NA,,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure","Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure","Active, not recruiting",NA,Phase 2/Phase 3,7517,Anticipated,Inovio Pharmaceuticals,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-10-27T11:17:49Z,2021-10-27T11:17:49Z,12
NCT05096845,"ClinicalTrials.gov processed this data on October 27, 2021",2021-10-21,NA,NA,2021-10-25,2021-10-25,2021-10-27,Estimate,NA,NA,NA,NA,NA,NA,2021-10-25,2021-10-27,Estimate,"August 25, 2021",Actual,2021-08-25,October 2021,2021-10-31,"April 22, 2023",Anticipated,2023-04-22,"March 2, 2023",Anticipated,2023-03-02,NA,Interventional,COVID-19,,Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III,"A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Adults Aged 18 Years and Older",Recruiting,NA,Phase 3,22500,Anticipated,Livzon Pharmaceutical Group Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-28T09:06:07Z,2021-10-28T09:06:07Z,5
NCT05096026,"ClinicalTrials.gov processed this data on October 27, 2021",2021-10-25,NA,NA,2021-10-26,2021-10-26,2021-10-27,Estimate,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"March 29, 2021",Actual,2021-03-29,October 2021,2021-10-31,"August 31, 2021",Actual,2021-08-31,"May 20, 2021",Actual,2021-05-20,NA,Interventional,NA,,Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination Among Elderly Patients,Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination Among Elderly Patients,Completed,NA,N/A,8287,Actual,Kaiser Permanente,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"December 1, 2022 through December 1, 2024","Deidentified data will be shared on submission of a protocol approved by the Kaiser Permanente Northern California Institutional Review Board or Research Determination Official, and contingent on appropriate data sharing agreement being completed.",NA,Yes,"Deidentified data will be shared on submission of a protocol approved by the Kaiser Permanente Northern California Institutional Review Board or Research Determination Official, and contingent on appropriate data sharing agreement being completed.",2021-10-28T09:06:47Z,2021-10-28T09:06:47Z,4
NCT04960228,"ClinicalTrials.gov processed this data on October 27, 2021",2021-06-30,NA,NA,2021-10-26,2021-07-09,2021-07-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"July 30, 2021",Actual,2021-07-30,October 2021,2021-10-31,"September 13, 2021",Actual,2021-09-13,"September 13, 2021",Actual,2021-09-13,NA,Interventional,NA,,Exploring Changes in COVID-19 Vaccination Intentions by Prompting Altruistic Motives Using a Video Intervention,Enhancing COVID-19 Vaccination Intentions by Eliciting Prosocial Altruistic Motives: Evaluating the Efficacy of a Brief Video-Based Intervention,Completed,NA,N/A,1623,Actual,Sir Mortimer B. Davis - Jewish General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Consent form, data collection method, and organizational policy means only aggregated data will be shared with other researchers.",2021-10-28T09:09:49Z,2021-10-28T09:09:49Z,4
NCT04952402,"ClinicalTrials.gov processed this data on October 27, 2021",2021-06-28,NA,NA,2021-10-26,2021-07-02,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"July 16, 2021",Actual,2021-07-16,October 2021,2021-10-31,June 2023,Anticipated,2023-06-30,June 2023,Anticipated,2023-06-30,NA,Interventional,NA,,SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine,SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine,Recruiting,NA,Phase 4,700,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",NA,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2021-10-28T09:09:52Z,2021-10-28T09:09:52Z,4
NCT04839042,"ClinicalTrials.gov processed this data on October 27, 2021",2021-04-07,NA,NA,2021-10-19,2021-04-07,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-19,2021-10-27,Estimate,"June 28, 2021",Actual,2021-06-28,October 2021,2021-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,"A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers","A Phase 1, First-In-Human, Open-label, Single Ascending Dose and Multidose Study to Assess the Safety, Reactogenicity, and Immunogenicity of the Adenovirus Vector SARS-CoV-2 Investigational Product SC-Ad6-1 Given Via Intramuscular or Intranasal Administration in Healthy Volunteers",Recruiting,NA,Phase 1,100,Anticipated,Tetherex Pharmaceuticals Corporation,,10,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2021-10-28T09:11:01Z,2021-10-28T09:11:01Z,11
NCT04535453,"ClinicalTrials.gov processed this data on October 27, 2021",2020-08-27,NA,NA,2021-10-26,2020-08-27,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"August 28, 2020",Actual,2020-08-28,October 2021,2021-10-31,"March 28, 2022",Anticipated,2022-03-28,"December 15, 2021",Anticipated,2021-12-15,NA,Interventional,NA,,A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents,"A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older and to Evaluate 2 Dose Levels of Ad26.COV2.S in Healthy Adolescents Aged 12 to 17 Years Inclusive","Active, not recruiting",NA,Phase 2,635,Actual,Janssen Vaccines & Prevention B.V.,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-10-28T09:12:57Z,2021-10-28T09:12:57Z,4
NCT04449276,"ClinicalTrials.gov processed this data on October 27, 2021",2020-06-18,NA,NA,2021-10-26,2020-06-23,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-26,2021-10-27,Estimate,"June 18, 2020",Actual,2020-06-18,July 2021,2021-07-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose Escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults","Active, not recruiting",NA,Phase 1,280,Actual,CureVac AG,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-28T09:13:43Z,2021-10-28T09:13:43Z,4
NCT04368728,"ClinicalTrials.gov processed this data on October 27, 2021",2020-04-27,NA,NA,2021-10-20,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-27,Estimate,"April 29, 2020",Actual,2020-04-29,October 2021,2021-10-31,"May 2, 2023",Anticipated,2023-05-02,"May 2, 2023",Anticipated,2023-05-02,NA,Interventional,NA,,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS",Recruiting,NA,Phase 3,43998,Anticipated,BioNTech SE,,20,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-28T09:14:20Z,2021-10-28T09:14:20Z,10
NCT05077176,"ClinicalTrials.gov processed this data on October 28, 2021",2021-10-13,NA,NA,2021-10-20,2021-10-13,2021-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"October 8, 2021",Actual,2021-10-08,October 2021,2021-10-31,"October 5, 2022",Anticipated,2022-10-05,"April 5, 2022",Anticipated,2022-04-05,NA,Interventional,NA,,Phase 3 Booster Vaccination Against SARS-CoV-2,"Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2",Recruiting,NA,Phase 3,7400,Anticipated,Health Institutes of Turkey,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-29T09:10:10Z,2021-10-29T09:10:10Z,10
NCT04999111,"ClinicalTrials.gov processed this data on October 28, 2021",2021-08-03,NA,NA,2021-10-20,2021-08-03,2021-08-10,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"August 6, 2021",Actual,2021-08-06,October 2021,2021-10-31,"March 2, 2022",Anticipated,2022-03-02,"October 22, 2021",Anticipated,2021-10-22,NA,Interventional,NA,,A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2,"A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Ad26.COV2.S Administered as Booster Vaccination in Adults 18 Years of Age and Older Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2",Recruiting,NA,Phase 2,1540,Anticipated,Janssen Vaccines & Prevention B.V.,,6,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2021-10-29T09:11:21Z,2021-10-29T09:11:21Z,10
NCT05069623,"ClinicalTrials.gov processed this data on October 28, 2021",2021-10-04,NA,NA,2021-10-27,2021-10-04,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"October 27, 2021",Anticipated,2021-10-27,October 2021,2021-10-31,October 2023,Anticipated,2023-10-31,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,,A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers,"A Phase 1/2, Open Label, Dose Escalation Study to Determine Safety and Immunogenicity of Two (Prophylactic) COVID 19 DNA Vaccine Candidates (VB10.2129 [C1], a RBD Candidate and VB10.2210 [C2], a T Cell Candidate), in Healthy Adult Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Vaccibody AS,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 25 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2021-10-29T09:10:21Z,2021-10-29T09:10:21Z,3
NCT04956224,"ClinicalTrials.gov processed this data on October 28, 2021",2021-06-21,NA,NA,2021-10-20,2021-06-29,2021-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"August 9, 2021",Actual,2021-08-09,October 2021,2021-10-31,March 2023,Anticipated,2023-03-31,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,Immunogenicity of VLA2101 Compared to VLA2001.,"A Randomized, Observer-Blind, Controlled, Non-Inferiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2101 Vaccine To VLA2001 Vaccine, In Volunteers Aged â‰¥12 Years.","Active, not recruiting",NA,Phase 3,900,Anticipated,Valneva Austria GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-29T09:11:47Z,2021-10-29T09:11:47Z,10
NCT04955626,"ClinicalTrials.gov processed this data on October 28, 2021",2021-06-09,NA,NA,2021-10-27,2021-06-29,2021-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"July 1, 2021",Actual,2021-07-01,October 2021,2021-10-31,"August 9, 2022",Anticipated,2022-08-09,"June 17, 2022",Anticipated,2022-06-17,NA,Interventional,NA,,Study to Evaluate the Safety and Efficacy of a Booster Dose of BNT162b2 Against COVID-19 in Participants â‰¥16 Years of Age.,A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2,Recruiting,NA,Phase 3,10000,Anticipated,BioNTech SE,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-29T09:11:48Z,2021-10-29T09:11:48Z,3
NCT04773067,"ClinicalTrials.gov processed this data on October 28, 2021",2021-02-23,NA,NA,2021-10-20,2021-02-24,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-20,2021-10-28,Estimate,"January 30, 2021",Actual,2021-01-30,September 2021,2021-09-30,"June 30, 2022",Anticipated,2022-06-30,"June 27, 2021",Actual,2021-06-27,NA,Interventional,NA,,"A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers","A Phase II, Placebo-controlled, Randomized, Observer-blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of UB-612 Vaccine Against COVID-19 in Adolescent, Younger and Elderly Adult Volunteers",Recruiting,NA,Phase 2,3850,Anticipated,"United Biomedical Inc., Asia",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-29T09:13:13Z,2021-10-29T09:13:13Z,10
NCT04756271,"ClinicalTrials.gov processed this data on October 28, 2021",2021-02-13,NA,NA,2021-10-21,2021-02-15,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-21,2021-10-28,Estimate,"February 11, 2021",Actual,2021-02-11,October 2021,2021-10-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection,Safety and Immunogenicity of Oxford AstraZeneca Vaccine in Zagazig University Hospital Health-care Workers,Recruiting,NA,Phase 3,140,Anticipated,Zagazig University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-29T09:13:17Z,2021-10-29T09:13:17Z,9
NCT04754594,"ClinicalTrials.gov processed this data on October 28, 2021",2021-02-09,NA,NA,2021-10-27,2021-02-11,2021-02-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-27,2021-10-28,Estimate,"February 16, 2021",Actual,2021-02-16,October 2021,2021-10-31,"October 15, 2022",Anticipated,2022-10-15,"October 15, 2022",Anticipated,2022-10-15,NA,Interventional,NA,,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older","A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER",Recruiting,NA,Phase 3,700,Anticipated,BioNTech SE,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-29T09:13:18Z,2021-10-29T09:13:18Z,3
NCT05079152,"ClinicalTrials.gov processed this data on October 15, 2021",2021-10-05,NA,NA,2021-10-05,2021-10-05,2021-10-15,Estimate,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-15,Estimate,"May 6, 2021",Actual,2021-05-06,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,"May 29, 2021",Actual,2021-05-29,NA,Interventional,NA,,Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4,"A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Inactivated SARS-CoV-2 Vaccines (Vero Cell) (COVAX) (Produced in Wuhan) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) or Quadrivalent Inactivated Influenza Vaccine (IIV4)","Active, not recruiting",NA,Phase 4,1404,Actual,China National Biotec Group Company Limited,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:40:12Z,2021-10-17T06:40:12Z,25
NCT05075499,"ClinicalTrials.gov processed this data on October 15, 2021",2021-10-06,NA,NA,2021-10-06,2021-10-06,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-12,Actual,"March 20, 2021",Actual,2021-03-20,October 2021,2021-10-31,September 2022,Anticipated,2022-09-30,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab,LONGEVITY OF IMMUNE RESPONSE TO COVID-19 VACCINE IN VACCINATED MULTIPLE SCLEROSIS PATIENTS TREATED WITH TERIFLUNOMIDE (AUBAGIO) OR ALEMTUZUMAB (LEMTRADA),Recruiting,NA,N/A,70,Anticipated,Sheba Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:40:51Z,2021-10-17T06:40:51Z,24
NCT05074368,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-24,NA,NA,2021-10-05,2021-10-05,2021-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-12,Actual,"July 6, 2021",Actual,2021-07-06,October 2021,2021-10-31,"June 30, 2022",Anticipated,2022-06-30,"November 19, 2021",Anticipated,2021-11-19,NA,Interventional,NA,,Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination,Comparative Analysis of Neutralizing Antibody Response Among Heterologous ChAdOx1-nCov-19/mRNA-1273 Vaccination and Homologous ChAdOx1-nCov-19 or Homologous mRNA-1273 Vaccination,"Active, not recruiting",NA,N/A,500,Anticipated,National Taiwan University Hospital,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:41:01Z,2021-10-17T06:41:01Z,25
NCT05069649,"ClinicalTrials.gov processed this data on October 15, 2021",2021-10-04,NA,NA,2021-10-07,2021-10-04,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-07,2021-10-14,Actual,"October 6, 2021",Actual,2021-10-06,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,,Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2,"Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Ergoferon as Non-specific COVID-19 Prevention During Vaccination Against SARS-CoV-2",Recruiting,NA,Phase 3,3600,Anticipated,Materia Medica Holding,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:41:43Z,2021-10-17T06:41:43Z,23
NCT05069454,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-10,NA,NA,2021-10-05,2021-10-05,2021-10-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"May 10, 2021",Actual,2021-05-10,July 2021,2021-07-31,"July 20, 2022",Anticipated,2022-07-20,"May 20, 2022",Anticipated,2022-05-20,NA,Interventional,VaccEffect,,Study on COVID-19 Vaccine Effectiveness Among Health Workers in Azerbaijan,Cohort Study to Measure COVID-19 Vaccine Effectiveness Among Health Workers in Azerbaijan,Recruiting,NA,N/A,1500,Anticipated,Public health and reforms Center of Ministry of Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T06:41:45Z,2021-10-17T06:41:45Z,25
NCT05067933,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-16,NA,NA,2021-10-01,2021-10-01,2021-10-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-05,Actual,October 2021,Anticipated,2021-10-31,October 2021,2021-10-31,June 2023,Anticipated,2023-06-30,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,,A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine,"A Phase 2, Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety, Immunogenicity and Efficacy of an Adenoviral-Vector Based Vaccine Expressing Severe Acute Respiratory Syndrome (SARS-CoV-2) and dsRNA Adjuvant Administered Orally",Recruiting,NA,Phase 2,896,Anticipated,Vaxart,,10,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:41:57Z,2021-10-17T06:41:57Z,29
NCT05060939,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-28,NA,NA,2021-09-28,2021-09-28,2021-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-29,Actual,"July 30, 2021",Actual,2021-07-30,September 2021,2021-09-30,"July 30, 2023",Anticipated,2023-07-30,"July 30, 2022",Anticipated,2022-07-30,NA,Interventional,COVID-IVAC,,SARS-CoV-2 Infection in COVID-19 Vaccinated Patients,Characterization of the Viral Genome and Humoral Immune Response in COVID-19 Vaccinated Patients With SARS-CoV-2 Infection,Recruiting,NA,N/A,5000,Anticipated,Hospices Civils de Lyon,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:42:53Z,2021-10-17T06:42:53Z,32
NCT05060991,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-24,NA,NA,2021-09-27,2021-09-27,2021-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"September 24, 2021",Actual,2021-09-24,September 2021,2021-09-30,"September 24, 2022",Anticipated,2022-09-24,"December 24, 2021",Anticipated,2021-12-24,NA,Interventional,ADIVKT,,Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients,Impact of Immunosuppression Adjustment on the Immune Response to SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients (ADIVKT),Recruiting,NA,Phase 4,50,Anticipated,"University of California, Davis",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T06:42:52Z,2021-10-17T06:42:52Z,33
NCT05059106,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-24,NA,NA,2021-09-24,2021-09-24,2021-09-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-28,Actual,"June 1, 2021",Actual,2021-06-01,September 2021,2021-09-30,"October 30, 2022",Anticipated,2022-10-30,"June 1, 2022",Anticipated,2022-06-01,NA,Interventional,NA,,"EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19","EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19",Recruiting,NA,Phase 2/Phase 3,29637,Anticipated,Federal University of Espirito Santo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:43:07Z,2021-10-17T06:43:07Z,36
NCT05057923,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-21,NA,NA,2021-09-23,2021-09-23,2021-09-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-27,Actual,"July 10, 2021",Actual,2021-07-10,September 2021,2021-09-30,"November 1, 2021",Anticipated,2021-11-01,"October 20, 2021",Anticipated,2021-10-20,NA,Interventional,NA,,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores,The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores Expressing and Displaying the Receptor Binding Domain of Spike Protein of SARS-COV2,Recruiting,NA,N/A,30,Anticipated,DreamTec Research Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:43:17Z,2021-10-17T06:43:17Z,37
NCT05057182,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-24,NA,NA,2021-09-24,2021-09-24,2021-09-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-27,Actual,"September 27, 2021",Anticipated,2021-09-27,September 2021,2021-09-30,"December 31, 2023",Anticipated,2023-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,,Third Dose of mRNA Vaccination to Boost COVID-19 Immunity,"mRNA Vaccination to Boost Antibodies Against SARS-CoV-2 in Recipients of Inactivated Vaccines (the ""mBoost"" Study)",Recruiting,NA,Phase 4,100,Anticipated,The University of Hong Kong,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2021-10-17T06:43:23Z,2021-10-17T06:43:23Z,36
NCT05050474,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-13,NA,NA,2021-09-13,2021-09-13,2021-09-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-20,Actual,"August 7, 2021",Actual,2021-08-07,September 2021,2021-09-30,"February 3, 2022",Anticipated,2022-02-03,"August 23, 2021",Actual,2021-08-23,NA,Interventional,NA,,Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01),A Clinical Study to Evaluate the Immunogenicity and Safety of the Third Dose Booster Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Participants,"Active, not recruiting",NA,Phase 1,43,Actual,Livzon Pharmaceutical Group Inc.,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:44:15Z,2021-10-17T06:44:15Z,47
NCT05048849,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-03,NA,NA,2021-10-05,2021-09-15,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"July 19, 2021",Actual,2021-07-19,September 2021,2021-09-30,March 2022,Anticipated,2022-03-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study","A Phase II, Prospective, Open-Label, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Extension Study","Active, not recruiting",NA,Phase 2,500,Anticipated,Medigen Vaccine Biologics Corp.,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:44:29Z,2021-10-17T06:44:29Z,25
NCT05047692,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-14,NA,NA,2021-09-14,2021-09-14,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-17,Actual,"September 9, 2021",Actual,2021-09-09,September 2021,2021-09-30,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,,Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers,"A Dose Escalation, Multicenter, Open, Phase I Study to Assess the Safety and Immunogenicity of AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers.",Recruiting,NA,Phase 1,40,Anticipated,"Cellid Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:44:38Z,2021-10-17T06:44:38Z,46
NCT05047445,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-27,NA,NA,2021-10-06,2021-09-16,2021-09-17,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-14,Actual,"September 30, 2021",Actual,2021-09-30,October 2021,2021-10-31,June 2022,Anticipated,2022-06-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,A First Time in Human Phase 1 Open-Label Study of the COVIDITY Vaccine Administered by Needle-free Injection,"A First Time in Human Phase 1 Open-Label Study of the Safety, Tolerability, and Immunogenicity of COVIDITY Vaccine Administered by Needle-free Intradermal Injection or Needle-free Intramuscular Injection in Healthy Adults (COVIDITY-001)",Recruiting,NA,Phase 1,40,Anticipated,Scancell Ltd,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is not a plan to make individual patient data available.,2021-10-17T06:44:40Z,2021-10-17T06:44:40Z,24
NCT05046548,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-26,NA,NA,2021-09-13,2021-09-13,2021-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-16,Actual,"October 3, 2020",Actual,2020-10-03,September 2021,2021-09-30,October 2021,Anticipated,2021-10-31,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,,"This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19","Double-blind, Placebo-controlled, Randomized Study of Tolerability, Safety and Immunogenicity of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine, Produced by FSBSI ""Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products"", on Volunteers at the Age of 18-60 Years","Active, not recruiting",NA,Phase 1/Phase 2,400,Actual,Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:44:49Z,2021-10-17T06:44:49Z,47
NCT05043259,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-13,NA,NA,2021-09-15,2021-09-13,2021-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"September 13, 2021",Actual,2021-09-13,September 2021,2021-09-30,"May 1, 2022",Anticipated,2022-05-01,"October 13, 2021",Anticipated,2021-10-13,NA,Interventional,NA,,Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming With an Inactivated SARS-CoV-2 Vaccine,"Immunogenicity and Safety of the Heterologous Prime-boost Immunization With an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Two-dose Priming With an Inactivated SARS-CoV-2 Vaccine in Adults at 18 Years of Age or Above: a Randomised, Open-label, Parallel-controlled Clinical Trial",Recruiting,NA,Phase 1/Phase 2,420,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:45:16Z,2021-10-17T06:45:16Z,45
NCT05037266,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-06,NA,NA,2021-09-23,2021-09-06,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-24,Actual,"September 20, 2021",Actual,2021-09-20,September 2021,2021-09-30,"October 31, 2023",Anticipated,2023-10-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,CoviCompare_J,,Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen,Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen,Recruiting,NA,Phase 4,120,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:46:07Z,2021-10-17T06:46:07Z,37
NCT05038618,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-25,NA,NA,2021-10-05,2021-08-31,2021-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"August 2, 2021",Actual,2021-08-02,October 2021,2021-10-31,February 2022,Anticipated,2022-02-28,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,"A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study","A Phase II, Prospective, Open-Label, Single-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Sub-study","Active, not recruiting",NA,Phase 2,400,Anticipated,Medigen Vaccine Biologics Corp.,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:45:55Z,2021-10-17T06:45:55Z,25
NCT05037097,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-30,NA,NA,2021-09-03,2021-09-03,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-03,2021-09-08,Actual,"August 30, 2021",Actual,2021-08-30,September 2021,2021-09-30,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,NA,,A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults,"A Phase 1/2 Randomized, Observer-Blind Study of the Safety, Reactogenicity, and Immunogenicity of 3 SARS-CoV-2 RNA Vaccine Candidates in Adults Previously Vaccinated and Not Previously Vaccinated Against SARS-CoV-2",Recruiting,NA,Phase 1/Phase 2,72,Anticipated,"Arcturus Therapeutics, Inc.",,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Individual participant data will only be made available to study investigators at this time.,2021-10-17T06:46:08Z,2021-10-17T06:46:08Z,57
NCT05037188,"ClinicalTrials.gov processed this data on October 15, 2021",2021-09-07,NA,NA,2021-09-07,2021-09-07,2021-09-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"August 10, 2021",Actual,2021-08-10,September 2021,2021-09-30,December 2022,Anticipated,2022-12-31,August 2022,Anticipated,2022-08-31,NA,Interventional,COVER,,Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19),"A Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless Phase I / II Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5-RBD-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Biocad,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:46:07Z,2021-10-17T06:46:07Z,53
NCT05033860,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-30,NA,NA,2021-09-01,2021-09-01,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-05,Actual,"August 18, 2021",Actual,2021-08-18,August 2021,2021-08-31,"September 20, 2021",Anticipated,2021-09-20,"September 20, 2021",Anticipated,2021-09-20,NA,Interventional,NA,,The Influence of Education During Waiting Time of Vaccination on the Knowledge Towards COVID-19 Among Chinese Residents,The Influence of Education During Waiting Time of Vaccination on the Knowledge Towards COVID-19 Among Chinese Residents: A Randomized Controlled Trial,Recruiting,NA,N/A,312,Anticipated,Ningbo No. 1 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:46:34Z,2021-10-17T06:46:34Z,59
NCT05033158,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-02,NA,NA,2021-08-31,2021-08-31,2021-09-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-02,Actual,"April 1, 2021",Actual,2021-04-01,April 2021,2021-04-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,REAL-V,,The Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population.,Investigation to Reveal the Immune Reaction Upon COVID-19 Vaccination in the Belgian Cancer Population: COVID-19 Protection and Vaccine Safety (REAL-V),Recruiting,NA,N/A,3000,Anticipated,"University Hospital, Antwerp",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:46:40Z,2021-10-17T06:46:40Z,60
NCT05033847,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-30,NA,NA,2021-10-08,2021-09-01,2021-09-05,Actual,NA,NA,NA,NA,NA,NA,2021-10-08,2021-10-15,Estimate,"September 12, 2021",Actual,2021-09-12,October 2021,2021-10-31,January 2024,Anticipated,2024-01-31,November 2023,Anticipated,2023-11-30,NA,Interventional,NA,,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above,Recruiting,NA,Phase 3,1800,Anticipated,"National Vaccine and Serum Institute, China",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:46:34Z,2021-10-17T06:46:34Z,22
NCT05028374,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-23,NA,NA,2021-08-29,2021-08-29,2021-08-31,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-08-31,Actual,"August 17, 2021",Actual,2021-08-17,August 2021,2021-08-31,"January 31, 2023",Anticipated,2023-01-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,NA,,COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies,Phase II Trial Evaluating the Efficacy of Moderna COVID-19 Vaccine Booster Dosing in Patients With Hematologic Malignancies Who Did Not Have an Adequate Response to Prior Vaccination,Recruiting,NA,Phase 2,171,Anticipated,Barbara Ann Karmanos Cancer Institute,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T06:47:19Z,2021-10-17T06:47:19Z,62
NCT05027672,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-18,NA,NA,2021-08-24,2021-08-24,2021-08-30,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-30,Actual,"July 30, 2021",Actual,2021-07-30,August 2021,2021-08-31,"September 6, 2021",Anticipated,2021-09-06,"August 30, 2021",Anticipated,2021-08-30,NA,Interventional,NA,,Strategies for Combining the First Component of Sputnik V With Other Adenoviral or mRNA-based Vaccines.,"Randomised Phase II Study to Assess the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schedules (rAd26-rAd5, rAd26-rAd26, rAd26-ChAdOx1 and rAd26-mRNA-1273).","Active, not recruiting",NA,Phase 2,348,Actual,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T06:47:24Z,2021-10-17T06:47:24Z,67
NCT05021016,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-19,NA,NA,2021-08-26,2021-08-19,2021-08-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-26,2021-08-27,Actual,"November 19, 2020",Actual,2020-11-19,August 2021,2021-08-31,"January 30, 2021",Actual,2021-01-30,"January 30, 2021",Actual,2021-01-30,NA,Interventional,NA,,Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above,"An Open Study of the Safety, Reactogenicity and Immunogenicity of the Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), With the Involvement of Volunteers Aged 60 Years and Above (Phase III-IV)",Completed,NA,Phase 3,150,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:48:20Z,2021-10-17T06:48:20Z,65
NCT05022329,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-23,NA,NA,2021-10-06,2021-08-25,2021-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-06,2021-10-07,Actual,"September 30, 2021",Actual,2021-09-30,October 2021,2021-10-31,"September 30, 2023",Anticipated,2023-09-30,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,BOOST KIDNEY,,COVID-19 Vaccine Boosters in Patients With CKD,A Multi-Centre 12 Month Parallel-Group Randomized Control Trial of BNT162b2 Versus mRNA( Messenger Ribonucleic Acid) -1273 COVID-19 Vaccine Boosters in Chronic Kidney Disease and Dialysis Patients With Poor Humoral Response Following COVID-19 ( Corona Virus Disease of 2019)Vaccination,Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Sunnybrook Health Sciences Centre,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T06:48:09Z,2021-10-17T06:48:09Z,24
NCT05022472,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-18,NA,NA,2021-08-24,2021-08-24,2021-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"July 16, 2021",Actual,2021-07-16,August 2021,2021-08-31,"January 31, 2026",Anticipated,2026-01-31,July 2022,Anticipated,2022-07-31,NA,Interventional,2VIDA!,,Project 2VIDA! COVID-19 Vaccine Intervention Delivery for Adults in Southern California,Project 2VIDA! SARS-CoV-2 Vaccine Intervention Delivery for Adults in Southern California,Recruiting,NA,Phase 4,1000,Anticipated,"University of California, San Diego",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2021-10-17T06:48:08Z,2021-10-17T06:48:08Z,67
NCT05018078,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-18,NA,NA,2021-09-01,2021-08-20,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-01,2021-09-02,Actual,"August 30, 2021",Actual,2021-08-30,August 2021,2021-08-31,"June 30, 2023",Anticipated,2023-06-30,"December 30, 2022",Anticipated,2022-12-30,NA,Interventional,NA,,Safety and Immunogenicity of COVID-19 Vaccination in Patients With Cancer,The Fifth Medical Center of Chinese PLA General Hospital,Recruiting,NA,N/A,300,Anticipated,Beijing 302 Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:48:43Z,2021-10-17T06:48:43Z,59
NCT05017792,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-23,NA,NA,2021-08-29,2021-08-23,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-09-02,Actual,"August 30, 2021",Anticipated,2021-08-30,August 2021,2021-08-31,"December 31, 2022",Anticipated,2022-12-31,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,NA,,"Evaluation of Clinical and Antibody Response to Covid-19 Vaccination Strategy in TBRI, Egypt","Evaluation of Clinical and Antibody Response to Covid-19 Vaccination Strategy in TBRI, Egypt",Recruiting,NA,Phase 3,200,Anticipated,Theodor Bilharz Research Institute,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T06:48:47Z,2021-10-17T06:48:47Z,62
NCT05017805,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-12,NA,NA,2021-09-12,2021-08-20,2021-08-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-12,2021-09-16,Actual,"August 15, 2021",Actual,2021-08-15,August 2021,2021-08-31,"June 15, 2023",Anticipated,2023-06-15,"December 15, 2022",Anticipated,2022-12-15,NA,Interventional,NA,,COVID-19 Vaccines in Patients With Chronic Liver Disease,Safety and Immunogenicity of COVID-19 Vaccines in Patients With Chronic Liver Disease: A Multi-center Prospective Study,Recruiting,NA,N/A,300,Anticipated,Beijing 302 Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:48:46Z,2021-10-17T06:48:46Z,48
NCT05012800,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-12,NA,NA,2021-08-18,2021-08-18,2021-08-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-19,Actual,"July 28, 2021",Actual,2021-07-28,July 2021,2021-07-31,"September 30, 2022",Anticipated,2022-09-30,"August 31, 2022",Anticipated,2022-08-31,NA,Interventional,NA,,Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults,Safety and Immunogenicity of COVID-19 Vaccine Administered in Older Adults: A Multicenter Prospective Study,Recruiting,NA,Phase 4,300,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2021-10-17T06:49:26Z,2021-10-17T06:49:26Z,73
NCT05007509,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-12,NA,NA,2021-09-22,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-23,Actual,"August 16, 2021",Actual,2021-08-16,September 2021,2021-09-30,September 2022,Anticipated,2022-09-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19),A Phase I/IIa Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers,"Active, not recruiting",NA,Phase 1/Phase 2,30,Anticipated,"Laboratorios Hipra, S.A.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,To be decided,2021-10-17T06:50:13Z,2021-10-17T06:50:13Z,38
NCT05007496,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-11,NA,NA,2021-08-16,2021-08-12,2021-08-16,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-20,Actual,"April 14, 2021",Actual,2021-04-14,August 2021,2021-08-31,"May 31, 2021",Actual,2021-05-31,"May 31, 2021",Actual,2021-05-31,NA,Interventional,NA,,"Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19","Phase II Randomized Double Blind Clinical Trial Three Preventive Vaccine Formulations Consisting of Autologous Dendritic Cells and Lymphocytes Incubated With Different Quantities of Spike Protein Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), in Subjects Not Proven Actively Infected or Never Infected With COVID-19",Completed,NA,Phase 2,145,Actual,"Aivita Biomedical, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T06:50:13Z,2021-10-17T06:50:13Z,75
NCT05005156,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-07,NA,NA,2021-09-14,2021-08-06,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-21,Actual,"June 24, 2021",Actual,2021-06-24,September 2021,2021-09-30,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,COVID-19,,Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older.,"A Randomized, Double-blind, Placebo-controlled, Phase IIb Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One or Two Doses of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years of Age and Older, Living With HIV, on Stable Treatment, and Virologically Suppressed for at Least 6 Months.",Recruiting,NA,Phase 2,876,Anticipated,FundaciÃ³n HuÃ©sped,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:50:32Z,2021-10-17T06:50:32Z,46
NCT05005559,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-11,NA,NA,2021-10-04,2021-08-11,2021-08-13,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"August 7, 2021",Actual,2021-08-07,August 2021,2021-08-31,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2022",Anticipated,2022-03-01,NA,Interventional,NA,,Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"A Phase III, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)","Active, not recruiting",NA,Phase 3,16876,Anticipated,Cinnagen,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:50:29Z,2021-10-17T06:50:29Z,26
NCT05000216,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-06,NA,NA,2021-10-13,2021-08-06,2021-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-13,2021-10-15,Estimate,"August 13, 2021",Actual,2021-08-13,October 2021,2021-10-31,December 2022,Anticipated,2022-12-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,,COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders,Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01),Recruiting,NA,Phase 2,600,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,15,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"On average, within 24 months after database lock for the trial.",Open access.,https://www.immport.org/home,Yes,"The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.",2021-10-17T06:51:13Z,2021-10-17T06:51:13Z,17
NCT04996238,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-05,NA,NA,2021-08-05,2021-08-05,2021-08-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-05,2021-08-09,Actual,"February 11, 2021",Actual,2021-02-11,August 2021,2021-08-31,"January 31, 2022",Anticipated,2022-01-31,"January 31, 2022",Anticipated,2022-01-31,NA,Interventional,COVACC2,,Local and General Immune Response After Coronavirus Disease (COVID-19) Vaccination in Volunteers,COVACC2: Local and General Immune Response After COVID-19 Vaccination in Volunteers,"Active, not recruiting",NA,N/A,300,Anticipated,"University Hospital, Ghent",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:51:45Z,2021-10-17T06:51:45Z,86
NCT04993586,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-30,NA,NA,2021-10-04,2021-08-05,2021-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-06,Actual,"July 29, 2021",Actual,2021-07-29,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"March 26, 2022",Anticipated,2022-03-26,NA,Interventional,NA,,Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose),"A Randomized, Open-label, Uncontrolled, Phase I/II Study to Assess Safety and Immunogenicity of Two or Three Dosing of Intramuscular/Intradermal AG0302-COVID19","Active, not recruiting",NA,Phase 1/Phase 2,400,Anticipated,"AnGes, Inc.",,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:52:09Z,2021-10-17T06:52:09Z,26
NCT04993209,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-03,NA,NA,2021-08-04,2021-08-04,2021-08-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-06,Actual,"July 9, 2021",Actual,2021-07-09,August 2021,2021-08-31,September 2023,Anticipated,2023-09-30,April 2023,Anticipated,2023-04-30,NA,Interventional,ADAPTCOV,,"Clinical Trial of the COVID-19 Vaccine (Recombinant, Inactivated) in Brazil","Phase I/II Double-blind, Randomized, Stepwise, Adaptive, Controlled Clinical Trial to Assess the Safety and Immunogenicity of the COVID-19 Vaccine (Recombinant, Inactivated) in Adults, in Brazil - ADAPTCOV.",Recruiting,NA,Phase 1/Phase 2,5394,Anticipated,Butantan Institute,,32,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:52:12Z,2021-10-17T06:52:12Z,87
NCT04992260,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-03,NA,NA,2021-09-22,2021-08-03,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-24,Actual,"September 10, 2021",Actual,2021-09-10,July 2021,2021-07-31,"April 1, 2023",Anticipated,2023-04-01,"November 25, 2021",Anticipated,2021-11-25,NA,Interventional,NA,,"Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and Adolescents","A Multi-center, Randomized, Double-blind, Placebo-controlled Phase â…¢ Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine(Vero Cell) ,Inactivated in Children and Adolescents Aged 6 Months to 17 Years",Recruiting,NA,Phase 3,14000,Anticipated,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:52:20Z,2021-10-17T06:52:20Z,38
NCT04992182,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-02,NA,NA,2021-08-04,2021-08-04,2021-08-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"July 8, 2021",Actual,2021-07-08,August 2021,2021-08-31,"June 30, 2022",Anticipated,2022-06-30,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,REFUERZO,,"Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster","Reactogenicidad, Seguridad e Inmunogenicidad de Dosis de Refuerzo de Vacunas Contra SARS-CoV-2 en Chile (Estudio REFUERZO)","Active, not recruiting",NA,Phase 2,534,Actual,Universidad del Desarrollo,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,"Owing to data privacy regulations, the individual-level data in this study cannot be shared (Law N19.628).",2021-10-17T06:52:21Z,2021-10-17T06:52:21Z,87
NCT04990544,"ClinicalTrials.gov processed this data on October 15, 2021",2021-08-02,NA,NA,2021-08-02,2021-08-02,2021-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-04,Actual,"July 31, 2021",Actual,2021-07-31,August 2021,2021-08-31,October 2022,Anticipated,2022-10-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell),"A Randomized, Double-blinded, Placebo-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 18 Years and Above",Recruiting,NA,Phase 2,1056,Anticipated,"Shanghai Zerun Biotechnology Co.,Ltd",,8,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T06:52:34Z,2021-10-17T06:52:34Z,89
NCT04988048,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-29,NA,NA,2021-09-24,2021-07-29,2021-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-24,2021-09-29,Actual,"August 3, 2021",Actual,2021-08-03,September 2021,2021-09-30,"February 15, 2022",Anticipated,2022-02-15,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,ECEHeVac,,Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina,Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina,Recruiting,NA,Phase 2,1760,Anticipated,"Ministry of Public Health, Argentina",,14,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:52:56Z,2021-10-17T06:52:56Z,36
NCT04983537,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-28,NA,NA,2021-07-28,2021-07-28,2021-07-30,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"July 26, 2021",Actual,2021-07-26,July 2021,2021-07-31,"September 26, 2021",Anticipated,2021-09-26,"September 26, 2021",Anticipated,2021-09-26,NA,Interventional,NA,,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Recruiting,NA,Phase 2,120,Anticipated,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T06:53:35Z,2021-10-17T06:53:35Z,94
NCT04982068,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-26,NA,NA,2021-07-29,2021-07-27,2021-07-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-29,2021-08-03,Actual,"July 12, 2021",Actual,2021-07-12,July 2021,2021-07-31,October 2022,Anticipated,2022-10-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell),"A Randomized, Double-blinded, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Immunogenicity of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 18 Years and Above",Recruiting,NA,Phase 1,144,Anticipated,"Shanghai Zerun Biotechnology Co.,Ltd",,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:53:50Z,2021-10-17T06:53:50Z,93
NCT04973449,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-02,NA,NA,2021-09-15,2021-07-21,2021-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-22,Actual,"June 27, 2021",Actual,2021-06-27,September 2021,2021-09-30,"June 15, 2022",Anticipated,2022-06-15,"October 8, 2021",Anticipated,2021-10-08,NA,Interventional,AZD2816,,"Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults","A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Adults to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19",Recruiting,NA,Phase 2/Phase 3,2849,Anticipated,AstraZeneca,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
URL:
https://astrazenecagroup-dt.pharmacm.com/DT/Home",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-10-17T06:55:02Z,2021-10-17T06:55:02Z,45
NCT04977479,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-24,NA,NA,2021-09-22,2021-07-24,2021-07-27,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-23,Actual,"September 8, 2021",Actual,2021-09-08,"September 20, 2021",2021-09-20,"December 30, 2022",Anticipated,2022-12-30,"December 30, 2022",Anticipated,2022-12-30,NA,Interventional,NA,,The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose,"A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose",Recruiting,NA,Phase 2,100,Anticipated,National Institutes of Health Clinical Center (CC),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:54:26Z,2021-10-17T06:54:26Z,38
NCT04977024,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-11,NA,NA,2021-09-07,2021-07-22,2021-07-26,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-09,Actual,"October 1, 2021",Anticipated,2021-10-01,September 2021,2021-09-30,"June 1, 2023",Anticipated,2023-06-01,"June 1, 2023",Anticipated,2023-06-01,NA,Interventional,NA,,SARS-CoV-2 Vaccine (COH04S1) Versus Emergency Use Authorization SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients With Blood Cancer,"A Multi-Center, Observer-Blinded, EUA Vaccine-Controlled, Randomized Phase II Study to Evaluate the Biological Activity of COH04S1 (SARS-CoV-2 Vaccine) Compared to EUA SARS-CoV-2 Vaccines in Hematology Patients Who Have Received Cellular Therapy (HCT or CAR-T)",Recruiting,NA,Phase 2,240,Anticipated,City of Hope Medical Center,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T06:54:30Z,2021-10-17T06:54:30Z,53
NCT04967742,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-12,NA,NA,2021-09-27,2021-07-15,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-27,2021-09-29,Actual,"August 5, 2021",Actual,2021-08-05,September 2021,2021-09-30,"December 31, 2021",Anticipated,2021-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,,"A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-Label Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Recruiting,NA,Phase 1,60,Anticipated,"United Biomedical Inc., Asia",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:55:51Z,2021-10-17T06:55:51Z,33
NCT04969276,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-16,NA,NA,2021-09-15,2021-07-16,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"July 16, 2021",Actual,2021-07-16,"September 15, 2021",2021-09-15,"February 2, 2022",Anticipated,2022-02-02,"February 2, 2022",Anticipated,2022-02-02,NA,Interventional,NA,,Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine,"A Phase II, Open-label Study to Assess the Safety and Immunogenicity of FluzoneÂ® High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine",Recruiting,NA,Phase 2,300,Anticipated,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-17T06:55:36Z,2021-10-17T06:55:36Z,45
NCT04969263,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-16,NA,NA,2021-10-04,2021-07-16,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"August 10, 2021",Actual,2021-08-10,October 2021,2021-10-31,October 2022,Anticipated,2022-10-31,November 2021,Anticipated,2021-11-30,NA,Interventional,CPAT,,COVID-19 Protection After Transplant Pilot Study,Immunogenicity of a Third Dose of Either the Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond After Two Previous Doses,"Active, not recruiting",NA,Phase 2,81,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"On average, within 24 months after database lock for the trial.",Open access.,https://www.immport.org/home,Yes,"The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.",2021-10-17T06:55:36Z,2021-10-17T06:55:36Z,26
NCT04967807,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-29,NA,NA,2021-08-09,2021-07-16,2021-07-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-09,2021-08-16,Actual,"August 5, 2021",Actual,2021-08-05,June 2021,2021-06-30,"June 14, 2022",Anticipated,2022-06-14,"June 14, 2022",Anticipated,2022-06-14,NA,Interventional,MYOVAX,,Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study),Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study),Recruiting,NA,N/A,80,Anticipated,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:55:51Z,2021-10-17T06:55:51Z,82
NCT04964154,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-13,NA,NA,2021-07-13,2021-07-13,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-13,2021-07-15,Actual,"February 17, 2021",Actual,2021-02-17,July 2021,2021-07-31,"June 30, 2022",Anticipated,2022-06-30,"March 30, 2022",Anticipated,2022-03-30,NA,Interventional,BRAVE,,Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study,Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans' Perceptions/Beliefs About COVID-19 Testing and Vaccination Study,Recruiting,NA,N/A,4000,Anticipated,North Carolina Central University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:56:20Z,2021-10-17T06:56:20Z,109
NCT04962906,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-08,NA,NA,2021-08-18,2021-07-13,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-08-18,2021-08-20,Actual,"July 5, 2021",Actual,2021-07-05,July 2021,2021-07-31,"August 15, 2021",Actual,2021-08-15,"August 5, 2021",Actual,2021-08-05,NA,Interventional,NA,,Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes,"Randomised Phase II Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes (rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV).",Completed,NA,Phase 2,192,Actual,Ministerio de Salud de Ciudad AutÃ³noma de Buenos Aires,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T06:56:30Z,2021-10-17T06:56:30Z,73
NCT04962893,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-12,NA,NA,2021-10-04,2021-07-14,2021-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-06,Actual,"June 26, 2021",Actual,2021-06-26,July 2021,2021-07-31,September 2022,Anticipated,2022-09-30,December 2021,Anticipated,2021-12-31,NA,Interventional,COVID-19,,Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine,"Phase II Study to Assess the Safety, Efficacy, and Immunogenicity of Authentic SARS-CoV-2 or Alpha Variant Spike Containing VLP Vaccines and Their Combination for the Prevention of COVID-19 in Healthy Adult Volunteers (SAVE STUDY)",Recruiting,NA,Phase 2,330,Anticipated,The Scientific and Technological Research Council of Turkey,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:56:30Z,2021-10-17T06:56:30Z,26
NCT04961541,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-09,NA,NA,2021-10-11,2021-07-09,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-10-11,2021-10-12,Actual,"September 8, 2021",Actual,2021-09-08,October 2021,2021-10-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,,Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine,"A Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a Quadrivalent Hemagglutinin Nanoparticle Influenza and SARS-CoV-2 rS Nanoparticle Combination Vaccine With Matrix M1â„¢ Adjuvant in Healthy Participants â‰¥ 50 to â‰¤ 70 Years of Age","Active, not recruiting",NA,Phase 1/Phase 2,642,Actual,Novavax,,16,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2021-10-17T06:56:40Z,2021-10-17T06:56:40Z,19
NCT04961502,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-04,NA,NA,2021-07-12,2021-07-12,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-14,Actual,"March 11, 2021",Actual,2021-03-11,June 2021,2021-06-30,September 2021,Anticipated,2021-09-30,August 2021,Anticipated,2021-08-31,NA,Interventional,COGEVAX-BIO,,Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions,Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions,Recruiting,NA,N/A,80,Anticipated,GÃ©rond'if,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:56:41Z,2021-10-17T06:56:41Z,110
NCT04962308,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-13,NA,NA,2021-09-22,2021-07-13,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-24,Actual,"June 19, 2021",Actual,2021-06-19,June 2021,2021-06-30,"December 19, 2021",Anticipated,2021-12-19,"August 19, 2021",Actual,2021-08-19,NA,Interventional,NA,,Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults,"An Open-label,Phase â…£ Clinical Trial to Evaluate the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 18 to 59 Years.",Recruiting,NA,Phase 4,1400,Anticipated,"Sinovac Biotech Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:56:34Z,2021-10-17T06:56:34Z,38
NCT04961359,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-08,NA,NA,2021-07-19,2021-07-08,2021-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-23,Actual,"July 3, 2021",Actual,2021-07-03,July 2021,2021-07-31,December 2022,Anticipated,2022-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2ï¼ˆCOVID-19ï¼‰ Phase I Clinical Trial (3~17 Years Old),"A Randomized, Blinded, Placebo-controlled Phase â…  Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age",Recruiting,NA,Phase 1,75,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:56:42Z,2021-10-17T06:56:42Z,103
NCT04954469,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-05,NA,NA,2021-07-07,2021-07-07,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"June 30, 2021",Actual,2021-06-30,July 2021,2021-07-31,"March 31, 2022",Anticipated,2022-03-31,"February 1, 2022",Anticipated,2022-02-01,NA,Interventional,B-pVAC,,B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency,B-pVAC-SARS-CoV-2: Phase I/II Multicenter Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults With Bcell/ Antibody Deficiency,Recruiting,NA,Phase 1/Phase 2,68,Anticipated,University Hospital Tuebingen,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:57:39Z,2021-10-17T06:57:39Z,115
NCT04954287,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-30,NA,NA,2021-09-13,2021-06-30,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-16,Actual,"August 6, 2021",Actual,2021-08-06,September 2021,2021-09-30,November 2022,Anticipated,2022-11-30,December 2021,Anticipated,2021-12-31,NA,Interventional,CVXGA1-001,,Phase 1 Study of Intranasal PIV5-vectored COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults,"A Phase 1 Open-Label, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of Intranasal Parainfluenza Virus Type 5-SARS CoV-2 S Vaccine (CVXGA1) in Healthy Adults Aged 18 to 75 Years",Recruiting,NA,Phase 1,80,Anticipated,CyanVac LLC,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"5 years, beginning as soon as possible (but no later than 12 months) after article publication",Data will be made available to investigators and institutions upon request. Requests should be directed to the CyanVac authors of the publication(s).,NA,Yes,"De-identified IPD underlying the results reported in any published articles (text, tables, figures, appendices) will be shared.",2021-10-17T06:57:40Z,2021-10-17T06:57:40Z,47
NCT04954092,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-05,NA,NA,2021-09-08,2021-07-07,2021-07-08,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-16,Actual,"July 5, 2021",Actual,2021-07-05,September 2021,2021-09-30,"December 31, 2023",Anticipated,2023-12-31,"November 6, 2022",Anticipated,2022-11-06,NA,Interventional,OLSTAD,,Study of Gam-COVID-Vac in Adolescents,"An Open Label Study With an Open Dose Selection Period to Assess the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac, a Combined Vector Vaccine for the Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Virus"", With the Participation of Adolescent Volunteers",Recruiting,NA,Phase 2/Phase 3,3000,Anticipated,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T06:57:42Z,2021-10-17T06:57:42Z,52
NCT04953325,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-05,NA,NA,2021-07-25,2021-07-05,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-25,2021-07-27,Actual,"July 9, 2021",Actual,2021-07-09,July 2021,2021-07-31,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine,Immunogenicity and Safety of an Inactivated COVID-19 Vaccine for Prevention of COVID-19 in Healthy Population Aged 18 Years and Older,Recruiting,NA,Phase 4,270,Anticipated,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:57:50Z,2021-10-17T06:57:50Z,97
NCT04952766,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-16,NA,NA,2021-07-07,2021-07-06,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-13,Actual,"March 29, 2021",Actual,2021-03-29,July 2021,2021-07-31,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,EREVA,,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults,Recruiting,NA,Phase 4,240,Anticipated,Centre Hospitalier RÃ©gional d'OrlÃ©ans,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:57:55Z,2021-10-17T06:57:55Z,115
NCT04952727,"ClinicalTrials.gov processed this data on October 15, 2021",2021-07-03,NA,NA,2021-09-23,2021-07-03,2021-07-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-23,2021-09-29,Actual,"August 26, 2021",Actual,2021-08-26,July 2021,2021-07-31,"May 26, 2022",Anticipated,2022-05-26,"November 26, 2021",Anticipated,2021-11-26,NA,Interventional,NA,,Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults,"Safety and Immunogenicity of Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) inChinese Healthy Adults Aged 60 and Above: a Randomized, Observer-blind,Parallel-controlled Clinical Trial",Recruiting,NA,Phase 4,300,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:57:55Z,2021-10-17T06:57:55Z,37
NCT04951388,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-30,NA,NA,2021-10-05,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"July 22, 2021",Actual,2021-07-22,August 2021,2021-08-31,May 2022,Anticipated,2022-05-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents,"A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents",Recruiting,NA,Phase 2,385,Anticipated,Medigen Vaccine Biologics Corp.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:58:06Z,2021-10-17T06:58:06Z,25
NCT04951323,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-02,NA,NA,2021-10-12,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Actual,"March 22, 2021",Actual,2021-03-22,October 2021,2021-10-31,"January 1, 2023",Anticipated,2023-01-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,,Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo),Impact of the Immune System on Response to COVID-19 Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo),Recruiting,NA,Phase 3,50,Anticipated,University of Liege,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T06:58:06Z,2021-10-17T06:58:06Z,18
NCT04951310,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-16,NA,NA,2021-07-01,2021-07-01,2021-07-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"June 7, 2021",Actual,2021-06-07,July 2021,2021-07-31,"August 14, 2021",Anticipated,2021-08-14,"August 14, 2021",Anticipated,2021-08-14,NA,Interventional,NA,,COVID-19 Vaccinations With a Sweepstakes,COVID-19 Vaccinations With a Sweepstakes,"Active, not recruiting",NA,N/A,3827656,Anticipated,University of Pennsylvania,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:58:06Z,2021-10-17T06:58:06Z,121
NCT04944368,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-19,NA,NA,2021-10-04,2021-06-28,2021-06-29,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-11,Actual,"May 30, 2021",Actual,2021-05-30,October 2021,2021-10-31,"December 15, 2021",Anticipated,2021-12-15,"July 19, 2021",Actual,2021-07-19,NA,Interventional,NA,,Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen),"A Phase II, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)","Active, not recruiting",NA,Phase 2,400,Actual,Cinnagen,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:59:04Z,2021-10-17T06:59:04Z,26
NCT04939519,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-07,NA,NA,2021-08-10,2021-06-23,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-12,Actual,"March 29, 2021",Actual,2021-03-29,August 2021,2021-08-31,"September 22, 2022",Anticipated,2022-09-22,"September 22, 2022",Anticipated,2022-09-22,NA,Interventional,NA,,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers,SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Among Utah Community Health Centers,"Active, not recruiting",NA,N/A,110270,Actual,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:59:44Z,2021-10-17T06:59:44Z,81
NCT04939402,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-22,NA,NA,2021-06-24,2021-06-24,2021-06-25,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-25,Actual,"May 5, 2021",Actual,2021-05-05,April 2021,2021-04-30,June 2022,Anticipated,2022-06-30,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the UZ Brussel Following COVID-19 Vaccination Using an Adenoviral Vector,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following COVID-19 Vaccination Using an Adenoviral Vector,Recruiting,NA,N/A,200,Anticipated,Universitair Ziekenhuis Brussel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T06:59:46Z,2021-10-17T06:59:46Z,128
NCT04936997,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-18,NA,NA,2021-06-24,2021-06-22,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-24,2021-06-28,Actual,"June 7, 2021",Actual,2021-06-07,June 2021,2021-06-30,"September 1, 2021",Anticipated,2021-09-01,"September 1, 2021",Anticipated,2021-09-01,NA,Interventional,NA,,Immune Response to the COVID-19 Vaccine,Immune Response to the COVID-19 Vaccine,Recruiting,NA,Early Phase 1,1000,Anticipated,University of Arizona,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:00:08Z,2021-10-17T07:00:08Z,128
NCT04935528,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-18,NA,NA,2021-06-22,2021-06-22,2021-06-23,Actual,NA,NA,NA,NA,NA,NA,2021-06-22,2021-06-23,Actual,"June 2, 2021",Actual,2021-06-02,June 2021,2021-06-30,"June 2, 2022",Anticipated,2022-06-02,"June 2, 2022",Anticipated,2022-06-02,NA,Interventional,CANSEROVAX,,Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center,Study of Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response Between 1 and 3 Months After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center,Recruiting,NA,N/A,430,Anticipated,Centre Georges Francois Leclerc,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:00:20Z,2021-10-17T07:00:20Z,130
NCT04932824,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-13,NA,NA,2021-06-17,2021-06-17,2021-06-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-21,Actual,"January 19, 2021",Actual,2021-01-19,April 2021,2021-04-30,"September 14, 2023",Anticipated,2023-09-14,"May 31, 2023",Anticipated,2023-05-31,NA,Interventional,NA,,Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.,"A Long-term Follow-up Study to the Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of SCB-2019, a Recombinant SARS-CoV-2 Trimeric S-Protein Subunit Vaccine for COVID-19",Recruiting,NA,Phase 1,150,Anticipated,Clover Biopharmaceuticals AUS Pty Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:00:42Z,2021-10-17T07:00:42Z,135
NCT04930965,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-16,NA,NA,2021-10-12,2021-06-16,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-14,Actual,"October 5, 2021",Actual,2021-10-05,October 2021,2021-10-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,,Impact of LA-CEAL HALT COVID-19 Ambassador Program on Likelihood to Vaccinate,Louisiana Community-Engagement Alliance Against COVID-19 Disparities (LA-CEAL): Impact of HALT COVID Ambassador Program on Likelihood to Vaccinate,Recruiting,NA,N/A,100,Anticipated,Tulane University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:00:59Z,2021-10-17T07:00:59Z,18
NCT04930003,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-22,NA,NA,2021-07-22,2021-06-15,2021-06-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-29,Actual,"June 15, 2021",Actual,2021-06-15,January 2021,2021-01-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,"Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- I Study and Randomized, Open Phase Phase-II Study of QazCoVac-P - COVID-19 Subunit Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder","Active, not recruiting",NA,Phase 1/Phase 2,244,Anticipated,Research Institute for Biological Safety Problems,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:01:07Z,2021-10-17T07:01:07Z,100
NCT04928456,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-11,NA,NA,2021-06-14,2021-06-14,2021-06-16,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-16,Actual,"June 11, 2021",Actual,2021-06-11,June 2021,2021-06-30,"December 30, 2022",Anticipated,2022-12-30,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,NA,,Augmentation of Immune Response to COVID-19 mRNA Vaccination Through OMT With Lymphatic Pumps,Augmentation of Immune Response to COVID-19 mRNA Vaccination Through Osteopathic Manipulative Treatment Including Lymphatic Pumps,Recruiting,NA,N/A,200,Anticipated,Western University of Health Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:01:20Z,2021-10-17T07:01:20Z,138
NCT04927065,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-14,NA,NA,2021-08-27,2021-06-14,2021-06-15,Actual,NA,NA,NA,NA,NA,NA,2021-08-27,2021-09-02,Actual,"May 28, 2021",Actual,2021-05-28,August 2021,2021-08-31,"September 30, 2022",Anticipated,2022-09-30,"June 16, 2022",Anticipated,2022-06-16,NA,Interventional,NA,,A Study to Evaluate the Immunogenicity and Safety of mRNA-1273.211 Vaccine for COVID-19 Variants,A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants,"Active, not recruiting",NA,Phase 2/Phase 3,1768,Actual,"ModernaTX, Inc.",,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:01:32Z,2021-10-17T07:01:32Z,64
NCT04922788,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-08,NA,NA,2021-06-10,2021-06-10,2021-06-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-11,Actual,"June 7, 2021",Actual,2021-06-07,June 2021,2021-06-30,"August 7, 2022",Anticipated,2022-08-07,"July 7, 2022",Anticipated,2022-07-07,NA,Interventional,NA,,"Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19","a Phase 3, Adaptive, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Immunogenicity, and Efficacy of the Nanocovax Vaccine Against COVID-19 in Volunteer Subjects 18 Years of Age and Older.",Recruiting,NA,Phase 3,13000,Anticipated,Nanogen Pharmaceutical Biotechnology Joint Stock Company,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:02:11Z,2021-10-17T07:02:11Z,142
NCT04918940,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-04,NA,NA,2021-06-07,2021-06-07,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-09,Actual,"May 21, 2021",Actual,2021-05-21,May 2021,2021-05-31,"May 21, 2022",Anticipated,2022-05-21,"August 21, 2021",Anticipated,2021-08-21,NA,Interventional,VAXIMAB,,Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma,Post-vaccination Immunization Against SARS-CoV-2 in Patients Undergoing Maintenance With Anti-CD20 Antibodies for Follicular Lymphoma (FL) or Mantle Cell,Recruiting,NA,N/A,40,Anticipated,Centre Henri Becquerel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:02:46Z,2021-10-17T07:02:46Z,145
NCT04918797,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-18,NA,NA,2021-07-01,2021-06-02,2021-06-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-02,Actual,"May 26, 2021",Actual,2021-05-26,July 2021,2021-07-31,"January 25, 2022",Anticipated,2022-01-25,"August 15, 2021",Anticipated,2021-08-15,NA,Interventional,COVAXIN-Peds,,COVAXIN in a Pediatric Cohort,"A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXINÂ®) in Healthy Volunteers Ages â‰¤18 to â‰¥ 2 Years.",Recruiting,NA,Phase 2/Phase 3,525,Anticipated,Bharat Biotech International Limited,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:02:48Z,2021-10-17T07:02:48Z,121
NCT04916886,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-30,NA,NA,2021-06-04,2021-06-04,2021-06-08,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-08,Actual,"June 3, 2021",Actual,2021-06-03,June 2021,2021-06-30,August 2022,Anticipated,2022-08-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,,A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.,To Evaluate the Immunogenicity Bridging Between Different Manufacture Scales and Between Different Lots of Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Population 6-59 Years of Age.,Recruiting,NA,N/A,2016,Anticipated,CanSino Biologics Inc.,,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:03:05Z,2021-10-17T07:03:05Z,148
NCT04915820,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-28,NA,NA,2021-09-10,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-14,Actual,"May 29, 2021",Actual,2021-05-29,September 2021,2021-09-30,"September 9, 2021",Actual,2021-09-09,"September 9, 2021",Actual,2021-09-09,NA,Interventional,NA,,Iron and COVID-19 Vaccine Response,Iron and Vaccine-preventable Viral Disease,Completed,NA,N/A,121,Actual,Jomo Kenyatta University of Agriculture and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:03:14Z,2021-10-17T07:03:14Z,50
NCT04915989,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-03,NA,NA,2021-06-04,2021-06-04,2021-06-07,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"February 16, 2021",Actual,2021-02-16,June 2021,2021-06-30,"March 31, 2022",Anticipated,2022-03-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,NA,,"Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals","A Phase 1, Multicenter, Open-Label, Single Arm Study to Investigate the Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals","Active, not recruiting",NA,Phase 1,30,Actual,"Genexine, Inc.",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:03:13Z,2021-10-17T07:03:13Z,148
NCT04911790,"ClinicalTrials.gov processed this data on October 15, 2021",2021-06-02,NA,NA,2021-09-22,2021-06-02,2021-06-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-24,Actual,"June 5, 2021",Actual,2021-06-05,May 2021,2021-05-31,"December 31, 2022",Anticipated,2022-12-31,"October 5, 2021",Anticipated,2021-10-05,NA,Interventional,NA,,Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults,"Safety Observation of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Population Aged 18 Years and Older: A Multicenter,Open-label Study",Recruiting,NA,Phase 4,121000,Anticipated,"Sinovac Biotech Co., Ltd",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:03:50Z,2021-10-17T07:03:50Z,38
NCT04907331,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-25,NA,NA,2021-09-09,2021-05-25,2021-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-09,2021-09-10,Actual,"May 10, 2021",Actual,2021-05-10,May 2021,2021-05-31,"December 30, 2021",Anticipated,2021-12-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,HeVacc,,Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2,Comparison of Heterologous Vaccination With an Vaxzevria (ChAdOx1-S) Prime and a Comirnaty (BNT162b2) Boost to Homolog Vaccination,Recruiting,NA,Phase 2,3000,Anticipated,Medical University Innsbruck,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:04:28Z,2021-10-17T07:04:28Z,51
NCT04904744,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-25,NA,NA,2021-07-27,2021-05-25,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"May 28, 2021",Actual,2021-05-28,July 2021,2021-07-31,"December 31, 2021",Anticipated,2021-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,,"Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination","Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination","Active, not recruiting",NA,N/A,1235,Actual,"Children's Hospital Medical Center, Cincinnati",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:04:50Z,2021-10-17T07:04:50Z,95
NCT04904549,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-26,NA,NA,2021-10-01,2021-05-26,2021-05-27,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-08,Actual,"May 26, 2021",Actual,2021-05-26,October 2021,2021-10-31,"January 27, 2023",Anticipated,2023-01-27,"January 27, 2023",Anticipated,2023-01-27,NA,Interventional,VAT00008,,Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older,"A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older",Recruiting,NA,Phase 3,21046,Anticipated,Sanofi,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-17T07:04:52Z,2021-10-17T07:04:52Z,29
NCT04900467,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-21,NA,NA,2021-07-31,2021-05-21,2021-05-25,Actual,NA,NA,NA,NA,NA,NA,2021-07-31,2021-08-03,Actual,"May 28, 2021",Actual,2021-05-28,July 2021,2021-07-31,January 2022,Anticipated,2022-01-31,"July 2, 2021",Actual,2021-07-02,NA,Interventional,ARNCOMBI,,Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine,"Multicenter, Randomized, Open-label Trial Comparing the Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine: Non-inferiority Trial","Active, not recruiting",NA,N/A,418,Actual,Assistance Publique - HÃ´pitaux de Paris,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:05:27Z,2021-10-17T07:05:27Z,91
NCT04896788,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-18,NA,NA,2021-05-21,2021-05-19,2021-05-21,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-24,Actual,"May 19, 2021",Actual,2021-05-19,May 2021,2021-05-31,"May 1, 2024",Anticipated,2024-05-01,"November 1, 2023",Anticipated,2023-11-01,NA,Interventional,COVIDIM,,Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff,Monitoring of the Post-vaccination Immune Response to COVID-19 Among Hospital Staff,Recruiting,NA,N/A,300,Anticipated,"University Hospital, Clermont-Ferrand",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:06:02Z,2021-10-17T07:06:02Z,162
NCT04895449,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-24,NA,NA,2021-08-29,2021-05-15,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-29,2021-09-02,Actual,"July 16, 2021",Actual,2021-07-16,August 2021,2021-08-31,"March 1, 2022",Anticipated,2022-03-01,"March 1, 2022",Anticipated,2022-03-01,NA,Interventional,MVA-SARS2-ST,,"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19","A Multi-center, Randomized Controlled, Phase Ib/IIa Trial to Assess the Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST in Adults",Recruiting,NA,Phase 1/Phase 2,240,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:06:13Z,2021-10-17T07:06:13Z,62
NCT04894435,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-18,NA,NA,2021-08-19,2021-05-19,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-25,Actual,"May 20, 2021",Actual,2021-05-20,August 2021,2021-08-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,MOSAIC,,Mix and Match of the Second COVID-19 Vaccine Dose for Safety and Immunogenicity,Immunogenicity and Adverse Events Following Immunization With Alternate Schedules of Authorized COVID-19 Vaccines in Canada: MOSAIC Study (Mix and Match of the Second cOvid-19 Vaccine Dose for SAfety and ImmunogeniCity),Recruiting,NA,Phase 2,1200,Anticipated,Canadian Immunization Research Network,,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:06:21Z,2021-10-17T07:06:21Z,72
NCT04894227,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-10,NA,NA,2021-08-16,2021-05-19,2021-05-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"May 11, 2021",Actual,2021-05-11,May 2021,2021-05-31,"November 30, 2021",Anticipated,2021-11-30,"May 11, 2021",Actual,2021-05-11,NA,Interventional,NA,,Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy Adults,"A Double-blind, Randomized Clinical Trial to Evaluate the Lot-to-lot Consistency, Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVacï¼‰ in Health Adults Aged 26-45 Years","Active, not recruiting",NA,Phase 4,1080,Anticipated,"Sinovac Biotech Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:06:23Z,2021-10-17T07:06:23Z,75
NCT04892459,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-10,NA,NA,2021-06-29,2021-05-16,2021-05-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-29,2021-06-30,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,"December 25, 2021",Anticipated,2021-12-25,"July 25, 2021",Anticipated,2021-07-25,NA,Interventional,NA,,Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector),"Safety and Immunogenicity of Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector) in Chinese Healthy Adults Aged 18-59 Years: a Randomized, Observer-blind, Parallel-controlled Clinical Trial","Active, not recruiting",NA,Phase 4,300,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:06:38Z,2021-10-17T07:06:38Z,123
NCT04889274,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-06,NA,NA,2021-05-14,2021-05-14,2021-05-17,Actual,NA,NA,NA,NA,NA,NA,2021-05-14,2021-05-17,Actual,"May 10, 2021",Actual,2021-05-10,May 2021,2021-05-31,"May 10, 2022",Anticipated,2022-05-10,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,NA,,Investigation of the Effects of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women (DiNOVasc-COVID-19),"A Double-blind, Randomised, Placebo-controlled Parallel Study to Investigate the Effect of Dietary Nitrate and Sex on COVID-19 Vaccine Induced Vascular Dysfunction in Healthy Men and Women",Recruiting,NA,Phase 1,98,Anticipated,Queen Mary University of London,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:07:05Z,2021-10-17T07:07:05Z,169
NCT04885907,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-09,NA,NA,2021-06-03,2021-05-09,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-03,2021-06-07,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,"August 30, 2021",Anticipated,2021-08-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,NA,,Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients,"A Randomised, Blinded, Controlled Trial of a Third Dose of Moderna COVID-19 Vaccine Versus Placebo in Solid Organ Transplant Recipients","Active, not recruiting",NA,Phase 4,120,Actual,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:07:34Z,2021-10-17T07:07:34Z,149
NCT04885764,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-08,NA,NA,2021-05-08,2021-05-08,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-05-08,2021-05-13,Actual,"February 23, 2021",Actual,2021-02-23,May 2021,2021-05-31,"December 1, 2021",Anticipated,2021-12-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,ASU-VAC,,Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University,Profiling Antibody Status and Vaccine Effectiveness in Post Vaccination With SARS CoV2 in Ain Shams University,Recruiting,NA,Phase 2/Phase 3,4000,Anticipated,Ain Shams University,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:07:36Z,2021-10-17T07:07:36Z,175
NCT04885361,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-07,NA,NA,2021-06-08,2021-05-12,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-09,Actual,"May 26, 2021",Actual,2021-05-26,June 2021,2021-06-30,"March 31, 2022",Anticipated,2022-03-31,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,COVEPIT 3,,"To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults","A Randomized, Open Label, Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of OSE-13E, a Multiepitope-based Vaccine Candidate Against COVID-19, in Healthy Adults (COVEPIT-3)",Recruiting,NA,Phase 1,48,Anticipated,OSE Immunotherapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:07:39Z,2021-10-17T07:07:39Z,144
NCT04884685,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-07,NA,NA,2021-09-22,2021-05-07,2021-05-13,Actual,NA,NA,NA,NA,NA,NA,2021-09-22,2021-09-24,Actual,"May 3, 2021",Actual,2021-05-03,May 2021,2021-05-31,"January 3, 2022",Anticipated,2022-01-03,"August 1, 2021",Actual,2021-08-01,NA,Interventional,NA,,Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents,"A Randomized, Double-Blinded, Placebo-Controlled, Phase â…¡b Clinical Trial, to Evaluate the Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Healthy Population Aged From 3 to 17 Years.","Active, not recruiting",NA,Phase 2,500,Anticipated,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:07:46Z,2021-10-17T07:07:46Z,38
NCT04881227,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-10,NA,NA,2021-06-21,2021-05-10,2021-05-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-21,2021-06-22,Actual,"May 25, 2021",Actual,2021-05-25,June 2021,2021-06-30,May 2023,Anticipated,2023-05-31,May 2023,Anticipated,2023-05-31,NA,Interventional,NA,,The Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions in ESPERES Cohort (ESPERES-COVID-19-CHATBOT),The ESPERES Prospective Cohort of Healthcare Workers in France: Study on the Impact of a Chatbot on COVID-19 Vaccine Perceptions and Intentions,Recruiting,NA,N/A,892,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:08:16Z,2021-10-17T07:08:16Z,131
NCT04880174,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-16,NA,NA,2021-05-05,2021-05-05,2021-05-10,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"March 22, 2021",Actual,2021-03-22,April 2021,2021-04-30,March 2022,Anticipated,2022-03-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination,Recruiting,NA,N/A,800,Anticipated,Universitair Ziekenhuis Brussel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:08:25Z,2021-10-17T07:08:25Z,178
NCT04878211,"ClinicalTrials.gov processed this data on October 15, 2021",2021-05-03,NA,NA,2021-08-10,2021-05-06,2021-05-07,Actual,NA,NA,NA,NA,NA,NA,2021-08-10,2021-08-11,Actual,"June 10, 2021",Actual,2021-06-10,August 2021,2021-08-31,"November 18, 2022",Anticipated,2022-11-18,"November 26, 2021",Anticipated,2021-11-26,NA,Interventional,NA,,A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab,An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously,Recruiting,NA,Phase 4,66,Anticipated,Novartis,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.",2021-10-17T07:08:41Z,2021-10-17T07:08:41Z,81
NCT04873128,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-30,NA,NA,2021-06-10,2021-05-04,2021-05-05,Actual,NA,NA,NA,NA,NA,NA,2021-06-10,2021-06-15,Actual,"June 10, 2021",Actual,2021-06-10,June 2021,2021-06-30,"July 1, 2023",Anticipated,2023-07-01,"July 1, 2022",Anticipated,2022-07-01,NA,Interventional,COVID 19-VAC,,Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach,Comparative Genetic and Immune Response Analysis of Different COVID-19 Vaccine Candidates Using Multi-OMICS Approach,Recruiting,NA,N/A,110,Anticipated,University Hospital Tuebingen,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Data will become available after analysis and unlimited.,NA,NA,Yes,The COVID19-VAC study will provide data in a pseudonymised manner to national and international databases set up to increase the diagnostic yield through advanced analysis tools and matchmaking against other cohorts,2021-10-17T07:09:27Z,2021-10-17T07:09:27Z,142
NCT04871737,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-21,NA,NA,2021-05-26,2021-04-30,2021-05-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-26,2021-05-27,Actual,"May 20, 2021",Actual,2021-05-20,May 2021,2021-05-31,June 2022,Anticipated,2022-06-30,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,,Study of a Live rNDV Based Vaccine Against COVID-19,"Dose-escalation, Open-label, Non-randomized Phase I Study to Evaluate the Safety and Immunogenicity of Three Concentrations of a rNDV Vaccine Against SARS-CoV-2 Administered by the Intranasal and Intramuscular Route to Healthy Volunteers",Recruiting,NA,Phase 1,90,Anticipated,"Laboratorio Avi-Mex, S.A. de C.V.",,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:09:39Z,2021-10-17T07:09:39Z,157
NCT04870593,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-28,NA,NA,2021-06-20,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-20,2021-06-23,Actual,"April 17, 2021",Actual,2021-04-17,June 2021,2021-06-30,"July 10, 2021",Anticipated,2021-07-10,"July 10, 2021",Anticipated,2021-07-10,NA,Interventional,NA,,What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India,What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India,"Active, not recruiting",NA,N/A,3006,Actual,"National Bureau of Economic Research, Inc.",,8,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:09:50Z,2021-10-17T07:09:50Z,132
NCT04869358,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-29,NA,NA,2021-09-14,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-14,2021-09-16,Actual,"May 27, 2021",Actual,2021-05-27,September 2021,2021-09-30,"January 16, 2023",Anticipated,2023-01-16,"December 22, 2021",Anticipated,2021-12-22,NA,Interventional,KYRIOS,,Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab,Tracking the Immune Response to SARS-CoV-2 modRNA Vaccines in an Open-label Multicenter Study in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab s.c. (KYRIOS),Recruiting,NA,Phase 4,40,Anticipated,Novartis,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.",2021-10-17T07:10:01Z,2021-10-17T07:10:01Z,46
NCT04869592,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-24,NA,NA,2021-05-05,2021-04-29,2021-05-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-07,Actual,"April 25, 2021",Actual,2021-04-25,May 2021,2021-05-31,"October 25, 2022",Anticipated,2022-10-25,"October 25, 2022",Anticipated,2022-10-25,NA,Interventional,NA,,A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19,"Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy People Aged 3 Years and Older",Recruiting,NA,Phase 1/Phase 2,3580,Anticipated,"National Vaccine and Serum Institute, China",,15,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:09:59Z,2021-10-17T07:09:59Z,178
NCT04867174,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-27,NA,NA,2021-10-04,2021-04-28,2021-04-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"May 24, 2021",Actual,2021-05-24,October 2021,2021-10-31,"May 24, 2022",Anticipated,2022-05-24,"August 15, 2021",Actual,2021-08-15,NA,Interventional,NA,,COVID-19 Vaccination Take-Up,COVID-19 Vaccination Take-Up in a County-Run Medicaid Managed Care Population,"Active, not recruiting",NA,N/A,2825,Actual,University of Southern California,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Our partner will not allow data sharing. Code will be shared.,2021-10-17T07:10:21Z,2021-10-17T07:10:21Z,26
NCT04863131,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-15,NA,NA,2021-04-29,2021-04-23,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-04-29,2021-04-30,Actual,"April 28, 2021",Actual,2021-04-28,April 2021,2021-04-30,"January 31, 2023",Anticipated,2023-01-31,"January 31, 2023",Anticipated,2023-01-31,NA,Interventional,NA,,Safety and Immunogenicity of EXG-5003,Safety and Immunogenicity of Intradermal SARS-CoV-2 Vaccine EXG-5003 in Healthy Adults,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,Fujita Health University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:10:55Z,2021-10-17T07:10:55Z,184
NCT04866069,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-26,NA,NA,2021-05-03,2021-04-26,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-05-03,2021-05-06,Actual,"April 25, 2021",Actual,2021-04-25,May 2021,2021-05-31,April 2022,Anticipated,2022-04-30,October 2021,Anticipated,2021-10-31,NA,Interventional,COVID-19,,Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults,"Phase I Study Evaluating the Safety and Efficacy of the Protective Adjuvanted Inactivated Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously in Two Different Dosages.",Recruiting,NA,Phase 1,50,Anticipated,The Scientific and Technological Research Council of Turkey,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:10:29Z,2021-10-17T07:10:29Z,180
NCT04864561,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-23,NA,NA,2021-06-07,2021-04-24,2021-04-29,Actual,NA,NA,NA,NA,NA,NA,2021-06-07,2021-06-08,Actual,"April 26, 2021",Actual,2021-04-26,June 2021,2021-06-30,"June 30, 2022",Anticipated,2022-06-30,"July 15, 2021",Anticipated,2021-07-15,NA,Interventional,COV-COMPARE,,"Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine","A Randomized, Observer-Blind, Controlled, Superiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine, In Adults","Active, not recruiting",NA,Phase 3,4019,Actual,Valneva Austria GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:10:42Z,2021-10-17T07:10:42Z,145
NCT04863638,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-27,NA,NA,2021-05-11,2021-04-27,2021-04-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-11,2021-05-13,Actual,"April 29, 2021",Actual,2021-04-29,April 2021,2021-04-30,"March 31, 2024",Anticipated,2024-03-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,COVID-19,,"A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated","A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated in Population Aged â‰¥ 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years Old",Recruiting,NA,Phase 4,4400,Anticipated,China National Biotec Group Company Limited,,18,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:10:51Z,2021-10-17T07:10:51Z,172
NCT04860739,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-22,NA,NA,2021-05-01,2021-04-22,2021-04-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"April 24, 2021",Actual,2021-04-24,April 2021,2021-04-30,"April 30, 2022",Anticipated,2022-04-30,"May 20, 2021",Anticipated,2021-05-20,NA,Interventional,CombiVacS,,Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose,"A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the Immunogenicity Against SARS-Cov2 and Safety of Boosted Vaccination With COMIRNATY in Subjects Having Received Prime Vaccination With VAXZERIA","Active, not recruiting",NA,Phase 2,676,Actual,Spanish Clinical Research Network - SCReN,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Within one year after study end,Published in EudraCT,NA,Yes,Will submit data to European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) and share data result.,2021-10-17T07:11:16Z,2021-10-17T07:11:16Z,182
NCT04860258,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-22,NA,NA,2021-10-01,2021-04-22,2021-04-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"April 22, 2021",Actual,2021-04-22,January 2021,2021-01-31,"September 21, 2021",Actual,2021-09-21,"September 21, 2021",Actual,2021-09-21,NA,Interventional,NA,,"A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities for COVID-19","COVID-19: A Phase 3 Multicenter Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Above With Co-morbidities",Completed,NA,Phase 3,129,Actual,CureVac AG,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:11:20Z,2021-10-17T07:11:20Z,29
NCT04847050,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-14,NA,NA,2021-09-02,2021-04-14,2021-04-15,Actual,NA,NA,NA,NA,NA,NA,2021-09-02,2021-09-05,Actual,"April 28, 2021",Actual,2021-04-28,"August 31, 2021",2021-08-31,"February 25, 2023",Anticipated,2023-02-25,"January 1, 2022",Anticipated,2022-01-01,NA,Interventional,NA,,"A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy","A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy",Recruiting,NA,Phase 2,120,Anticipated,National Institutes of Health Clinical Center (CC),,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:13:17Z,2021-10-17T07:13:17Z,58
NCT04844346,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-13,NA,NA,2021-04-16,2021-04-13,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-04-16,2021-04-20,Actual,"April 19, 2021",Anticipated,2021-04-19,April 2021,2021-04-30,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,,Plant Stanol Esters and COVID-19 Vaccination Response,The Effect of Plant Stanol Ester Consumption on the Vaccination Response to a COVID-19 Vaccine,Recruiting,NA,N/A,100,Anticipated,Maastricht University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:13:39Z,2021-10-17T07:13:39Z,197
NCT04844489,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-02,NA,NA,2021-06-15,2021-04-13,2021-04-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-15,2021-06-21,Actual,"April 16, 2021",Actual,2021-04-16,June 2021,2021-06-30,"July 31, 2023",Anticipated,2023-07-31,"April 16, 2023",Anticipated,2023-04-16,NA,Interventional,COVIVAC-ID,,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Recruiting,NA,N/A,485,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:13:38Z,2021-10-17T07:13:38Z,137
NCT04839315,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-05,NA,NA,2021-04-07,2021-04-07,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-07,2021-04-09,Actual,"February 15, 2021",Actual,2021-02-15,April 2021,2021-04-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,COVID-19 Vaccination in Rheumatic Disease Patients,Immunological Consequences of COVID-19 Vaccination in Patients With Rheumatic Diseases,Recruiting,NA,Early Phase 1,100,Anticipated,Mayo Clinic,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:14:22Z,2021-10-17T07:14:22Z,206
NCT04842708,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-29,NA,NA,2021-04-11,2021-04-11,2021-04-13,Actual,NA,NA,NA,NA,NA,NA,2021-04-11,2021-04-13,Actual,"December 24, 2020",Actual,2020-12-24,December 2020,2020-12-31,"October 24, 2021",Anticipated,2021-10-24,"October 24, 2021",Anticipated,2021-10-24,NA,Interventional,COVID-19,,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,Recruiting,NA,N/A,50,Anticipated,Scentech Medical Technologies Ltd,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,IPD is not to be shared with other researchers.,2021-10-17T07:13:54Z,2021-10-17T07:13:54Z,202
NCT04840992,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-08,NA,NA,2021-07-27,2021-04-08,2021-04-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"April 20, 2021",Actual,2021-04-20,April 2021,2021-04-30,"July 15, 2022",Anticipated,2022-07-15,"April 15, 2022",Anticipated,2022-04-15,NA,Interventional,NA,,Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation,"A Randomized, Double-blind, Placebo-Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV for Inhalation in Adults 18 Years of Age and Older",Recruiting,NA,Phase 1/Phase 2,840,Anticipated,CanSino Biologics Inc.,,22,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:14:09Z,2021-10-17T07:14:09Z,95
NCT04839146,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-11,NA,NA,2021-04-13,2021-04-08,2021-04-09,Actual,NA,NA,NA,NA,NA,NA,2021-04-13,2021-04-19,Actual,"March 11, 2021",Actual,2021-03-11,March 2021,2021-03-31,"December 20, 2021",Anticipated,2021-12-20,"December 20, 2021",Anticipated,2021-12-20,NA,Interventional,COUGH-1,,Safety and Tolerability of COVID-19 Vaccine (ABNCoV2),First-in-human Trial of the Coronavirus Virus-like Particle Subunit Vaccine ABNCoV2 in SARS-CoV-2-naÃ¯ve Adult Volunteers in Good Health,Recruiting,NA,Phase 1,42,Anticipated,Radboud University,,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:14:24Z,2021-10-17T07:14:24Z,200
NCT04838080,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-06,NA,NA,2021-04-10,2021-04-07,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-04-10,2021-04-13,Actual,"March 19, 2021",Actual,2021-03-19,April 2021,2021-04-30,"October 20, 2021",Anticipated,2021-10-20,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,Safety and Immunogenicity of the Inactivated KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine Compared to Placebo,"Phase 1 Study for the Determination of Safety and Immunogenicity of Different Strengths of KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.",Recruiting,NA,Phase 1,38,Anticipated,Kocak Farma,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:14:32Z,2021-10-17T07:14:32Z,203
NCT04834726,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-06,NA,NA,2021-08-30,2021-04-06,2021-04-08,Actual,NA,NA,NA,NA,NA,NA,2021-08-30,2021-09-01,Actual,"April 29, 2021",Actual,2021-04-29,August 2021,2021-08-31,"July 6, 2021",Actual,2021-07-06,"June 4, 2021",Actual,2021-06-04,NA,Interventional,NA,,COVID-19 Vaccine Text Outreach,Pragmatic Trial of COVID Vaccine Text Outreach Interventions,Completed,NA,N/A,19554,Actual,University of Pennsylvania,,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:15:02Z,2021-10-17T07:15:02Z,61
NCT04833101,"ClinicalTrials.gov processed this data on October 15, 2021",2021-04-03,NA,NA,2021-08-04,2021-04-03,2021-04-06,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-11,Actual,"April 7, 2021",Actual,2021-04-07,June 2021,2021-06-30,"December 15, 2021",Anticipated,2021-12-15,"June 15, 2021",Actual,2021-06-15,NA,Interventional,NA,,Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine,Safety and Immunogenicity of a Heterologous Immunization of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine Against COVID-19 in Chinese Healthy Population,"Active, not recruiting",NA,Phase 4,120,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:15:17Z,2021-10-17T07:15:17Z,87
NCT04830800,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-12,NA,NA,2021-04-01,2021-04-01,2021-04-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-01,2021-04-05,Actual,"March 10, 2021",Actual,2021-03-10,April 2021,2021-04-30,"September 30, 2022",Anticipated,2022-09-30,"May 30, 2022",Anticipated,2022-05-30,NA,Interventional,NA,,A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC,"A Phase 1/2 Randomized, Placebo-controlled, Observer-blind Trial to Assess the Safety and Immunogenicity of COVIVAC Vaccine Produced by IVAC in Adults Aged 18-75 Years in Vietnam",Recruiting,NA,Phase 1/Phase 2,420,Anticipated,"Institute of Vaccines and Medical Biologicals, Vietnam",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There should be an agreement and approval by IRB before sharing IDP,2021-10-17T07:15:36Z,2021-10-17T07:15:36Z,212
NCT04824638,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-07,NA,NA,2021-08-02,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-02,2021-08-09,Actual,"March 8, 2021",Actual,2021-03-08,August 2021,2021-08-31,"October 30, 2023",Anticipated,2023-10-30,"June 29, 2021",Actual,2021-06-29,NA,Interventional,CoviCompareP,,BNT162b2 Vaccination With Two Doses in COVID-19 Negative Adult Volunteers and With a Single Dose in COVID-19 Positive Adult Volunteers,A Phase II Trial Assessing Immunogenicity and Safety of COVID-19 mRNA Vaccine BNT162b2 in Adult Volunteers With no History of SARS-CoV-2 Infection Administered With Two Doses of Vaccine (D1-D29) and in Adult Volunteers With Documented History of SARS-CoV-2 Infection (of More Than 5 Months) Administered With Only One Dose of Vaccine,"Active, not recruiting",NA,Phase 2,267,Actual,"ANRS, Emerging Infectious Diseases",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:16:28Z,2021-10-17T07:16:28Z,89
NCT04822025,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-25,NA,NA,2021-10-05,2021-03-28,2021-03-30,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"May 20, 2021",Actual,2021-05-20,June 2021,2021-06-30,January 2022,Anticipated,2022-01-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults,"A Phase II, Prospective, Randomized, Double-Blind, Dose-Comparison, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901 in Elderly Adults","Active, not recruiting",NA,Phase 2,400,Anticipated,Medigen Vaccine Biologics Corp.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:16:53Z,2021-10-17T07:16:53Z,25
NCT04824391,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-25,NA,NA,2021-03-30,2021-03-30,2021-04-01,Actual,NA,NA,NA,NA,NA,NA,2021-03-30,2021-04-01,Actual,"February 10, 2021",Actual,2021-02-10,March 2021,2021-03-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,"Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19","Phase 2 Study for the Determination of Efficacy, Immunogenicity and Safety of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, in a Placebo Controlled, Randomized, Double Blind Study Design.",Recruiting,NA,Phase 2,250,Anticipated,Health Institutes of Turkey,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:16:30Z,2021-10-17T07:16:30Z,214
NCT04821674,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-25,NA,NA,2021-07-07,2021-03-25,2021-03-29,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-08,Actual,"March 15, 2021",Actual,2021-03-15,July 2021,2021-07-31,"December 31, 2022",Anticipated,2022-12-31,"July 31, 2022",Anticipated,2022-07-31,NA,Interventional,NA,,Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects,"A Phase 1/2 Study to Assess the Safety, Immunogenicity and Recommended Dose of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects","Active, not recruiting",NA,Phase 1/Phase 2,152,Anticipated,"Daiichi Sankyo, Inc.",,10,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:16:56Z,2021-10-17T07:16:56Z,115
NCT04818801,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-19,NA,NA,2021-08-23,2021-03-23,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-25,Actual,"June 18, 2021",Actual,2021-06-18,March 2021,2021-03-31,July 2022,Anticipated,2022-07-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,"Safety, Reactogenicity and Immunogenicity Study of ReCOV","A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of ReCOV, a Vaccine for COVID-19, in Healthy Adult Subjects",Recruiting,NA,Early Phase 1,160,Anticipated,"Jiangsu Rec-Biotechnology Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:17:22Z,2021-10-17T07:17:22Z,68
NCT04818281,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-24,NA,NA,2021-07-12,2021-03-24,2021-03-26,Actual,NA,NA,NA,NA,NA,NA,2021-07-12,2021-07-13,Actual,"March 27, 2021",Actual,2021-03-27,July 2021,2021-07-31,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,COVID-19,,Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults,"Phase I Study Evaluating the Basic Pharmacological and Toxicological Effects of the Protective VLP Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously, in Two Different Dosages.",Recruiting,NA,Phase 1,36,Anticipated,The Scientific and Technological Research Council of Turkey,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:17:26Z,2021-10-17T07:17:26Z,110
NCT04816669,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-24,NA,NA,2021-09-29,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-09-30,Actual,"April 1, 2021",Actual,2021-04-01,September 2021,2021-09-30,"October 30, 2021",Anticipated,2021-10-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,NA,,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE","Active, not recruiting",NA,Phase 3,629,Actual,BioNTech SE,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-17T07:17:40Z,2021-10-17T07:17:40Z,31
NCT04816643,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-19,NA,NA,2021-09-29,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-09-29,2021-10-07,Actual,"March 24, 2021",Actual,2021-03-24,September 2021,2021-09-30,"June 18, 2024",Anticipated,2024-06-18,"June 18, 2024",Anticipated,2024-06-18,NA,Interventional,NA,,"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults","PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN and Young Adults",Recruiting,NA,Phase 2/Phase 3,7922,Anticipated,BioNTech SE,,19,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-17T07:17:40Z,2021-10-17T07:17:40Z,31
NCT04816019,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-15,NA,NA,2021-10-04,2021-03-24,2021-03-25,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-11,Actual,"April 1, 2021",Actual,2021-04-01,October 2021,2021-10-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,A Study of Intranasal ChAdOx1 nCOV-19,"A Phase I Study to Determine Safety, Tolerability and Immunogenicity of Intranasal Administration of the COVID Vaccine ChAdOx1 nCOV-19 in Healthy UK Adults",Recruiting,NA,Phase 1,54,Anticipated,University of Oxford,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:17:46Z,2021-10-17T07:17:46Z,26
NCT04813796,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-22,NA,NA,2021-09-17,2021-03-22,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-21,Actual,"March 11, 2021",Actual,2021-03-11,September 2021,2021-09-30,"April 13, 2022",Anticipated,2022-04-13,"April 13, 2022",Anticipated,2022-04-13,NA,Interventional,NA,,"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19","A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years","Active, not recruiting",NA,Phase 1,106,Actual,"ModernaTX, Inc.",,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:18:05Z,2021-10-17T07:18:05Z,43
NCT04813770,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-23,NA,NA,2021-05-05,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-10,Actual,"April 6, 2021",Actual,2021-04-06,May 2021,2021-05-31,"April 26, 2021",Actual,2021-04-26,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions,Completed,NA,N/A,1113,Actual,University of Glasgow,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,On publication of the study results for a period of ten years.,Data will be made publicly available.,NA,Yes,Anonymised individual level study data will be shared via the University of Glasgow's repository Enlighten: Research Data.,2021-10-17T07:18:05Z,2021-10-17T07:18:05Z,178
NCT04813562,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-19,NA,NA,2021-05-22,2021-03-23,2021-03-24,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"March 23, 2021",Actual,2021-03-23,May 2021,2021-05-31,"June 30, 2022",Anticipated,2022-06-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,NA,,Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells),"A Single-center, Randomized, Double Blinded, Placebo Controlled, Phase 2 Clinical Trial of Recombinant COVID-19 Vaccine (CHO Cells), in the Subjects From Healthy Aged 18 Years and Above",Recruiting,NA,Phase 2,480,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:18:07Z,2021-10-17T07:18:07Z,161
NCT04811664,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-19,NA,NA,2021-08-06,2021-03-19,2021-03-23,Actual,NA,NA,NA,NA,NA,NA,2021-08-06,2021-08-09,Actual,"March 24, 2021",Actual,2021-03-24,August 2021,2021-08-31,"December 22, 2021",Anticipated,2021-12-22,"December 22, 2021",Anticipated,2021-12-22,NA,Interventional,CoVPN 3006,,A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine,"A Randomized Controlled Study to Assess SARS CoV-2 Infection, Viral Shedding, and Subsequent Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine",Recruiting,NA,Phase 3,37500,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:18:22Z,2021-10-17T07:18:22Z,85
NCT04805931,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-11,NA,NA,2021-06-25,2021-03-17,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-06-25,2021-06-28,Actual,"March 15, 2021",Actual,2021-03-15,June 2021,2021-06-30,"November 1, 2021",Anticipated,2021-11-01,"May 1, 2021",Actual,2021-05-01,NA,Interventional,VEText,,VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans,COVID-19 Vaccine Rollout: VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans,Recruiting,NA,N/A,4311,Anticipated,VA Puget Sound Health Care System,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:19:10Z,2021-10-17T07:19:10Z,127
NCT04806113,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-12,NA,NA,2021-06-13,2021-03-17,2021-03-19,Actual,NA,NA,NA,NA,NA,NA,2021-06-13,2021-06-15,Actual,"March 11, 2021",Actual,2021-03-11,June 2021,2021-06-30,"June 15, 2022",Anticipated,2022-06-15,"June 13, 2021",Actual,2021-06-13,NA,Interventional,COVIAAD,,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,"Active, not recruiting",NA,Phase 3,220,Actual,McGill University Health Centre/Research Institute of the McGill University Health Centre,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:19:09Z,2021-10-17T07:19:09Z,139
NCT04805125,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-15,NA,NA,2021-06-14,2021-03-15,2021-03-18,Actual,NA,NA,NA,NA,NA,NA,2021-06-14,2021-06-15,Actual,"April 19, 2021",Actual,2021-04-19,June 2021,2021-06-30,July 2022,Anticipated,2022-07-31,July 2022,Anticipated,2022-07-31,NA,Interventional,COVERALL,,Immunocompromised Swiss Cohorts Based Trial Platform,Randomised Controlled Trials to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: A Master Protocol for the Set-up of a Swiss Cohorts Based Trial Platform,"Active, not recruiting",NA,Phase 3,431,Actual,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:19:17Z,2021-10-17T07:19:17Z,138
NCT04801888,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-15,NA,NA,2021-07-23,2021-03-15,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"March 23, 2021",Actual,2021-03-23,March 2021,2021-03-31,"May 28, 2021",Actual,2021-05-28,"May 28, 2021",Actual,2021-05-28,NA,Interventional,NA,,Study on Combined Vaccination With SARS-CoV-2 Inactivated Vaccine and Quadrivalent Influenza Vaccine,A Study to Evaluate the Safety and Immunogenicity of Concomitant Administration of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) With Quadrivalent Influenza Vaccine in Adults Aged From 18 to 59 Years,Completed,NA,Phase 4,480,Actual,"Sinovac Biotech Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:19:44Z,2021-10-17T07:19:44Z,99
NCT04801524,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-15,NA,NA,2021-03-22,2021-03-15,2021-03-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-24,Actual,"February 7, 2021",Actual,2021-02-07,March 2021,2021-03-31,"January 1, 2022",Anticipated,2022-01-01,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Text-based Reminders to Promote COVID-19 Vaccinations,Text-based Reminders to Promote COVID-19 Vaccinations,Enrolling by invitation,NA,N/A,250000,Anticipated,"University of California, Los Angeles",,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:19:47Z,2021-10-17T07:19:47Z,222
NCT04800965,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-06,NA,NA,2021-03-22,2021-03-14,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-22,2021-03-24,Actual,"January 31, 2021",Actual,2021-01-31,March 2021,2021-03-31,"January 1, 2022",Anticipated,2022-01-01,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Text-based Interventions to Promote COVID-19 Vaccinations,Text-based Interventions to Promote COVID-19 Vaccinations,Enrolling by invitation,NA,N/A,400000,Anticipated,"University of California, Los Angeles",,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:19:52Z,2021-10-17T07:19:52Z,222
NCT04800133,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-01,NA,NA,2021-07-07,2021-03-15,2021-03-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-07,2021-07-13,Actual,"May 8, 2021",Actual,2021-05-08,July 2021,2021-07-31,"March 31, 2025",Anticipated,2025-03-31,"March 31, 2025",Anticipated,2025-03-31,NA,Interventional,COVA,,Covid-19 Vaccination in Adolescents,To Compare the Reactogenicity and Immunogenicity of Recommended COVID-19 Vaccines in Young Adolescents in Hong Kong,Recruiting,NA,Phase 2,900,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:19:59Z,2021-10-17T07:19:59Z,115
NCT04798677,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-12,NA,NA,2021-07-20,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"October 29, 2020",Actual,2020-10-29,March 2021,2021-03-31,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,,Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine,"Efficacy and Tolerability of a Nutritional Supplementation With ABBC-1, a Symbiotic Combination of Beta-glucans and Selenium and Zinc Enriched Probiotics, in Volunteers Receiving the Influenza or the Covid-19 Vaccines",Recruiting,NA,N/A,90,Anticipated,AB Biotek,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,IPD will be available upon request (blood analysis results and clinical assessment outcomes),2021-10-17T07:20:12Z,2021-10-17T07:20:12Z,102
NCT04798027,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-11,NA,NA,2021-09-15,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-09-15,2021-09-16,Actual,"March 12, 2021",Actual,2021-03-12,September 2021,2021-09-30,"November 11, 2022",Anticipated,2022-11-11,"November 11, 2022",Anticipated,2022-11-11,NA,Interventional,VAW00001,,Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older,Immunogenicity and Safety of the First-in-Human SARS-CoV-2 mRNA Vaccine Formulation in Healthy Adults 18 Years of Age and Older,Recruiting,NA,Phase 1/Phase 2,333,Anticipated,Sanofi,,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-17T07:20:18Z,2021-10-17T07:20:18Z,45
NCT04798001,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-09,NA,NA,2021-07-01,2021-03-12,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-07,Actual,"April 12, 2021",Actual,2021-04-12,July 2021,2021-07-31,"October 31, 2022",Anticipated,2022-10-31,"October 31, 2022",Anticipated,2022-10-31,NA,Interventional,NA,,Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults,"Phase 1, Open-Label, Dose-Escalation Study to Evaluate Tolerability, Safety, and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine Expressing Spike Protein of SARS-CoV-2 in Healthy Adults Ages 18 - 69 Years",Recruiting,NA,Phase 1,130,Anticipated,"Meissa Vaccines, Inc.",,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:20:18Z,2021-10-17T07:20:18Z,121
NCT04796896,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-11,NA,NA,2021-10-12,2021-03-11,2021-03-15,Actual,NA,NA,NA,NA,NA,NA,2021-10-12,2021-10-13,Actual,"March 15, 2021",Actual,2021-03-15,October 2021,2021-10-31,"June 12, 2023",Anticipated,2023-06-12,"June 12, 2023",Anticipated,2023-06-12,NA,Interventional,NA,,A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age,"A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age",Recruiting,NA,Phase 2/Phase 3,13275,Anticipated,"ModernaTX, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:20:28Z,2021-10-17T07:20:28Z,18
NCT04794946,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-08,NA,NA,2021-06-18,2021-03-11,2021-03-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-18,2021-06-23,Actual,"March 19, 2021",Actual,2021-03-19,March 2021,2021-03-31,"March 19, 2022",Anticipated,2022-03-19,"March 19, 2022",Anticipated,2022-03-19,NA,Interventional,NA,,"Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis","Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis - A Pilot Study",Recruiting,NA,N/A,2200,Anticipated,"Institute of Liver and Biliary Sciences, India",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:20:44Z,2021-10-17T07:20:44Z,134
NCT04792567,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-08,NA,NA,2021-05-28,2021-03-08,2021-03-11,Actual,NA,NA,NA,NA,NA,NA,2021-05-28,2021-06-01,Actual,"April 19, 2021",Actual,2021-04-19,May 2021,2021-05-31,"April 2, 2022",Anticipated,2022-04-02,"January 17, 2022",Anticipated,2022-01-17,NA,Interventional,AMA-VACC,,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod),Recruiting,NA,Phase 4,60,Anticipated,Novartis,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.",2021-10-17T07:21:07Z,2021-10-17T07:21:07Z,155
NCT04791423,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-22,NA,NA,2021-07-26,2021-03-09,2021-03-10,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-30,Actual,"March 15, 2021",Actual,2021-03-15,March 2021,2021-03-31,"April 30, 2022",Anticipated,2022-04-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,COVITAR,,Study of GRAd-COV2 for the Prevention of COVID-19 in Adults,"A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 2/Phase 3,10300,Anticipated,ReiThera Srl,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:21:17Z,2021-10-17T07:21:17Z,96
NCT04789356,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-05,NA,NA,2021-07-22,2021-03-08,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-22,2021-07-26,Actual,"March 18, 2021",Actual,2021-03-18,July 2021,2021-07-31,March 2022,Anticipated,2022-03-31,"July 5, 2021",Actual,2021-07-05,NA,Interventional,COVACMANAUS,,Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity,"Phase IV Study to Evaluate the Effectiveness of the Inactivated Adsorbed Vaccine Against COVID-19 CoronaVac, Among Public Safety and Education Workers With Risk Factors for Severity, in Manaus (Amazonas)","Active, not recruiting",NA,Phase 4,6233,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:21:34Z,2021-10-17T07:21:34Z,100
NCT04788459,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-01,NA,NA,2021-10-04,2021-03-05,2021-03-09,Actual,NA,NA,NA,NA,NA,NA,2021-10-04,2021-10-05,Actual,"February 25, 2021",Actual,2021-02-25,October 2021,2021-10-31,September 2022,Anticipated,2022-09-30,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,"Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers","A Phase I/II Study to Assess the Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,Takis,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:21:42Z,2021-10-17T07:21:42Z,26
NCT04785144,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-04,NA,NA,2021-08-12,2021-03-04,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-19,Actual,"March 29, 2021",Actual,2021-03-29,"April 6, 2021",2021-04-06,"August 31, 2022",Anticipated,2022-08-31,"August 31, 2022",Anticipated,2022-08-31,NA,Interventional,NA,,Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in NaÃ¯ve and Previously Vaccinated Adults,"Phase 1, Open-Label, Randomized Study of the Safety and Immunogenicity of a SARS-CoV-2 Variant Vaccine (mRNA-1273.351) in NaÃ¯ve and Previously Vaccinated Adults","Active, not recruiting",NA,Phase 1,135,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,10,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:22:11Z,2021-10-17T07:22:11Z,79
NCT04784767,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-03,NA,NA,2021-09-13,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-09-13,2021-09-14,Actual,"April 5, 2021",Actual,2021-04-05,September 2021,2021-09-30,"October 30, 2023",Anticipated,2023-10-30,"October 30, 2022",Anticipated,2022-10-30,NA,Interventional,NA,,SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults,"A PHASE 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Ranging Doses of SARS-COV-2-Spike-Ferritin-Nanoparticle (SPFN_1B-06-PL) Vaccine With Army Liposomal Formulation QS21 (ALFQ) for Prevention of COVID-19 in Healthy Adults.","Active, not recruiting",NA,Phase 1,29,Actual,U.S. Army Medical Research and Development Command,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:22:14Z,2021-10-17T07:22:14Z,47
NCT04783311,"ClinicalTrials.gov processed this data on October 15, 2021",2021-03-03,NA,NA,2021-04-23,2021-03-03,2021-03-05,Actual,NA,NA,NA,NA,NA,NA,2021-04-23,2021-04-26,Actual,"February 23, 2021",Actual,2021-02-23,February 2021,2021-02-28,January 2023,Anticipated,2023-01-31,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,,"Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults","A Phase 1/2 Dose-exploration, Randomized, Observer-blind, Placebo-controlled Study to Determine Safety, Tolerance and Immunogenicity of EuCorVac-19, a Recombinant Protein Vaccine, for the Prevention of COVID-19 in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,280,Anticipated,"EuBiologics Co.,Ltd",,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:22:27Z,2021-10-17T07:22:27Z,190
NCT04780659,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-19,NA,NA,2021-09-08,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-09-08,2021-09-09,Actual,"February 23, 2021",Actual,2021-02-23,September 2021,2021-09-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,COVAXID,,COVID-19 Vaccination of Immunodeficient Persons (COVAXID),"Immunological Responses After Vaccination for COVID-19 With the Messenger Ribonucleic Acid (mRNA) Vaccine Comirnaty in Immunosuppressed and Immunocompetent Individuals. An Open and Non-randomized, Phase IV Multicenter Study","Active, not recruiting",NA,Phase 4,540,Anticipated,Karolinska University Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,Within one year after study end.,Published in EudraCT and national COVID-19 data portal (SciLifeLab Data Centre),https://eudract.ema.europa.eu/index.html,Yes,"Will submit data to European Union Drug Regulating Authorities Clinical Trials Database (EudraCT) and share data result. Will share research results and data through national COVID-19 data portal, operated by SciLifeLab Data Centre, Sweden.",2021-10-17T07:22:50Z,2021-10-17T07:22:50Z,52
NCT04780035,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-25,NA,NA,2021-03-02,2021-03-02,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-03,Actual,"November 18, 2020",Actual,2020-11-18,February 2021,2021-02-28,September 2021,Anticipated,2021-09-30,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,,"Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19","Multicenter Double-blind Placebo-controlled Comparative Randomized Study of the Tolerability, Safety, Immunogenicity and Prophylactic Efficacy of the EpiVacCorona Peptide Antigen-based Vaccine for the Prevention of COVID-19, With the Participation of 3000 Volunteers Aged 18 Years and Above (Phase III-IV)","Active, not recruiting",NA,Phase 3,3000,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:22:55Z,2021-10-17T07:22:55Z,242
NCT04779827,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-21,NA,NA,2021-05-06,2021-03-01,2021-03-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-07,Actual,"May 4, 2021",Actual,2021-05-04,May 2021,2021-05-31,"December 30, 2022",Anticipated,2022-12-30,"October 30, 2022",Anticipated,2022-10-30,NA,Interventional,NA,,Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks,Improving Health Equity for COVID-19 Vaccination and Related Health Behaviors for At-risk Populations Using Online Social Networks,Recruiting,NA,N/A,1920,Anticipated,University of Pennsylvania,,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available when the primary intervention paper is published.,"Data will be shared as a part of the published paper, in forms of supplementary materials. The public can access the data through the publisher's website.",NA,Yes,We will share the data collected from our online experiments. All sets of data are anonymous.,2021-10-17T07:22:56Z,2021-10-17T07:22:56Z,177
NCT04776317,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-25,NA,NA,2021-08-19,2021-02-25,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-25,Actual,"March 25, 2021",Actual,2021-03-25,"August 17, 2021",2021-08-17,"September 19, 2022",Anticipated,2022-09-19,"September 19, 2022",Anticipated,2022-09-19,NA,Interventional,NA,,Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults,"A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults",Recruiting,NA,Phase 1,147,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,17,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:23:27Z,2021-10-17T07:23:27Z,72
NCT04775069,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-24,NA,NA,2021-05-21,2021-02-26,2021-03-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"May 21, 2021",Actual,2021-05-21,May 2021,2021-05-31,"March 31, 2022",Anticipated,2022-03-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Antibody Response to COVID-19 Vaccines in Liver Disease Patients,"A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA, Inactivated Virus and Adenovirus Vector COVID-19 Vaccines",Recruiting,NA,Phase 4,900,Anticipated,Humanity & Health Medical Group Limited,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:23:38Z,2021-10-17T07:23:38Z,162
NCT04773665,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-24,NA,NA,2021-10-01,2021-02-25,2021-02-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-08,Actual,"March 15, 2021",Actual,2021-03-15,October 2021,2021-10-31,November 2022,Anticipated,2022-11-30,November 2022,Anticipated,2022-11-30,NA,Interventional,NA,,"Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a","A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults",Recruiting,NA,Phase 1,141,Anticipated,VBI Vaccines Inc.,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:23:50Z,2021-10-17T07:23:50Z,29
NCT04771559,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-17,NA,NA,2021-08-01,2021-02-24,2021-02-25,Actual,NA,NA,NA,NA,NA,NA,2021-08-01,2021-08-03,Actual,"March 1, 2021",Actual,2021-03-01,August 2021,2021-08-31,"July 1, 2021",Actual,2021-07-01,"June 1, 2021",Actual,2021-06-01,NA,Interventional,NA,,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Evaluation of the Effect and Side Effect Profile of Covid-19 Vaccine in Cancer Patients,Completed,NA,N/A,1500,Actual,Bezmialem Vakif University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:24:08Z,2021-10-17T07:24:08Z,90
NCT04765839,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-02,NA,NA,2021-07-28,2021-02-19,2021-02-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-28,2021-07-30,Actual,"February 12, 2021",Actual,2021-02-12,July 2021,2021-07-31,"April 3, 2021",Actual,2021-04-03,"April 3, 2021",Actual,2021-04-03,NA,Interventional,CERC,,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With Minority Populations,Completed,NA,N/A,74,Actual,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:24:57Z,2021-10-17T07:24:57Z,94
NCT04765436,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-16,NA,NA,2021-06-28,2021-02-19,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-06-28,2021-06-30,Actual,"January 14, 2021",Actual,2021-01-14,June 2021,2021-06-30,"February 12, 2022",Anticipated,2022-02-12,"February 12, 2022",Anticipated,2022-02-12,NA,Interventional,NA,,"PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","A Phase I, First-in-Human, Observer-Blinded, Randomized, Placebo Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64","Active, not recruiting",NA,Phase 1,60,Anticipated,Providence Therapeutics Holdings Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:25:01Z,2021-10-17T07:25:01Z,124
NCT04762680,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-18,NA,NA,2021-08-24,2021-02-18,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-24,2021-08-26,Actual,"February 24, 2021",Actual,2021-02-24,August 2021,2021-08-31,"December 24, 2022",Anticipated,2022-12-24,"December 24, 2022",Anticipated,2022-12-24,NA,Interventional,VAT00002,,Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent),Recruiting,NA,Phase 2/Phase 3,5414,Anticipated,Sanofi,,15,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-17T07:25:26Z,2021-10-17T07:25:26Z,67
NCT04761822,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-17,NA,NA,2021-08-31,2021-02-17,2021-02-21,Actual,NA,NA,NA,NA,NA,NA,2021-08-31,2021-09-01,Actual,"April 7, 2021",Actual,2021-04-07,August 2021,2021-08-31,November 2021,Anticipated,2021-11-30,October 2021,Anticipated,2021-10-31,NA,Interventional,SARS,,COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations,Systemic Allergic Reactions to SARS-CoV-2 Vaccination,Recruiting,NA,Phase 2,3400,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"After completion of the trial, within 24 months status post database lock.","Registration is available for the Immunology Database and Analysis Portal (ImmPort) at: https://www.immport.org/registration. Submit a rationale for the purpose of requesting study data access.
ImmPort is a long-term archive of clinical and mechanistic data, a National Institute of Allergy and Infectious Diseases Division of Allergy, Immunology and Transplantation (NIAID DAIT)-funded data repository. This archive is in support of the NIH mission to share data with the public. Data shared through ImmPort is provided by NIH-funded programs, other research organizations and individual scientists, ensuring these discoveries will be the foundation of future research.",https://www.immport.org/home,Yes,Participant level data access and additional relevant materials will be made available upon completion of the trial.,2021-10-17T07:25:34Z,2021-10-17T07:25:34Z,60
NCT04760743,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-17,NA,NA,2021-02-17,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-02-17,2021-02-18,Actual,"December 17, 2020",Actual,2020-12-17,February 2021,2021-02-28,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19),"A Phase I, Placebo-controlled, Randomized, Observer-blinded, Dose-escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults Aged at 19 to 55 Years","Active, not recruiting",NA,Phase 1,50,Actual,"SK Chemicals Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:25:43Z,2021-10-17T07:25:43Z,255
NCT04760132,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-08,NA,NA,2021-02-23,2021-02-17,2021-02-18,Actual,NA,NA,NA,NA,NA,NA,2021-02-23,2021-02-26,Actual,"February 8, 2021",Actual,2021-02-08,February 2021,2021-02-28,"December 31, 2024",Anticipated,2024-12-31,"December 31, 2024",Anticipated,2024-12-31,NA,Interventional,ENFORCE,,National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE),National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines,Recruiting,NA,Phase 4,10000,Anticipated,"Rigshospitalet, Denmark",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:25:50Z,2021-10-17T07:25:50Z,249
NCT04758962,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-08,NA,NA,2021-09-10,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-10,2021-09-13,Actual,"February 15, 2021",Actual,2021-02-15,September 2021,2021-09-30,"May 2, 2022",Anticipated,2022-05-02,"June 4, 2021",Actual,2021-06-04,NA,Interventional,NA,,A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults,"A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age","Active, not recruiting",NA,Phase 1,10,Actual,GlaxoSmithKline,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",NA,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2021-10-17T07:26:03Z,2021-10-17T07:26:03Z,50
NCT04758273,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-09,NA,NA,2021-02-16,2021-02-16,2021-02-17,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"October 7, 2020",Actual,2020-10-07,February 2021,2021-02-28,"February 28, 2022",Anticipated,2022-02-28,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase I Clinical Trial","Active, not recruiting",NA,Phase 1,180,Actual,"Beijing Minhai Biotechnology Co., Ltd",,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:26:09Z,2021-10-17T07:26:09Z,256
NCT04756830,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-15,NA,NA,2021-07-06,2021-02-15,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-09,Actual,"February 19, 2021",Actual,2021-02-19,July 2021,2021-07-31,June 2023,Anticipated,2023-06-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19,An Open-label Uncontrolled Study to Assess the Safety and Immunogenicity of the Inactivated Adsorbed Vaccine Against COVID-19 (Coronavac) in Individuals Over 18 Years of Age During 24 Months of Follow-up,"Active, not recruiting",NA,Phase 4,1200,Actual,D'Or Institute for Research and Education,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:26:21Z,2021-10-17T07:26:21Z,116
NCT04756323,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-09,NA,NA,2021-02-16,2021-02-14,2021-02-16,Actual,NA,NA,NA,NA,NA,NA,2021-02-16,2021-02-17,Actual,"October 27, 2020",Actual,2020-10-27,February 2021,2021-02-28,"February 28, 2022",Anticipated,2022-02-28,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Evaluation of the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above: a Randomized, Double-blind, Placebo Parallel-controlled Phase II Clinical Trial","Active, not recruiting",NA,Phase 2,1000,Actual,"Beijing Minhai Biotechnology Co., Ltd",,12,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:26:25Z,2021-10-17T07:26:25Z,256
NCT04751682,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-08,NA,NA,2021-06-17,2021-02-11,2021-02-12,Actual,NA,NA,NA,NA,NA,NA,2021-06-17,2021-06-22,Actual,"March 1, 2021",Actual,2021-03-01,June 2021,2021-06-30,"November 30, 2021",Anticipated,2021-11-30,"June 25, 2021",Anticipated,2021-06-25,NA,Interventional,NA,,Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19,"A Phase 1, Randomized, Double-blinded, Multicenter Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of an Intranasal Adenovirus Vector COVID-19 Vaccine (BBV154) in Healthy Volunteers","Active, not recruiting",NA,Phase 1,175,Anticipated,Bharat Biotech International Limited,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:27:09Z,2021-10-17T07:27:09Z,135
NCT04750343,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-10,NA,NA,2021-10-14,2021-02-10,2021-02-11,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"February 3, 2021",Actual,2021-02-03,February 2021,2021-02-28,June 2022,Anticipated,2022-06-30,"July 28, 2021",Actual,2021-07-28,NA,Interventional,NA,,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19),"A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 in Healthy Younger and Older Adults","Active, not recruiting",NA,Phase 1/Phase 2,328,Actual,"SK Bioscience Co., Ltd.",,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:27:20Z,2021-10-17T07:27:20Z,16
NCT04747821,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-05,NA,NA,2021-04-06,2021-02-08,2021-02-10,Actual,NA,NA,NA,NA,NA,NA,2021-04-06,2021-04-08,Actual,"February 7, 2021",Actual,2021-02-07,April 2021,2021-04-30,February 2022,Anticipated,2022-02-28,May 2021,Anticipated,2021-05-31,NA,Interventional,Projeto S,,An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine,A Stepped-wedge Cluster Randomized Trial to Assess the Effectiveness of the Use of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac,"Active, not recruiting",NA,Phase 4,27711,Actual,Butantan Institute,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:27:41Z,2021-10-17T07:27:41Z,207
NCT04742738,"ClinicalTrials.gov processed this data on October 15, 2021",2021-02-04,NA,NA,2021-10-14,2021-02-05,2021-02-08,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"January 20, 2021",Actual,2021-01-20,January 2021,2021-01-31,April 2022,Anticipated,2022-04-30,"July 30, 2021",Actual,2021-07-30,NA,Interventional,NA,,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19),"A 2-Stage, Phase I/II, Placebo-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide in Healthy Younger and Older Adults","Active, not recruiting",NA,Phase 1/Phase 2,260,Actual,"SK Bioscience Co., Ltd.",,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:28:25Z,2021-10-17T07:28:25Z,16
NCT04732819,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-27,2021-07-22,NA,2021-09-01,2021-01-29,2021-02-01,Actual,2021-09-01,2021-09-05,Actual,NA,NA,NA,2021-09-01,2021-09-05,Actual,"December 21, 2020",Actual,2020-12-21,September 2021,2021-09-30,"April 16, 2021",Actual,2021-04-16,"March 31, 2021",Actual,2021-03-31,NA,Interventional,NA,"The overall number of baseline participants includes the number of residents and staff in each arm. The unit analyzed was nursing home facility. Baseline characteristics were obtained for residents and nursing home facilities, but not for staff.",Improving COVID-19 Vaccine Uptake in Nursing Homes,IMPACT-C: Improving Vaccine Uptake in Skilled Nursing Facilities,Completed,NA,N/A,23768,Actual,Brown University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,The IPD and supporting documentation will be available through the CDCC within 6 months of the completion of the trial.,"Staff and patient data will be aggregated at the level of the facility. This data will be shared with the RADx-UP CDCC, who plans to make a central database that will ultimately be publicly available.",NA,Yes,"Data will be aggregated at the level of the facility. We will provide aggregated data to the RADx-UP Coordination and Data Collection Center (CDCC); however, given the nature of this data it will not be identifiable or linkable. The CDCC will facilitate cross-site pooling of data, whenever possible, and create a publicly available dataset with this information.",2021-10-17T07:29:58Z,2021-10-17T07:29:58Z,59
NCT04732468,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-27,NA,NA,2021-07-19,2021-01-28,2021-02-01,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"February 24, 2021",Actual,2021-02-24,January 2021,2021-01-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Subcutaneously and Orally Administered Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral COVID-19 in Normal Healthy Volunteers","Active, not recruiting",NA,Phase 1,26,Actual,"ImmunityBio, Inc.",,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:30:03Z,2021-10-17T07:30:03Z,103
NCT04728594,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-26,2021-07-16,NA,2021-07-22,2021-01-26,2021-01-28,Actual,2021-07-22,2021-07-26,Actual,NA,NA,NA,2021-07-22,2021-07-26,Actual,"January 15, 2021",Actual,2021-01-15,July 2021,2021-07-31,"January 20, 2021",Actual,2021-01-20,"January 17, 2021",Actual,2021-01-17,NA,Interventional,NA,"The baseline outcome measure was not applicable, since registration for vaccination was the outcome, and all participants were selected for not being registered.",Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Evaluation of an Email Intervention Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,NA,N/A,9566,Actual,Geisinger Clinic,"In the original ClinicalTrials record, the researchers preregistered that the study would examine primary and secondary outcomes after two days. This was extended to about three days, which was the time when the delayed control group was emailed. This altered timing was dictated by when the organization's marketing department was ready to send emails to the delayed control group.",3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will become available after publication of study results in a scientific journal and will be available as long as the Open Science Framework hosts the data.,The data on the Open Science Framework will be open to anyone requesting that information.,http://osf.io,Yes,Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.,2021-10-17T07:30:37Z,2021-10-17T07:30:37Z,100
NCT04715997,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-18,NA,NA,2021-01-18,2021-01-18,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-18,2021-01-20,Actual,"December 30, 2020",Actual,2020-12-30,January 2021,2021-01-31,"March 30, 2022",Anticipated,2022-03-30,"May 30, 2021",Anticipated,2021-05-30,NA,Interventional,NA,,"Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Subjects",Recruiting,NA,Phase 1/Phase 2,170,Anticipated,"Genexine, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:32:31Z,2021-10-17T07:32:31Z,285
NCT04715438,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-11,NA,NA,2021-10-05,2021-01-15,2021-01-20,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-14,Actual,"January 8, 2021",Actual,2021-01-08,October 2021,2021-10-31,April 2023,Anticipated,2023-04-30,"June 4, 2021",Actual,2021-06-04,NA,Interventional,VOICE,,Vaccination Against COVID-19 in Cancer,Vaccination Against cOvid In CancEr,"Active, not recruiting",NA,N/A,791,Actual,University Medical Center Groningen,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,we start the make interim results available second half of 2021,"we aim to share as much as possible also through own website, and COVID-19 platforms that are considered for this kind of research",NA,Yes,"Alignment and reuse Our options for reusing data, biological materials, and/or other resources (from research or practice) in your project.
Data: Clinicopathological parameters as described in the protocol
Biological materials: Blood
Research software: R statistical package, Castor, MOLGENIS
Other resources, i.e.,Nederlandse Kankerregistratie (NKR), the Dutch Cancer Registry, electronic patient dossiers (EPDs)
FAIR data within the COVID-19 research community
A COVID-19 related or other Findability, Accessibility, Interoperability, and Reuse (FAIR) data points
COVID-19 research platform for data sharing
we will make protocol etc. available on the website soon voicetrial.nl",2021-10-17T07:32:35Z,2021-10-17T07:32:35Z,25
NCT04713553,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-15,NA,NA,2021-08-04,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-04,2021-08-05,Actual,"February 15, 2021",Actual,2021-02-15,August 2021,2021-08-31,"July 22, 2021",Actual,2021-07-22,"July 22, 2021",Actual,2021-07-22,NA,Interventional,NA,,"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED COVID-19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50 YEARS OF AGE",Completed,NA,Phase 3,1530,Actual,BioNTech SE,,7,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-17T07:32:52Z,2021-10-17T07:32:52Z,87
NCT04713488,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-13,NA,NA,2021-02-01,2021-01-15,2021-01-19,Actual,NA,NA,NA,NA,NA,NA,2021-02-01,2021-02-02,Actual,"January 15, 2021",Actual,2021-01-15,January 2021,2021-01-31,"July 31, 2021",Anticipated,2021-07-31,"July 20, 2021",Anticipated,2021-07-20,NA,Interventional,NA,,"An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" Vaccine","An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" t Vaccine for Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Viruso","Active, not recruiting",NA,Phase 1/Phase 2,110,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:32:52Z,2021-10-17T07:32:52Z,271
NCT04710303,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-13,NA,NA,2021-03-09,2021-01-13,2021-01-14,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"March 2, 2021",Actual,2021-03-02,January 2021,2021-01-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of a Prophylactic COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults (ProVIVA-SA-1)",Recruiting,NA,Phase 1,35,Anticipated,"ImmunityBio, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:33:19Z,2021-10-17T07:33:19Z,235
NCT04706403,"ClinicalTrials.gov processed this data on October 15, 2021",2021-01-05,NA,NA,2021-07-26,2021-01-11,2021-01-12,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-08-02,Actual,"January 12, 2021",Actual,2021-01-12,July 2021,2021-07-31,"February 1, 2021",Actual,2021-02-01,"February 1, 2021",Actual,2021-02-01,NA,Interventional,NA,,Views on COVID-19 and Vaccination,"If We Build It, Will They Come? A Pilot Study to Develop and Test Messages to Maximize Uptake of Coronavirus Vaccine When Available",Completed,NA,N/A,1706,Actual,"University of Massachusetts, Worcester",,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:33:54Z,2021-10-17T07:33:54Z,96
NCT04695652,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-31,NA,NA,2021-07-01,2021-01-04,2021-01-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-06,Actual,"December 30, 2020",Actual,2020-12-30,December 2020,2020-12-31,June 2022,Anticipated,2022-06-30,"June 2, 2021",Actual,2021-06-02,NA,Interventional,COVID-19,,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult,"A Phase II, Prospective, Double-blinded, Multi-Center, Multi-Regional Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901","Active, not recruiting",NA,Phase 2,3700,Anticipated,Medigen Vaccine Biologics Corp.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:35:29Z,2021-10-17T07:35:29Z,121
NCT04691947,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-14,NA,NA,2020-12-31,2020-12-30,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2020-12-31,2021-01-05,Actual,"November 5, 2020",Actual,2020-11-05,December 2020,2020-12-31,"March 15, 2022",Anticipated,2022-03-15,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,ERUCOV-VAC,,Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC,"Phase 1 Study for the Determination of Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.",Recruiting,NA,Phase 1,44,Anticipated,Health Institutes of Turkey,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:35:59Z,2021-10-17T07:35:59Z,303
NCT04691908,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-21,NA,NA,2021-07-23,2020-12-29,2020-12-31,Actual,NA,NA,NA,NA,NA,NA,2021-07-23,2021-07-26,Actual,"December 25, 2020",Actual,2020-12-25,December 2020,2020-12-31,"July 11, 2021",Actual,2021-07-11,"April 26, 2021",Actual,2021-04-26,NA,Interventional,NA,,"Immunogenicity, Efficacy and Safety of QazCovid-inÂ® COVID-19 Vaccine","Multicenter, Randomized, Blind, Placebo-controlled Clinical Study of III Phase on Assessment of Preventive Efficiency, Safety and Immunogenicity QazCovid-inÂ®-Vaccine Against COVID-19 in Healthy Adult Volunteers",Completed,NA,Phase 3,3000,Actual,Research Institute for Biological Safety Problems,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:36:00Z,2021-10-17T07:36:00Z,99
NCT04690387,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-28,NA,NA,2021-07-14,2020-12-29,2020-12-30,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-20,Actual,"December 7, 2020",Actual,2020-12-07,July 2021,2021-07-31,"January 15, 2021",Actual,2021-01-15,"January 13, 2021",Actual,2021-01-13,NA,Interventional,NA,,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection","Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Completed,NA,Phase 1,27,Actual,"Aivita Biomedical, Inc.",,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:36:12Z,2021-10-17T07:36:12Z,108
NCT04685603,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-22,NA,NA,2020-12-24,2020-12-24,2020-12-28,Actual,NA,NA,NA,NA,NA,NA,2020-12-24,2020-12-29,Actual,"December 7, 2020",Actual,2020-12-07,December 2020,2020-12-31,"January 31, 2022",Anticipated,2022-01-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,NA,,Dendritic Cell Vaccine to Prevent COVID-19,"Adaptive Phase I Clinical Trial of Preventive Vaccine Consisting of Autologous Dendritic Cells Previously Incubated With S-protein From SARS-CoV-2, in Subjects Negative for COVID-19 Infection and Anti-SARS-CoV-2 Antibodies",Recruiting,NA,Phase 1,27,Anticipated,Indonesia-MoH,,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:36:55Z,2021-10-17T07:36:55Z,310
NCT04681092,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-22,NA,NA,2021-07-21,2020-12-22,2020-12-23,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-28,Actual,"April 6, 2021",Actual,2021-04-06,July 2021,2021-07-31,"October 30, 2021",Anticipated,2021-10-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,ACT,,Anti-COVID19 AKS-452 - ACT Study,Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study,Recruiting,NA,Phase 1/Phase 2,112,Anticipated,University Medical Center Groningen,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:37:32Z,2021-10-17T07:37:32Z,101
NCT04679909,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-21,NA,NA,2021-07-14,2020-12-21,2020-12-22,Actual,NA,NA,NA,NA,NA,NA,2021-07-14,2021-07-15,Actual,"February 25, 2021",Actual,2021-02-25,July 2021,2021-07-31,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,,Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study),"A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of the Safety and Immunogenicity of AdCOVID Administered as One or Two Doses","Active, not recruiting",NA,Phase 1,92,Actual,"Altimmune, Inc.",,8,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:37:42Z,2021-10-17T07:37:42Z,108
NCT04674189,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-14,NA,NA,2021-07-20,2020-12-14,2020-12-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-20,2021-07-21,Actual,"December 23, 2020",Actual,2020-12-23,January 2021,2021-01-31,"July 12, 2022",Anticipated,2022-07-12,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,NA,,A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19,"COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Workers in Mainz (Germany)","Active, not recruiting",NA,Phase 3,2360,Actual,CureVac AG,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:38:36Z,2021-10-17T07:38:36Z,102
NCT04673149,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-11,NA,NA,2020-12-23,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-23,2020-12-24,Actual,"December 23, 2020",Actual,2020-12-23,December 2020,2020-12-31,"December 31, 2022",Anticipated,2022-12-31,"July 31, 2022",Anticipated,2022-07-31,NA,Interventional,NA,,GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19),"Multicenter, Randomized, Combined Phase I Dose-escalation and Phase IIa Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Immunogenicity of GLS-5310 DNA Vaccine, Administered Intradermally Against SARS-CoV-2 in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,345,Anticipated,"GeneOne Life Science, Inc.",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:38:46Z,2021-10-17T07:38:46Z,311
NCT04672291,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-05,NA,NA,2021-08-17,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"July 21, 2021",Actual,2021-07-21,February 2021,2021-02-28,"January 31, 2023",Anticipated,2023-01-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,NA,,Nasal Poly-ICLC (HiltonolÂ®) in Healthy COVID-19 Vaccinated Adults,"A Phase I-Ib, Double-blinded, Randomized Repeated Dose Single Center, Safety and Immunogenicity Study of Nasal Poly-ICLC (HiltonolÂ®) in Healthy COVID-19 Vaccinated Adults",Recruiting,NA,Phase 1,43,Anticipated,"Oncovir, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:38:54Z,2021-10-17T07:38:54Z,74
NCT04671017,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-15,NA,NA,2021-03-08,2020-12-15,2020-12-17,Actual,NA,NA,NA,NA,NA,NA,2021-03-08,2021-03-09,Actual,"December 16, 2020",Actual,2020-12-16,March 2021,2021-03-31,"August 28, 2021",Anticipated,2021-08-28,"February 26, 2021",Actual,2021-02-26,NA,Interventional,NA,,"Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults","A Phase I/II Randomized, Two Parts, Dose-Finding Study To Evaluate The Safety, Tolerability and Immunogenicity Of An Inactivated, Adjuvanted Sars-Cov-2 Virus Vaccine Candidate (VLA2001), Against Covid-19 In Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,153,Actual,Valneva Austria GmbH,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:39:05Z,2021-10-17T07:39:05Z,236
NCT04668339,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-25,NA,NA,2021-03-26,2020-12-10,2020-12-16,Actual,NA,NA,NA,NA,NA,NA,2021-03-26,2021-03-29,Actual,"January 7, 2021",Actual,2021-01-07,March 2021,2021-03-31,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,NA,,A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults,"A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants","Active, not recruiting",NA,Phase 2,600,Anticipated,"Arcturus Therapeutics, Inc.",,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Individual participant data will only be made available to study investigators at this time.,2021-10-17T07:39:27Z,2021-10-17T07:39:27Z,218
NCT04666012,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-10,NA,NA,2021-07-26,2020-12-11,2020-12-14,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"December 29, 2020",Actual,2020-12-29,July 2021,2021-07-31,April 2022,Anticipated,2022-04-30,"July 9, 2021",Actual,2021-07-09,NA,Interventional,NA,,Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers,"A Phase 1/2a Study (Dose Escalation, Single Center, Open, Phase 1 and Multicenter, Open, Phase 2a) to Assess the Safety and Immunogenicity of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,150,Actual,"Cellid Co., Ltd.",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:39:48Z,2021-10-17T07:39:48Z,96
NCT04659941,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-08,NA,NA,2020-12-08,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2020-12-08,2020-12-09,Actual,"October 1, 2020",Actual,2020-10-01,December 2020,2020-12-31,"October 1, 2022",Anticipated,2022-10-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,ProBCG,,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Recruiting,NA,Phase 2,1000,Anticipated,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:40:39Z,2021-10-17T07:40:39Z,326
NCT04659239,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-05,NA,NA,2021-02-09,2020-12-08,2020-12-09,Actual,NA,NA,NA,NA,NA,NA,2021-02-09,2021-02-10,Actual,"January 28, 2021",Actual,2021-01-28,February 2021,2021-02-28,July 2022,Anticipated,2022-07-31,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,"The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19","A Randomized, Double-Blinded, Placebo Controlled Phase III Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above",Enrolling by invitation,NA,Phase 3,34020,Anticipated,Chinese Academy of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:40:45Z,2021-10-17T07:40:45Z,263
NCT04655625,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-26,NA,NA,2021-04-05,2020-12-04,2020-12-07,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"November 23, 2020",Actual,2020-11-23,April 2021,2021-04-30,"March 31, 2022",Anticipated,2022-03-31,"April 2, 2021",Actual,2021-04-02,NA,Interventional,NA,,Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19),"A Randomized, Double-blind, Placebo Controlled Phase II / III Study to Assess Safety, Immunogenicity and Efficacy of Twice Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults","Active, not recruiting",NA,Phase 2/Phase 3,500,Actual,"AnGes, Inc.",,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:41:19Z,2021-10-17T07:41:19Z,208
NCT04651790,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-20,NA,NA,2021-02-25,2020-12-01,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2021-02-25,2021-03-02,Actual,"November 27, 2020",Actual,2020-11-27,February 2021,2021-02-28,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,CoronaVac3CL,,"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults","Multicenter, Phase 3, Randomized Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against SARS-CoV-2 Infection in Adults.",Recruiting,NA,Phase 3,2300,Anticipated,Pontificia Universidad Catolica de Chile,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:41:52Z,2021-10-17T07:41:52Z,247
NCT04652102,"ClinicalTrials.gov processed this data on October 15, 2021",2020-12-01,NA,NA,2021-07-21,2020-12-01,2020-12-03,Actual,NA,NA,NA,NA,NA,NA,2021-07-21,2021-07-22,Actual,"December 14, 2020",Actual,2020-12-14,October 2020,2020-10-31,"May 15, 2022",Anticipated,2022-05-15,"April 16, 2021",Actual,2021-04-16,NA,Interventional,NA,,A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19,"COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older","Active, not recruiting",NA,Phase 2/Phase 3,39693,Actual,CureVac AG,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:41:50Z,2021-10-17T07:41:50Z,101
NCT04649021,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-17,NA,NA,2021-02-12,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-12,2021-02-15,Actual,"December 4, 2020",Actual,2020-12-04,February 2021,2021-02-28,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population: A Phase II, Randomized, Placebo-controlled, Observer-blinded Study","Active, not recruiting",NA,Phase 2,950,Actual,BioNTech SE,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:42:16Z,2021-10-17T07:42:16Z,260
NCT04649151,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-30,NA,NA,2021-08-19,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2021-08-19,2021-08-20,Actual,"December 9, 2020",Actual,2020-12-09,August 2021,2021-08-31,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2022",Anticipated,2022-06-30,NA,Interventional,TeenCove,,"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of Age","Active, not recruiting",NA,Phase 2/Phase 3,3732,Actual,"ModernaTX, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:42:14Z,2021-10-17T07:42:14Z,72
NCT04648800,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-18,NA,NA,2020-11-30,2020-11-30,2020-12-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-30,2020-12-02,Actual,"July 7, 2020",Actual,2020-07-07,November 2020,2020-11-30,April 2021,Anticipated,2021-04-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland,"A Multi-centre, Randomised, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland",Recruiting,NA,Phase 3,1000,Anticipated,University of Rzeszow,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:42:18Z,2021-10-17T07:42:18Z,334
NCT04646590,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-25,NA,NA,2021-05-06,2020-11-25,2020-11-30,Actual,NA,NA,NA,NA,NA,NA,2021-05-06,2021-05-07,Actual,"December 16, 2020",Actual,2020-12-16,February 2021,2021-02-28,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19,"A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO Cell) for Prevention of COVID-19",Recruiting,NA,Phase 3,29000,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:42:37Z,2021-10-17T07:42:37Z,177
NCT04641858,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-22,NA,NA,2021-10-14,2020-11-22,2020-11-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-14,2021-10-15,Estimate,"December 3, 2020",Actual,2020-12-03,October 2021,2021-10-31,August 2022,Anticipated,2022-08-31,June 2022,Anticipated,2022-06-30,NA,Interventional,EDCTP,,BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic,BCG Vaccine to Reduce Unplanned Absenteeism Due to Illness of Health Care Workers During the COVID-19 Pandemic. A Multi-center Randomised Controlled Trial (BCG-COVID-RCT),Recruiting,NA,Phase 4,1050,Anticipated,University of Southern Denmark,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,When follow-up has been completed and the dataset have been closed.,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to ifronteira@ihmt.unl.pt,NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to professor InÃªs Fronteira ifronteira@ihmt.unl.pt,2021-10-17T07:43:20Z,2021-10-17T07:43:20Z,16
NCT04641481,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-09,NA,NA,2021-03-18,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-18,2021-03-19,Actual,"November 16, 2020",Actual,2020-11-16,March 2021,2021-03-31,December 2022,Anticipated,2022-12-31,"January 8, 2021",Actual,2021-01-08,NA,Interventional,NA,,An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers,"An Event-Driven, Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy, Safety, Immunogenicity, Lot-to-Lot Consistency of BBV152, a Whole-Virion Inactivated SARS-CoV-2 Vaccine in Adultsâ‰¥18 Yrs of Age","Active, not recruiting",NA,Phase 3,25800,Actual,Bharat Biotech International Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:43:23Z,2021-10-17T07:43:23Z,226
NCT04640233,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-17,NA,NA,2021-05-31,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-05-31,2021-06-02,Actual,"November 30, 2020",Actual,2020-11-30,May 2021,2021-05-31,September 2021,Anticipated,2021-09-30,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,,Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Ð¡ov-2) Infection,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Ð¡ov-2 Infection in Indian Healthy Subjects","Active, not recruiting",NA,Phase 2/Phase 3,1600,Actual,Dr. Reddy's Laboratories Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:43:34Z,2021-10-17T07:43:34Z,152
NCT04640402,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-19,NA,NA,2021-03-28,2020-11-20,2020-11-23,Actual,NA,NA,NA,NA,NA,NA,2021-03-28,2021-03-30,Actual,"November 17, 2020",Actual,2020-11-17,November 2020,2020-11-30,"November 18, 2021",Anticipated,2021-11-18,"February 18, 2021",Actual,2021-02-18,NA,Interventional,NA,,A Phase â…¡ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),"A Single-center, Randomized, Double-Blinded, Placebo-Controlled, Phase â…¡ Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells), in the Subjects From Healthy Aged 18 Years and Above",Recruiting,NA,Phase 2,960,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,16,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:43:33Z,2021-10-17T07:43:33Z,216
NCT04639375,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-16,NA,NA,2021-08-23,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"November 15, 2020",Actual,2020-11-15,August 2021,2021-08-31,"June 12, 2022",Anticipated,2022-06-12,"June 12, 2021",Actual,2021-06-12,NA,Interventional,NA,,Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19),A Proof-of-concept Study of Poliovirus Vaccine (IPV) Activity to Induce an Immune Response That Cross-reacts With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2),"Active, not recruiting",NA,Phase 4,300,Actual,E-MO Biology Inc,,1,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:43:42Z,2021-10-17T07:43:42Z,68
NCT04639466,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-04,NA,NA,2021-01-06,2020-11-19,2020-11-20,Actual,NA,NA,NA,NA,NA,NA,2021-01-06,2021-01-07,Actual,"December 11, 2020",Actual,2020-12-11,November 2020,2020-11-30,"November 10, 2022",Anticipated,2022-11-10,"November 10, 2022",Anticipated,2022-11-10,NA,Interventional,NA,,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19","Phase 1 Dose Escalation Study to Evaluate the Safety and Biologically Effective Dose of COH04S1, a Synthetic MVA-Based SARS-CoV-2 Vaccine, Administered as One or Two Injections to Healthy Adult Volunteers",Recruiting,NA,Phase 1,129,Anticipated,City of Hope Medical Center,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:43:41Z,2021-10-17T07:43:41Z,297
NCT04636333,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-17,NA,NA,2021-05-22,2020-11-17,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-05-22,2021-05-25,Actual,"October 30, 2020",Actual,2020-10-30,May 2021,2021-05-31,"January 7, 2022",Anticipated,2022-01-07,"December 7, 2021",Anticipated,2021-12-07,NA,Interventional,NA,,Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell),Safety and Immunogenicity of a Recombinant COVID-19 Vaccine (CHO Cell) in Healthy Population Aged 18 Years and Older: A Phase I Study,Recruiting,NA,Phase 1,216,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:44:09Z,2021-10-17T07:44:09Z,161
NCT04636697,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-12,NA,NA,2021-09-07,2020-11-18,2020-11-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-09,Actual,"November 19, 2020",Actual,2020-11-19,June 2021,2021-06-30,"April 30, 2022",Anticipated,2022-04-30,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults,"Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older","Active, not recruiting",NA,Phase 2/Phase 3,30918,Anticipated,Medicago,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:44:06Z,2021-10-17T07:44:06Z,53
NCT04627675,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-06,NA,NA,2021-06-02,2020-11-12,2020-11-13,Actual,NA,NA,NA,NA,NA,NA,2021-06-02,2021-06-03,Actual,"December 30, 2020",Actual,2020-12-30,June 2021,2021-06-30,May 2022,Anticipated,2022-05-31,July 2021,Anticipated,2021-07-31,NA,Interventional,CORVax12,,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),"CORVax12 - a Phase I Trial of SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine (CORVax) +/- pIL-12 (Tavokinogene Telseplasmid) in Healthy Volunteers, With Immunodynamic Biomarker Monitoring of Coordinated Cellular/Humoral Response","Active, not recruiting",NA,Phase 1,36,Anticipated,Providence Health & Services,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,TRUE,TRUE,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:45:32Z,2021-10-17T07:45:32Z,150
NCT04619628,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-05,NA,NA,2021-07-26,2020-11-05,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-28,Actual,"December 11, 2020",Actual,2020-12-11,July 2021,2021-07-31,May 2022,Anticipated,2022-05-31,"June 26, 2021",Actual,2021-06-26,NA,Interventional,NA,,"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19","First-in-human, Randomised, Double-blind, Placebo-controlled, Dose-escalation Study in Healthy Young Adults Evaluating the Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Candidate for Prevention of COVID-19","Active, not recruiting",NA,Phase 1,48,Anticipated,"Codagenix, Inc",,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:46:45Z,2021-10-17T07:46:45Z,96
NCT04617483,"ClinicalTrials.gov processed this data on October 15, 2021",2020-11-04,NA,NA,2021-07-26,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"October 31, 2020",Actual,2020-10-31,November 2020,2020-11-30,"May 31, 2021",Actual,2021-05-31,"November 28, 2020",Actual,2020-11-28,NA,Interventional,NA,,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults","A Randomized, Double-Blinded Clinical Trial, to Evaluate the Non-inferiority of the Commercial Scale Inactivated SARS-CoV-2 Vaccine Against That of the Pilot Scale Among Adults Aged 26-45 Years, and the Open-labelled, Bridging Non-inferiority of the Vaccine Induced Immunogenicity in Elderly Against That in Adults",Completed,NA,Phase 3,1040,Actual,"Sinovac Biotech Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:47:03Z,2021-10-17T07:47:03Z,96
NCT04612972,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-18,NA,NA,2021-04-27,2020-10-29,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2021-04-27,2021-04-30,Actual,"September 9, 2020",Actual,2020-09-09,April 2021,2021-04-30,"December 19, 2021",Anticipated,2021-12-19,"February 19, 2021",Actual,2021-02-19,NA,Interventional,Covid-Peru,,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru","Ensayo ClÃ­nico de Fase III, Aleatorio, Doble Ciego y Controlado Con Placebo Paralelo, Para Evaluar la Seguridad y la Eficacia Protectora de la Vacuna Inactivada Contra el SARS-CoV-2 en la PoblaciÃ³n Sana de 18 aÃ±os o mÃ¡s, en PerÃº","Active, not recruiting",NA,Phase 3,12000,Actual,Universidad Peruana Cayetano Heredia,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:47:43Z,2021-10-17T07:47:43Z,186
NCT04611802,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-30,NA,NA,2021-07-19,2020-10-30,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-26,Actual,"December 27, 2020",Actual,2020-12-27,July 2021,2021-07-31,"June 30, 2023",Anticipated,2023-06-30,"June 30, 2023",Anticipated,2023-06-30,NA,Interventional,NA,,"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults â‰¥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) at Risk for SARS-CoV-2","A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in Adult Participants â‰¥ 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years)","Active, not recruiting",NA,Phase 3,33000,Anticipated,Novavax,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:47:54Z,2021-10-17T07:47:54Z,103
NCT04608305,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-26,NA,NA,2021-04-25,2020-10-27,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2021-04-25,2021-04-27,Actual,"October 28, 2020",Actual,2020-10-28,April 2021,2021-04-30,"June 1, 2022",Anticipated,2022-06-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,,"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine","A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults",Recruiting,NA,Phase 1/Phase 2,1040,Anticipated,Israel Institute for Biological Research (IIBR),,18,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:48:26Z,2021-10-17T07:48:26Z,188
NCT04604743,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-25,NA,NA,2021-05-21,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2021-05-21,2021-05-25,Actual,"April 20, 2021",Actual,2021-04-20,May 2021,2021-05-31,"June 30, 2023",Anticipated,2023-06-30,"June 30, 2023",Anticipated,2023-06-30,NA,Interventional,NA,,Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama,Exploratory Sequential Mixed Methods Cluster Randomized Controlled Implementation Science Trial to Develop a Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for African American Older Adolescents in Rural Alabama,Recruiting,NA,N/A,4,Anticipated,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Data sharing with occur in compliance with Merck's data sharing policy.,2021-10-17T07:49:00Z,2021-10-17T07:49:00Z,162
NCT04591717,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-13,NA,NA,2021-07-19,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"October 19, 2020",Actual,2020-10-19,October 2020,2020-10-31,"November 19, 2021",Anticipated,2021-11-19,"November 19, 2021",Anticipated,2021-11-19,NA,Interventional,NA,,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Prophylactic Vaccination With 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers","Active, not recruiting",NA,Phase 1,34,Actual,"ImmunityBio, Inc.",,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:50:57Z,2021-10-17T07:50:57Z,103
NCT04591184,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-23,NA,NA,2021-09-07,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-14,Actual,"April 7, 2021",Actual,2021-04-07,September 2021,2021-09-30,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Interventional,NA,,A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults,"Phase I/II Trial to Evaluate Safety, Tolerability, and Immunogenicity of a Prophylactic Plasmid DNA Vaccine Against SARS CoV-2 [Covigenix VAX-001] in Healthy Adults 18 Years and Older","Active, not recruiting",NA,Phase 1/Phase 2,36,Anticipated,Entos Pharmaceuticals Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2021-10-17T07:51:01Z,2021-10-17T07:51:01Z,53
NCT04588480,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-14,NA,NA,2021-08-17,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"October 21, 2020",Actual,2020-10-21,August 2021,2021-08-31,"November 24, 2021",Anticipated,2021-11-24,"November 24, 2021",Anticipated,2021-11-24,NA,Interventional,NA,,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, AND OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY JAPANESE ADULTS","Active, not recruiting",NA,Phase 1/Phase 2,160,Actual,BioNTech SE,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2021-10-17T07:51:24Z,2021-10-17T07:51:24Z,74
NCT04587219,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-13,NA,NA,2021-01-20,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"October 22, 2020",Actual,2020-10-22,October 2020,2020-10-31,"April 30, 2021",Anticipated,2021-04-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","An Open Study of the Safety, Tolerability and Immunogenicity of the ""Gam-COVID-Vac""Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years","Active, not recruiting",NA,Phase 2,110,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:51:35Z,2021-10-17T07:51:35Z,283
NCT04583995,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-09,NA,NA,2021-08-11,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-11,2021-08-13,Actual,"November 28, 2020",Actual,2020-11-28,August 2021,2021-08-31,"January 14, 2022",Anticipated,2022-01-14,"January 14, 2022",Anticipated,2022-01-14,NA,Interventional,NA,,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom","Active, not recruiting",NA,Phase 3,15000,Anticipated,Novavax,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:52:09Z,2021-10-17T07:52:09Z,80
NCT04582344,"ClinicalTrials.gov processed this data on October 15, 2021",2020-10-01,NA,NA,2021-07-26,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"September 14, 2020",Actual,2020-09-14,February 2021,2021-02-28,"April 15, 2022",Anticipated,2022-04-15,"February 15, 2022",Anticipated,2022-02-15,NA,Interventional,NA,,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),"Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated","Active, not recruiting",NA,Phase 3,13000,Anticipated,Health Institutes of Turkey,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:52:23Z,2021-10-17T07:52:23Z,96
NCT04569383,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-21,NA,NA,2021-09-05,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-05,2021-09-13,Actual,"October 5, 2020",Actual,2020-10-05,September 2021,2021-09-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,Safety and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S and a Booster Vaccination With a Licensed Vaccine Against COVID-19,"An Open, Single-center Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Two Ascending Doses of the Candidate Vaccine MVA-SARS-2-S and Heterologous Booster Vaccinations With a Licensed Vaccine Against COVID-19","Active, not recruiting",NA,Phase 1,30,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:54:22Z,2021-10-17T07:54:22Z,55
NCT04569786,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-24,NA,NA,2021-03-02,2020-09-24,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2021-03-02,2021-03-04,Actual,"October 29, 2020",Actual,2020-10-29,March 2021,2021-03-31,"February 18, 2021",Actual,2021-02-18,"February 18, 2021",Actual,2021-02-18,NA,Interventional,NA,,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults",Terminated,NA,Phase 1,232,Actual,Merck Sharp & Dohme Corp.,,9,NA,The study was terminated based on an interim assessment of immunogenicity.,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-10-17T07:54:18Z,2021-10-17T07:54:18Z,242
NCT04568811,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-28,NA,NA,2021-02-08,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-10,Actual,"September 26, 2020",Actual,2020-09-26,September 2020,2020-09-30,"September 27, 2021",Anticipated,2021-09-27,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years","Active, not recruiting",NA,Phase 1,89,Actual,Jiangsu Province Centers for Disease Control and Prevention,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:54:27Z,2021-10-17T07:54:27Z,264
NCT04568031,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-21,NA,NA,2021-09-07,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"August 23, 2020",Actual,2020-08-23,September 2021,2021-09-30,"November 15, 2021",Anticipated,2021-11-15,"November 15, 2021",Anticipated,2021-11-15,NA,Interventional,NA,,Study of AZD1222 for the Prevention of COVID-19 in Japan,"A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19","Active, not recruiting",NA,Phase 1/Phase 2,256,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-10-17T07:54:34Z,2021-10-17T07:54:34Z,53
NCT04566770,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-22,NA,NA,2020-11-25,2020-09-24,2020-09-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"September 24, 2020",Actual,2020-09-24,September 2020,2020-09-30,"October 20, 2022",Anticipated,2022-10-20,"August 21, 2021",Anticipated,2021-08-21,NA,Interventional,NA,,A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),"A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV",Recruiting,NA,Phase 2,481,Anticipated,CanSino Biologics Inc.,,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:54:44Z,2021-10-17T07:54:44Z,339
NCT04563702,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-21,NA,NA,2021-04-05,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2021-04-05,2021-04-08,Actual,"September 21, 2020",Actual,2020-09-21,April 2021,2021-04-30,October 2021,Anticipated,2021-10-31,"May 10, 2021",Anticipated,2021-05-10,NA,Interventional,NA,,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1,35,Actual,Vaxart,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,A plan on how to share individual subject's outcomes will be defined within the next few months.,2021-10-17T07:55:15Z,2021-10-17T07:55:15Z,208
NCT04564716,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-24,NA,NA,2020-12-01,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-02,Actual,"September 28, 2020",Actual,2020-09-28,September 2020,2020-09-30,"April 10, 2021",Anticipated,2021-04-10,"March 28, 2021",Anticipated,2021-03-28,NA,Interventional,NA,,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Ð¡linical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-Ð¡oV-2 Infection Prophylactic Treatment in Republic of Belarus","Active, not recruiting",NA,Phase 3,100,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:55:06Z,2021-10-17T07:55:06Z,333
NCT04560881,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-16,NA,NA,2020-11-25,2020-09-21,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-25,2020-11-27,Actual,"September 16, 2020",Actual,2020-09-16,November 2020,2020-11-30,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years","Active, not recruiting",NA,Phase 3,3000,Actual,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:55:38Z,2021-10-17T07:55:38Z,339
NCT04551547,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-15,NA,NA,2021-07-26,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-07-26,2021-07-27,Actual,"October 31, 2020",Actual,2020-10-31,June 2021,2021-06-30,February 2022,Anticipated,2022-02-28,"April 30, 2021",Actual,2021-04-30,NA,Interventional,NA,,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3-17 Years",Enrolling by invitation,NA,Phase 1/Phase 2,552,Anticipated,"Sinovac Biotech Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:56:59Z,2021-10-17T07:56:59Z,96
NCT04552366,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-15,NA,NA,2020-12-03,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-12-03,2020-12-07,Actual,"September 29, 2020",Actual,2020-09-29,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,A Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and Older,"Active, not recruiting",NA,Phase 1,149,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:56:52Z,2021-10-17T07:56:52Z,331
NCT04550351,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-16,NA,NA,2021-01-26,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"August 19, 2020",Actual,2020-08-19,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 18, 2020",Actual,2020-12-18,NA,Interventional,NA,,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (â‰¥60 Years Old),"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above","Active, not recruiting",NA,Phase 1,50,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T07:57:09Z,2021-10-17T07:57:09Z,277
NCT04546841,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-26,NA,NA,2021-09-07,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2021-09-07,2021-09-08,Actual,"November 27, 2020",Actual,2020-11-27,August 2021,2021-08-31,"December 20, 2021",Anticipated,2021-12-20,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,pVAC,,Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,P-pVAC-SARS-CoV-2: Phase I Single-center Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,"Active, not recruiting",NA,Phase 1,36,Anticipated,University Hospital Tuebingen,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:57:41Z,2021-10-17T07:57:41Z,53
NCT04545749,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-02,NA,NA,2021-06-04,2020-09-10,2020-09-11,Actual,NA,NA,NA,NA,NA,NA,2021-06-04,2021-06-07,Actual,"September 25, 2020",Actual,2020-09-25,June 2021,2021-06-30,"May 24, 2021",Actual,2021-05-24,"January 18, 2021",Actual,2021-01-18,NA,Interventional,NA,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Completed,NA,Phase 1,60,Actual,"United Biomedical Inc., Asia",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:57:52Z,2021-10-17T07:57:52Z,148
NCT04542395,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-03,NA,NA,2021-07-27,2020-09-04,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2021-07-27,2021-08-02,Actual,"June 1, 2021",Actual,2021-06-01,September 2020,2020-09-30,"November 30, 2022",Anticipated,2022-11-30,"November 30, 2022",Anticipated,2022-11-30,NA,Interventional,NA,,COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents,Multilevel Participatory Intervention to Reduce Barriers and Promote Social and Behavioral Facilitators of COVID-19 Testing Among African Americans and Latinx Public Housing Residents,Recruiting,NA,N/A,310,Anticipated,Charles Drew University of Medicine and Science,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:58:25Z,2021-10-17T07:58:25Z,95
NCT04542330,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-07,NA,NA,2020-11-22,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-22,2020-11-24,Actual,"September 15, 2020",Actual,2020-09-15,November 2020,2020-11-30,March 2022,Anticipated,2022-03-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,,Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Senior Citizens During the COVID-19 Pandemic. A Randomized Clinical Trial.,Recruiting,NA,Phase 3,1900,Anticipated,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,When follow-up has been completed and the dataset have been closed,Per justified request on email (cbenn@health.sdu.dk),NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,2021-10-17T07:58:25Z,2021-10-17T07:58:25Z,342
NCT04540419,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-17,NA,NA,2021-07-19,2020-09-04,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2021-07-19,2021-07-20,Actual,"September 11, 2020",Actual,2020-09-11,July 2021,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,"June 19, 2021",Actual,2021-06-19,NA,Interventional,NA,,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers","Active, not recruiting",NA,Phase 3,500,Actual,NPO Petrovax,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:58:43Z,2021-10-17T07:58:43Z,103
NCT04540185,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-04,NA,NA,2020-09-05,2020-09-04,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-05,2020-09-09,Actual,"November 1, 2020",Anticipated,2020-11-01,September 2020,2020-09-30,"December 31, 2022",Anticipated,2022-12-31,"November 1, 2022",Anticipated,2022-11-01,NA,Interventional,OPV-NA831,,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,"A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19",Enrolling by invitation,NA,Phase 3,3600,Anticipated,"NeuroActiva, Inc.",,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,90 days after completion of the study,To be verified and determined at a later date,NA,Yes,We plan to share the Study Protocol and other information if needed,2021-10-17T07:58:46Z,2021-10-17T07:58:46Z,420
NCT04537663,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-28,NA,NA,2021-05-18,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-21,Actual,"August 25, 2020",Actual,2020-08-25,May 2021,2021-05-31,"July 25, 2021",Anticipated,2021-07-25,"June 25, 2021",Anticipated,2021-06-25,NA,Interventional,BCG-PRIME,,Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,Bacillus Calmette-GuÃ©rin Vaccination To Prevent Serious Respiratory Tract Infection And Covid-19 In Vulnerable Elderly - An Adaptive Randomized Controlled Trial,Recruiting,NA,Phase 4,5200,Anticipated,UMC Utrecht,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2021-10-17T07:59:08Z,2021-10-17T07:59:08Z,165
NCT04537949,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-02,NA,NA,2021-06-23,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-06-23,2021-06-25,Actual,"September 9, 2020",Actual,2020-09-09,June 2021,2021-06-30,February 2022,Anticipated,2022-02-28,"March 12, 2021",Actual,2021-03-12,NA,Interventional,NA,,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults","Active, not recruiting",NA,Phase 1/Phase 2,96,Actual,BioNTech SE,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T07:59:05Z,2021-10-17T07:59:05Z,129
NCT04537208,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-02,NA,NA,2021-01-26,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2021-01-26,2021-01-27,Actual,"September 3, 2020",Actual,2020-09-03,January 2021,2021-01-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older,"Active, not recruiting",NA,Phase 1/Phase 2,440,Anticipated,Sanofi,,21,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2021-10-17T07:59:11Z,2021-10-17T07:59:11Z,277
NCT04536051,"ClinicalTrials.gov processed this data on October 15, 2021",2020-09-01,NA,NA,2020-11-23,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-27,Actual,"June 2, 2020",Actual,2020-06-02,September 2020,2020-09-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV003),"A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine",Recruiting,NA,Phase 3,10300,Anticipated,University of Oxford,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T07:59:21Z,2021-10-17T07:59:21Z,341
NCT04533399,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-28,NA,NA,2020-10-30,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2020-10-30,2020-11-02,Actual,"August 17, 2020",Actual,2020-08-17,October 2020,2020-10-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,"A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV",Recruiting,NA,Phase 2,4400,Anticipated,Novavax,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T07:59:46Z,2021-10-17T07:59:46Z,365
NCT04530656,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-27,NA,NA,2021-02-08,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-02-08,2021-02-11,Actual,"August 28, 2020",Actual,2020-08-28,August 2020,2020-08-31,"August 28, 2021",Anticipated,2021-08-28,"October 28, 2020",Actual,2020-10-28,NA,Interventional,NA,,Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),"Safety, Tolerability and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell) in Chinese Healthy Population Aged 18 Years and Older: A Phase I, Single-center, Randomized, Placebo-controlled, Double-blind Study","Active, not recruiting",NA,Phase 1,168,Anticipated,Jiangsu Province Centers for Disease Control and Prevention,,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:00:17Z,2021-10-17T08:00:17Z,264
NCT04530396,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-25,NA,NA,2021-01-20,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-20,2021-01-22,Actual,"September 7, 2020",Actual,2020-09-07,August 2020,2020-08-31,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,RESIST,,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Randomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine in SARS-Ð¡oV-2 Infection Prophylactic Treatment","Active, not recruiting",NA,Phase 3,33758,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:00:20Z,2021-10-17T08:00:20Z,283
NCT04530357,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-26,NA,NA,2021-05-01,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2021-05-01,2021-05-04,Actual,"September 19, 2020",Actual,2020-09-19,February 2021,2021-02-28,"April 25, 2021",Actual,2021-04-25,"November 25, 2020",Actual,2020-11-25,NA,Interventional,NA,,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-INÂ®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder",Completed,NA,Phase 1/Phase 2,244,Actual,Research Institute for Biological Safety Problems,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:00:20Z,2021-10-17T08:00:20Z,182
NCT04528641,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-19,NA,NA,2021-07-09,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2021-07-09,2021-07-12,Actual,"August 10, 2020",Actual,2020-08-10,August 2020,2020-08-31,"May 19, 2021",Actual,2021-05-19,"May 19, 2021",Actual,2021-05-19,NA,Interventional,NA,,GRAd-COV2 Vaccine Against COVID-19,"A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects",Completed,NA,Phase 1,90,Actual,ReiThera Srl,,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:00:36Z,2021-10-17T08:00:36Z,113
NCT04527575,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-11,NA,NA,2021-02-20,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-02-20,2021-02-23,Actual,"July 27, 2020",Actual,2020-07-27,February 2021,2021-02-28,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,EpiVacCorona,,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)","Active, not recruiting",NA,Phase 1/Phase 2,100,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:00:45Z,2021-10-17T08:00:45Z,252
NCT04527081,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-24,NA,NA,2021-10-01,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-10-01,2021-10-04,Actual,"August 31, 2020",Actual,2020-08-31,October 2021,2021-10-31,"September 24, 2021",Actual,2021-09-24,"November 9, 2020",Actual,2020-11-09,NA,Interventional,NA,,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"A Randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:00:51Z,2021-10-17T08:00:51Z,29
NCT04526990,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-22,NA,NA,2021-01-21,2020-08-22,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2021-01-21,2021-01-22,Actual,"September 15, 2020",Actual,2020-09-15,December 2020,2020-12-31,"January 30, 2022",Anticipated,2022-01-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,,Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,"A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase â…¢ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older",Recruiting,NA,Phase 3,40000,Anticipated,CanSino Biologics Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:00:52Z,2021-10-17T08:00:52Z,282
NCT04523571,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-18,NA,NA,2020-11-17,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-17,2020-11-18,Actual,"July 28, 2020",Actual,2020-07-28,November 2020,2020-11-30,August 2021,Anticipated,2021-08-31,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study","Active, not recruiting",NA,Phase 1,144,Actual,BioNTech SE,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:01:30Z,2021-10-17T08:01:30Z,347
NCT04523246,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-20,NA,NA,2021-09-25,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2021-09-25,2021-09-28,Actual,"September 1, 2020",Actual,2020-09-01,September 2021,2021-09-30,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NH-Shingrix,,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents: A Randomized, Doubled-Blinded, Comparative Group Observational Study",Recruiting,NA,Early Phase 1,250,Anticipated,University of Oklahoma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2021-10-17T08:01:32Z,2021-10-17T08:01:32Z,35
NCT04516746,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-17,NA,NA,2021-07-01,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2021-07-01,2021-07-02,Actual,"August 28, 2020",Actual,2020-08-28,July 2021,2021-07-31,"February 14, 2023",Anticipated,2023-02-14,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19","Active, not recruiting",NA,Phase 3,32459,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2021-10-17T08:02:30Z,2021-10-17T08:02:30Z,121
NCT04515147,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-13,NA,NA,2021-08-23,2020-08-13,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"September 28, 2020",Actual,2020-09-28,November 2020,2020-11-30,"November 9, 2021",Anticipated,2021-11-09,"November 9, 2021",Anticipated,2021-11-09,NA,Interventional,NA,,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age","Active, not recruiting",NA,Phase 2,674,Actual,CureVac AG,,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:02:45Z,2021-10-17T08:02:45Z,68
NCT04510207,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-03,NA,NA,2021-04-02,2020-08-10,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2021-04-02,2021-04-05,Actual,"July 16, 2020",Actual,2020-07-16,April 2021,2021-04-30,"September 16, 2021",Anticipated,2021-09-16,"June 16, 2021",Anticipated,2021-06-16,NA,Interventional,COVID-19,,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above","Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,NA,Phase 3,45000,Anticipated,China National Biotec Group Company Limited,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:03:30Z,2021-10-17T08:03:30Z,211
NCT04508075,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-07,NA,NA,2021-09-06,2020-08-08,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2021-09-06,2021-09-08,Actual,"August 10, 2020",Actual,2020-08-10,September 2021,2021-09-30,"August 31, 2021",Actual,2021-08-31,"January 9, 2021",Actual,2021-01-09,NA,Interventional,COVID-19,,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia",Completed,NA,Phase 3,1620,Actual,PT Bio Farma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:03:48Z,2021-10-17T08:03:48Z,54
NCT04498247,"ClinicalTrials.gov processed this data on October 15, 2021",2020-08-03,NA,NA,2021-03-09,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-03-09,2021-03-11,Actual,"August 27, 2020",Actual,2020-08-27,March 2021,2021-03-31,"March 5, 2021",Actual,2021-03-05,"March 5, 2021",Actual,2021-03-05,NA,Interventional,NA,,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)","A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants",Terminated,NA,Phase 1/Phase 2,263,Actual,Merck Sharp & Dohme Corp.,,6,NA,The study was terminated based on an interim assessment of immunogenicity,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2021-10-17T08:05:19Z,2021-10-17T08:05:19Z,235
NCT04495933,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-13,NA,NA,2021-08-23,2020-07-31,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2021-08-23,2021-08-27,Actual,"July 13, 2020",Actual,2020-07-13,August 2021,2021-08-31,"February 2, 2022",Anticipated,2022-02-02,"November 6, 2021",Anticipated,2021-11-06,NA,Interventional,NA,,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults","A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and Over","Active, not recruiting",NA,Phase 1,216,Actual,The University of Queensland,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,"Immediately following publication, no end date",Available only to achieve the aims in the approved proposal,NA,Yes,individual participant data underlying published results only on a case-by-case basis at the discretion of Primary Sponsor,2021-10-17T08:05:40Z,2021-10-17T08:05:40Z,68
NCT04497298,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-31,NA,NA,2021-07-06,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2021-07-06,2021-07-09,Actual,"August 10, 2020",Actual,2020-08-10,July 2021,2021-07-31,"May 12, 2021",Actual,2021-05-12,"May 12, 2021",Actual,2021-05-12,NA,Interventional,COVID-19-101,,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,"A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase",Completed,NA,Phase 1,90,Actual,Institut Pasteur,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:05:29Z,2021-10-17T08:05:29Z,116
NCT04480957,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-17,NA,NA,2021-08-12,2020-07-17,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2021-08-12,2021-08-18,Actual,"August 4, 2020",Actual,2020-08-04,August 2021,2021-08-31,"January 29, 2021",Actual,2021-01-29,"January 29, 2021",Actual,2021-01-29,NA,Interventional,NA,,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,"A Phase 1/2 Randomised, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Immunogenicity of ARCT-021 in Healthy Adult Subjects",Completed,NA,Phase 1/Phase 2,106,Actual,"Arcturus Therapeutics, Inc.",,8,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:07:58Z,2021-10-17T08:07:58Z,79
NCT04475302,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-16,NA,NA,2021-09-17,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2021-09-17,2021-09-20,Actual,"July 1, 2020",Actual,2020-07-01,September 2021,2021-09-30,"December 30, 2021",Anticipated,2021-12-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India,"Active, not recruiting",NA,Phase 3,2175,Actual,"Tuberculosis Research Centre, India",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:08:48Z,2021-10-17T08:08:48Z,43
NCT04473690,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-14,NA,NA,2021-10-05,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"December 30, 2020",Actual,2020-12-30,October 2021,2021-10-31,"December 31, 2022",Anticipated,2022-12-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,,KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers,"A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85","Active, not recruiting",NA,Phase 1/Phase 2,101,Actual,"Kentucky BioProcessing, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Plan is to share study data by dosing group in publications,2021-10-17T08:09:03Z,2021-10-17T08:09:03Z,25
NCT04471519,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-11,NA,NA,2021-05-18,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2021-05-18,2021-05-20,Actual,"July 15, 2020",Actual,2020-07-15,May 2021,2021-05-31,"June 30, 2021",Anticipated,2021-06-30,"July 31, 2020",Actual,2020-07-31,NA,Interventional,BBV152,,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,755,Actual,Bharat Biotech International Limited,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:09:21Z,2021-10-17T08:09:21Z,165
NCT04470609,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-13,NA,NA,2020-07-13,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-14,Actual,"July 10, 2020",Actual,2020-07-10,July 2020,2020-07-31,November 2021,Anticipated,2021-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 Years,"A Randomized, Double-blind, Placebo-controlled, Phase Ib/IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged â©¾60 Years",Enrolling by invitation,NA,Phase 1/Phase 2,471,Anticipated,Chinese Academy of Medical Sciences,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:09:31Z,2021-10-17T08:09:31Z,474
NCT04470427,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-11,NA,NA,2021-06-08,2020-07-11,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2021-06-08,2021-06-10,Actual,"July 27, 2020",Actual,2020-07-27,June 2021,2021-06-30,"October 27, 2022",Anticipated,2022-10-27,"October 27, 2022",Anticipated,2022-10-27,NA,Interventional,NA,,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 3,30420,Actual,"ModernaTX, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:09:36Z,2021-10-17T08:09:36Z,144
NCT04466085,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-08,NA,NA,2020-12-01,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-03,Actual,"July 12, 2020",Actual,2020-07-12,December 2020,2020-12-31,"December 15, 2021",Anticipated,2021-12-15,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,,Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years","Active, not recruiting",NA,Phase 2,900,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:10:33Z,2021-10-17T08:10:33Z,333
NCT04463472,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-08,NA,NA,2021-08-17,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2021-08-17,2021-08-18,Actual,"June 29, 2020",Actual,2020-06-29,August 2021,2021-08-31,"August 12, 2021",Actual,2021-08-12,"September 28, 2020",Actual,2020-09-28,NA,Interventional,NA,,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"A Non-randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg/2mg) in Healthy Adults",Completed,NA,Phase 1/Phase 2,30,Actual,"AnGes, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:11:17Z,2021-10-17T08:11:17Z,74
NCT04461379,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-02,NA,NA,2020-11-12,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Actual,"July 21, 2020",Actual,2020-07-21,November 2020,2020-11-30,"January 1, 2021",Anticipated,2021-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,NA,,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Prevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical Trial","Active, not recruiting",NA,Phase 3,908,Anticipated,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:11:47Z,2021-10-17T08:11:47Z,352
NCT04460703,"ClinicalTrials.gov processed this data on October 15, 2021",2020-07-02,NA,NA,2020-07-18,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-18,2020-07-21,Actual,"July 3, 2020",Actual,2020-07-03,July 2020,2020-07-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,,"COVID-19 Vaccine Messaging, Part 1","Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1",Completed,NA,N/A,4000,Actual,Yale University,,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After publication,Anonymized data and analysis code will be posted in a public replication archive,NA,Yes,Anonymized data and analysis code will be posted in a public replication archive after publication.,2021-10-17T08:12:01Z,2021-10-17T08:12:01Z,469
NCT04456595,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-30,NA,NA,2021-02-10,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2021-02-10,2021-02-11,Actual,"July 21, 2020",Actual,2020-07-21,February 2021,2021-02-28,February 2022,Anticipated,2022-02-28,"December 17, 2020",Actual,2020-12-17,NA,Interventional,PROFISCOV,,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac","Active, not recruiting",NA,Phase 3,12688,Actual,Butantan Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2021-10-17T08:13:15Z,2021-10-17T08:13:15Z,262
NCT04453852,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-03,NA,NA,2021-05-05,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2021-05-05,2021-05-06,Actual,"June 30, 2020",Actual,2020-06-30,May 2021,2021-05-31,"April 14, 2021",Actual,2021-04-14,"February 1, 2021",Actual,2021-02-01,NA,Interventional,COVAX19,,Monovalent Recombinant COVID19 Vaccine,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects",Completed,NA,Phase 1,40,Actual,Vaxine Pty Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:13:39Z,2021-10-17T08:13:39Z,178
NCT04450004,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-18,NA,NA,2020-10-21,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"July 10, 2020",Actual,2020-07-10,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"September 20, 2021",Anticipated,2021-09-20,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age","Active, not recruiting",NA,Phase 1,180,Anticipated,Medicago,,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:14:42Z,2021-10-17T08:14:42Z,374
NCT04447781,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-16,NA,NA,2020-08-18,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"July 15, 2020",Actual,2020-07-15,August 2020,2020-08-31,"February 22, 2022",Anticipated,2022-02-22,"February 22, 2022",Anticipated,2022-02-22,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19","A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,International Vaccine Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,TRUE,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 3 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be anonymized and may be made available upon reasonable request.,2021-10-17T08:15:17Z,2021-10-17T08:15:17Z,438
NCT04445428,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-22,NA,NA,2021-10-05,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2021-10-05,2021-10-06,Actual,"July 15, 2020",Actual,2020-07-15,October 2021,2021-10-31,December 2021,Anticipated,2021-12-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,OPV as Potential Protection Against COVID-19,Oral Polio Vaccine as Potential Protection Against COVID-19: A Cluster-randomised Trial in Guinea-Bissau,"Active, not recruiting",NA,Phase 4,3400,Anticipated,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Provided request, data can be made available",2021-10-17T08:15:38Z,2021-10-17T08:15:38Z,25
NCT04445389,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-19,NA,NA,2020-07-24,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-28,Actual,"June 17, 2020",Actual,2020-06-17,July 2020,2020-07-31,"June 17, 2022",Anticipated,2022-06-17,"March 17, 2021",Anticipated,2021-03-17,NA,Interventional,NA,,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects",Recruiting,NA,Phase 1/Phase 2,210,Anticipated,"Genexine, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:15:38Z,2021-10-17T08:15:38Z,463
NCT04445194,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-16,NA,NA,2020-12-01,2020-06-21,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-12-01,2020-12-03,Actual,"June 22, 2020",Actual,2020-06-22,December 2020,2020-12-31,"September 20, 2021",Anticipated,2021-09-20,"October 22, 2020",Actual,2020-10-22,NA,Interventional,NA,,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age","Active, not recruiting",NA,Phase 1,50,Actual,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:15:40Z,2021-10-17T08:15:40Z,333
NCT04444674,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-15,NA,NA,2020-11-23,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-23,2020-11-27,Actual,"June 24, 2020",Actual,2020-06-24,November 2020,2020-11-30,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV","Active, not recruiting",NA,Phase 1/Phase 2,2130,Actual,University of Oxford,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,within 1 year of trial completion,Any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.,NA,Yes,"The data accumulated from this study will be stored at RMPRU/ Wits. In collaboration with UK collaborators, we aim to make the data available, within one year of completion of the study to any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.
De-identified data will be shared. Related trial documents will be available (protocol, ICFs, statistical analysis plan)",2021-10-17T08:15:46Z,2021-10-17T08:15:46Z,341
NCT04437875,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac Lyo"" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:16:49Z,2021-10-17T08:16:49Z,445
NCT04436471,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:17:02Z,2021-10-17T08:17:02Z,445
NCT04417335,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-25,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial","Active, not recruiting",NA,Phase 4,2014,Actual,Radboud University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2021-10-17T08:19:54Z,2021-10-17T08:19:54Z,514
NCT04414267,"ClinicalTrials.gov processed this data on October 15, 2021",2020-06-01,NA,NA,2021-05-09,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2021-05-09,2021-05-11,Actual,"May 26, 2020",Actual,2020-05-26,May 2021,2021-05-31,"May 7, 2021",Actual,2021-05-07,"April 28, 2021",Actual,2021-04-28,NA,Interventional,ACTIVATEII,,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial,Completed,NA,Phase 4,301,Actual,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:20:22Z,2021-10-17T08:20:22Z,174
NCT04412538,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-21,NA,NA,2020-06-02,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,September 2021,Anticipated,2021-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,"A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years",Recruiting,NA,Phase 1/Phase 2,942,Anticipated,Chinese Academy of Medical Sciences,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:20:36Z,2021-10-17T08:20:36Z,515
NCT04405908,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-25,NA,NA,2021-01-11,2020-05-25,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-01-11,2021-01-12,Actual,"June 19, 2020",Actual,2020-06-19,January 2021,2021-01-31,"May 25, 2021",Anticipated,2021-05-25,"October 16, 2020",Actual,2020-10-16,NA,Interventional,NA,,SCB-2019 as COVID-19 Vaccine,"A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.","Active, not recruiting",NA,Phase 1,150,Anticipated,Clover Biopharmaceuticals AUS Pty Ltd,,15,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:21:37Z,2021-10-17T08:21:37Z,292
NCT04405076,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-13,NA,NA,2021-09-28,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2021-09-28,2021-09-30,Actual,"May 29, 2020",Actual,2020-05-29,September 2021,2021-09-30,"October 31, 2021",Anticipated,2021-10-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 2,660,Actual,"ModernaTX, Inc.",,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:21:44Z,2021-10-17T08:21:44Z,32
NCT04384549,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-06,NA,NA,2020-08-17,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-18,Actual,"May 20, 2020",Actual,2020-05-20,August 2020,2020-08-31,"February 20, 2021",Anticipated,2021-02-20,"February 20, 2021",Anticipated,2021-02-20,NA,Interventional,COVID-BCG,,Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers,Randomized Controlled Trial Evaluating the Efficacy of Vaccination With Bacillus Calmette and GuÃ©rin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care Workers,Recruiting,NA,Phase 3,1120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2021-10-17T08:24:58Z,2021-10-17T08:24:58Z,439
NCT04383574,"ClinicalTrials.gov processed this data on October 15, 2021",2020-05-09,NA,NA,2021-08-16,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2021-08-16,2021-08-18,Actual,"May 22, 2020",Actual,2020-05-22,July 2021,2021-07-31,"July 30, 2022",Anticipated,2022-07-30,"December 28, 2021",Anticipated,2021-12-28,NA,Interventional,NA,,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"A Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cell), in Healthy Elderly Aged 60 Years and Above","Active, not recruiting",NA,Phase 1/Phase 2,422,Anticipated,"Sinovac Biotech Co., Ltd",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2021-10-17T08:25:08Z,2021-10-17T08:25:08Z,75
